0001558370-22-017009.txt : 20221109 0001558370-22-017009.hdr.sgml : 20221109 20221109072341 ACCESSION NUMBER: 0001558370-22-017009 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221109 DATE AS OF CHANGE: 20221109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Applied Therapeutics Inc. CENTRAL INDEX KEY: 0001697532 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38898 FILM NUMBER: 221370652 BUSINESS ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 212-220-9319 MAIL ADDRESS: STREET 1: 545 5TH AVENUE, SUITE 1400 CITY: NEW YORK STATE: NY ZIP: 10017 10-Q 1 aplt-20220930x10q.htm 10-Q
480001832617707933785386254725900001697532--12-312022Q3false00337853862547259048000183261770794805895626215514191010002841800068079000784250000.401.092.023.080http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent19101000284180000.401.0968079000784250002.023.080001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Memberus-gaap:MeasurementInputPriceVolatilityMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Memberus-gaap:MeasurementInputExpectedTermMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Memberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2019Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2019Memberus-gaap:MeasurementInputPriceVolatilityMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2019Memberus-gaap:MeasurementInputExpectedTermMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2019Memberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2018Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2018Memberus-gaap:MeasurementInputPriceVolatilityMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2018Memberus-gaap:MeasurementInputExpectedTermMember2022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2018Memberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-300001697532aplt:PreFundedAndCommonWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2022-09-300001697532aplt:PreFundedAndCommonWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2022-09-300001697532aplt:PreFundedAndCommonWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2022-09-300001697532aplt:PreFundedAndCommonWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2022-09-300001697532aplt:PreFundedAndCommonWarrantsMemberaplt:MeasurementInputChangeOfControlProbabilityMember2022-09-300001697532aplt:EquityDistributionAgreementJanuary2022Member2022-01-012022-09-300001697532aplt:SecondaryPublicOfferingFebruary2021OverAllotmentOptionMember2021-02-012021-02-280001697532aplt:SecondaryPublicOfferingExcludingOverAllotmentOptionMember2020-01-282020-01-280001697532aplt:SecondaryPublicOffering2020OverAllotmentOptionMember2020-01-282020-01-280001697532aplt:EmployeeStockPurchasePlan2019Member2019-05-012022-09-300001697532us-gaap:RetainedEarningsMember2022-09-300001697532us-gaap:AdditionalPaidInCapitalMember2022-09-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001697532us-gaap:RetainedEarningsMember2022-06-300001697532us-gaap:AdditionalPaidInCapitalMember2022-06-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000016975322022-06-300001697532us-gaap:RetainedEarningsMember2022-03-310001697532us-gaap:AdditionalPaidInCapitalMember2022-03-310001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-3100016975322022-03-310001697532us-gaap:RetainedEarningsMember2021-12-310001697532us-gaap:AdditionalPaidInCapitalMember2021-12-310001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001697532us-gaap:RetainedEarningsMember2021-09-300001697532us-gaap:AdditionalPaidInCapitalMember2021-09-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001697532us-gaap:RetainedEarningsMember2021-06-300001697532us-gaap:AdditionalPaidInCapitalMember2021-06-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-3000016975322021-06-300001697532us-gaap:RetainedEarningsMember2021-03-310001697532us-gaap:AdditionalPaidInCapitalMember2021-03-310001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-3100016975322021-03-310001697532us-gaap:RetainedEarningsMember2020-12-310001697532us-gaap:AdditionalPaidInCapitalMember2020-12-310001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001697532us-gaap:CommonStockMember2022-06-300001697532us-gaap:CommonStockMember2022-03-310001697532us-gaap:CommonStockMember2021-12-310001697532us-gaap:CommonStockMember2021-06-300001697532us-gaap:CommonStockMember2021-03-310001697532us-gaap:CommonStockMember2020-12-310001697532aplt:SecondaryPublicOfferingFebruary2021Member2021-02-280001697532aplt:SecondaryPublicOfferingJanuary2020Member2020-01-2800016975322021-01-012021-12-310001697532aplt:EquityIncentivePlan2019Member2022-09-300001697532us-gaap:EmployeeStockOptionMemberaplt:EquityIncentivePlan2019Member2019-05-310001697532aplt:EmployeeStockPurchasePlan2019Member2019-05-310001697532aplt:StockOptionsVestingBasedOnServiceMember2021-01-012021-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2021-12-310001697532us-gaap:EmployeeStockOptionMemberaplt:EquityIncentivePlan2019Member2019-05-012019-05-310001697532aplt:StockOptionsVestingBasedOnServiceMember2022-01-012022-09-300001697532aplt:UniversityOfMiamiMemberaplt:ResearchAgreement2020Member2022-07-012022-09-300001697532aplt:UniversityOfMiamiMemberaplt:ResearchAgreement2020Member2022-01-012022-09-300001697532aplt:UniversityOfMiamiMemberaplt:ResearchAgreement2020Member2021-07-012021-09-300001697532aplt:UniversityOfMiamiMemberaplt:ResearchAgreement2020Member2021-01-012021-09-300001697532aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember2022-07-012022-09-300001697532aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember2022-01-012022-09-300001697532aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember2021-07-012021-09-300001697532aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember2021-01-012021-09-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001697532us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2020-10-282022-09-300001697532aplt:ColumbiaUniversityMember2016-10-012022-09-300001697532us-gaap:RetainedEarningsMember2022-07-012022-09-300001697532us-gaap:RetainedEarningsMember2022-04-012022-06-300001697532us-gaap:RetainedEarningsMember2022-01-012022-03-310001697532us-gaap:RetainedEarningsMember2021-07-012021-09-300001697532us-gaap:RetainedEarningsMember2021-04-012021-06-300001697532us-gaap:RetainedEarningsMember2021-01-012021-03-310001697532us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2022-07-012022-09-300001697532aplt:ColumbiaUniversityMember2022-07-012022-09-300001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2022-01-012022-09-300001697532aplt:ColumbiaUniversityMember2022-01-012022-09-300001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2021-07-012021-09-300001697532aplt:ColumbiaUniversityMember2021-07-012021-09-300001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2021-01-012021-09-300001697532aplt:ColumbiaUniversityMember2021-01-012021-09-300001697532aplt:PreFundedWarrantsMember2022-09-300001697532aplt:CommonWarrantsMember2022-09-300001697532aplt:PreFundedWarrantsMember2022-01-012022-09-300001697532aplt:CommonWarrantsMember2022-01-012022-09-300001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Member2022-01-012022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2019Member2022-01-012022-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2018Member2022-01-012022-09-300001697532aplt:PreFundedAndCommonWarrantsMember2022-01-012022-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2021-09-300001697532aplt:VestedStockOptionAwardsMemberaplt:EquityIncentivePlan2019Member2022-08-022022-08-020001697532aplt:NonVestedStockOptionAwardsMemberaplt:EquityIncentivePlan2019Member2022-08-022022-08-020001697532aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember2022-09-300001697532aplt:WarrantsIssuedWith2018NotesMember2018-01-180001697532us-gaap:SubsequentEventMember2022-10-260001697532us-gaap:CommonStockMember2022-09-300001697532us-gaap:CommonStockMember2021-09-300001697532aplt:PreFundedAndCommonWarrantsMember2022-09-300001697532aplt:PreFundedAndCommonWarrantsMember2021-12-310001697532aplt:PreFundedWarrantsMemberaplt:June2022OfferingMember2022-09-300001697532aplt:CommonWarrantsMemberaplt:June2022OfferingMember2022-09-300001697532aplt:PreFundedWarrantsMemberaplt:June2022OfferingMember2022-06-270001697532aplt:CommonWarrantsMemberaplt:June2022OfferingMember2022-06-270001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2019Member2019-02-280001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2018Member2018-12-310001697532aplt:WarrantsIssuedWith2018NotesMember2018-11-050001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Member2017-01-2600016975322021-09-3000016975322020-12-310001697532us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:CashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:CashMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300001697532us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001697532us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:WarrantMember2022-01-012022-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001697532us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001697532us-gaap:WarrantMember2021-01-012021-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001697532us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001697532us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001697532us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001697532us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001697532us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001697532us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001697532us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300001697532us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001697532us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001697532us-gaap:EmployeeStockOptionMember2021-07-012021-09-300001697532us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001697532us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001697532us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001697532us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2019Member2019-02-012019-02-280001697532aplt:WarrantsIssuedWith2018NotesMember2018-11-052018-11-050001697532aplt:WarrantsIssuedWithSeriesBPreferredStockMemberaplt:Warrant2018Member2018-11-012018-12-310001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Member2017-01-262017-01-260001697532us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-3000016975322022-07-012022-09-3000016975322022-11-080001697532aplt:PreFundedAndCommonWarrantsMember2022-01-012022-09-300001697532us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532us-gaap:FairValueMeasurementsRecurringMember2022-09-300001697532aplt:PreFundedAndCommonWarrantsMember2022-06-272022-06-270001697532aplt:PreFundedWarrantsMemberaplt:June2022OfferingMember2022-01-012022-09-300001697532aplt:CommonWarrantsMemberaplt:June2022OfferingMember2022-01-012022-09-300001697532aplt:PreFundedAndCommonWarrantsMemberaplt:June2022OfferingMember2022-06-272022-06-270001697532aplt:EquityIncentivePlan2019Member2022-08-022022-08-020001697532srt:MinimumMemberaplt:EquityIncentivePlan2019Member2022-08-012022-08-010001697532srt:MaximumMemberaplt:EquityIncentivePlan2019Member2022-08-012022-08-010001697532aplt:EquityDistributionAgreementMember2020-06-122020-06-120001697532aplt:ShelfOfferingMember2020-06-042020-06-040001697532us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-3000016975322021-07-012021-09-300001697532us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001697532us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001697532us-gaap:CommonStockMember2022-07-012022-09-300001697532aplt:WarrantsIssuedWithSeriesPreferredStockMemberaplt:Warrant2017Member2021-02-052021-02-050001697532us-gaap:CommonStockMember2021-01-012021-03-310001697532aplt:PreFundedWarrantsMemberaplt:June2022OfferingMember2022-06-282022-06-2800016975322022-04-012022-06-3000016975322021-01-012021-03-310001697532aplt:EquityDistributionAgreementJanuary2022Member2022-01-262022-01-260001697532aplt:EquityDistributionAgreementMember2020-06-012020-06-300001697532us-gaap:CommonStockMember2021-07-012021-09-300001697532us-gaap:CommonStockMember2021-04-012021-06-300001697532us-gaap:RestrictedStockUnitsRSUMember2022-09-300001697532aplt:EquityIncentivePlan2019Member2019-05-012019-05-310001697532srt:MaximumMemberaplt:EmployeeStockPurchasePlan2019Member2019-05-012019-05-310001697532us-gaap:CommonStockMember2022-01-012022-03-310001697532aplt:June2022OfferingMember2022-06-272022-06-270001697532aplt:SecondaryPublicOfferingFebruary2021Member2021-02-012021-02-280001697532aplt:SecondaryPublicOfferingJanuary2020Member2020-01-282020-01-280001697532aplt:UniversityOfMiamiMembersrt:MinimumMemberaplt:LicenseAgreement2020Member2020-10-282020-10-280001697532aplt:UniversityOfMiamiMembersrt:MaximumMemberaplt:LicenseAgreement2020Member2020-10-282020-10-280001697532aplt:ColumbiaUniversityMemberaplt:ResearchServiceAgreementP13kMember2019-10-032019-10-030001697532aplt:ColumbiaUniversityMemberaplt:ResearchAgreement2019Member2019-03-012019-03-310001697532aplt:ColumbiaUniversityMemberaplt:LicenseAgreement2019Member2022-07-152022-07-150001697532aplt:ColumbiaUniversityMembersrt:MinimumMemberaplt:LicenseAgreement2016Member2016-10-012016-10-310001697532aplt:ColumbiaUniversityMemberaplt:LicenseAgreement2016Member2016-10-012016-10-310001697532aplt:ColumbiaUniversityMembersrt:MaximumMemberaplt:LicenseAgreement2019Member2019-01-012019-01-310001697532aplt:ColumbiaUniversityMembersrt:MaximumMemberaplt:LicenseAgreement2016Member2016-10-012016-10-310001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2020-10-282020-10-280001697532aplt:UniversityOfMiamiMemberaplt:ResearchAgreement2020Member2020-12-142020-12-140001697532aplt:June2022OfferingMember2022-06-270001697532us-gaap:CommonStockMember2022-04-012022-06-300001697532aplt:EquityIncentivePlan2019Member2019-05-3100016975322022-01-012022-09-3000016975322021-01-012021-09-300001697532us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000016975322021-04-012021-06-300001697532us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100016975322022-01-012022-03-310001697532aplt:UniversityOfMiamiMemberaplt:ResearchAgreement2020Member2022-09-300001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2022-09-300001697532aplt:ColumbiaUniversityMember2022-09-300001697532aplt:UniversityOfMiamiMemberaplt:ResearchAgreement2020Member2021-12-310001697532aplt:UniversityOfMiamiMemberaplt:LicenseAgreement2020Member2021-12-310001697532aplt:ColumbiaUniversityMember2021-12-3100016975322022-09-3000016975322021-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureaplt:Y

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 001-38898

Applied Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware

81-3405262

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

545 Fifth Avenue, Suite 1400

New York, New York 10017

(212) 220-9226

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.0001

APLT

The Nasdaq Global Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

  

  

Smaller reporting company

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of November 8, 2022, the registrant had 48,058,956 shares of common stock, $0.0001 par value per share, outstanding.

Table of Contents

Page

Special Note Regarding Forward-Looking Statements

2

PART I.

FINANCIAL INFORMATION

Item 1.

Financial Statements (Unaudited)

4

Condensed Balance Sheets

4

Condensed Statements of Operations

5

Condensed Statements of Comprehensive Loss

6

Condensed Statements of Stockholders’ Equity

7

Condensed Statements of Cash Flows

9

Notes to Condensed Financial Statements (Unaudited)

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

29

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

42

Item 4.

Controls and Procedures

43

PART II.

OTHER INFORMATION

Item 1.

Legal Proceedings

44

Item 1A.

Risk Factors

44

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

85

Item 3.

Defaults Upon Senior Securities

85

Item 4.

Mine Safety Disclosures

85

Item 5.

Other Information

85

Item 6.

Exhibits

86

Signatures

87

1

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q may contain “forward-looking statements” within the meaning of the federal securities laws made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “objective,” “opportunity,” “plan,” “predict,” “project”, “positioned,” “potential,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, including risks described in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q:

our plans to develop, market and commercialize our product candidates;
the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs;
our ability to take advantage of expedited regulatory pathways for any of our product candidates;
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies;
our ability to maintain and establish collaborations or obtain additional funding;
our ability to obtain and timing of regulatory approval of our current and future product candidates;
the anticipated indications for our product candidates, if approved;
our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates;
our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources;
the implementation of our business model and strategic plans for our business and product candidates;
our intellectual property position and the duration of our patent rights;
developments or disputes concerning our intellectual property or other proprietary rights;
the potential impact of the Covid-19 pandemic on the timing and progress of our ongoing clinical trials, our business, results of operations, liquidity, and operations and our ability to mitigate those potential impacts;
our expectations regarding government and third-party payor coverage and reimbursement;
our ability to compete in the markets we serve;
the impact of government laws and regulations and liabilities thereunder;

2

developments relating to our competitors and our industry; and
other factors that may impact our financial results.

The foregoing list of risks is not exhaustive. Other sections of this Quarterly Report on Form 10-Q may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.

In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Unless the context otherwise requires, the terms “Applied,” “Applied Therapeutics,” “the Company,” “we,” “us,” “our”, “the registrant” and similar references in this Quarterly Report on Form 10-Q refer to Applied Therapeutics, Inc.

3

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

Applied Therapeutics, Inc.

Condensed Balance Sheets

(in thousands, except share and per share data)

As of

As of

September 30, 

December 31,

2022

2021

    

(Unaudited)

    

ASSETS

 

 

CURRENT ASSETS:

 

  

 

  

Cash and cash equivalents

$

40,388

$

53,888

Investments

6,990

26,935

Prepaid expenses and other current assets

 

8,132

 

7,571

Total current assets

 

55,510

 

88,394

Operating lease right-of-use asset

970

1,298

Security deposits and leasehold improvements

199

200

TOTAL ASSETS

$

56,679

$

89,892

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

  

CURRENT LIABILITIES:

 

 

  

Current portion of operating lease liabilities

$

470

$

442

Accounts payable

6,973

9,461

Accrued expenses and other current liabilities

 

14,332

 

16,559

Warrant liability

24,739

Total current liabilities

 

46,514

 

26,462

NONCURRENT LIABILITIES:

Noncurrent portion of operating lease liabilities

536

891

Total noncurrent liabilities

536

891

Total liabilities

 

47,050

 

27,353

STOCKHOLDERS’ EQUITY:

 

  

 

  

Common stock, $0.0001 par value; 100,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 48,058,956 shares issued and outstanding as of September 30, 2022 and 26,215,514 shares issued and outstanding as of December 31, 2021

5

3

Preferred stock, par value $0.0001; 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021

-

-

Additional paid-in capital

 

343,995

 

328,958

Accumulated other comprehensive gain/(loss)

23

(107)

Accumulated deficit

 

(334,394)

 

(266,315)

Total stockholders' equity

 

9,629

 

62,539

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

56,679

$

89,892

The Notes to Condensed Financial Statements are an integral part of these statements.

4

Applied Therapeutics, Inc.

Condensed Statements of Operations

(in thousands, except share and per share data)

(Unaudited)

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2022

    

2021

    

2022

    

2021

OPERATING EXPENSES:

Research and development

$

13,116

$

17,597

$

43,542

$

46,846

General and administrative

6,240

10,833

20,436

31,658

Total operating expenses

 

19,356

28,430

 

63,978

78,504

LOSS FROM OPERATIONS

 

(19,356)

(28,430)

 

(63,978)

(78,504)

OTHER INCOME (EXPENSE), NET:

 

  

 

  

 

 

Interest income

 

227

76

 

414

321

Change in fair value of warrant liabilities

 

36

 

(4,321)

Other expense

 

(8)

(64)

 

(194)

(242)

Total other income (expense), net

 

255

12

 

(4,101)

79

Net loss

$

(19,101)

$

(28,418)

$

(68,079)

$

(78,425)

Net loss attributable to common stockholders—basic and diluted

$

(19,101)

$

(28,418)

$

(68,079)

$

(78,425)

Net loss per share attributable to common stockholders—basic and diluted

$

(0.40)

$

(1.09)

$

(2.02)

$

(3.08)

Weighted-average common stock outstanding—basic and diluted

 

48,000,183

 

26,177,079

 

33,785,386

 

25,472,590

The Notes to Condensed Financial Statements are an integral part of these statements.

5

Applied Therapeutics Inc.

Condensed Statements of Comprehensive Income (Loss)

(in thousands)

(Unaudited)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2022

    

2021

    

2022

    

2021

Net Loss

$

(19,101)

$

(28,418)

$

(68,079)

$

(78,425)

Other comprehensive income (loss)

 

 

Unrealized gain (loss) on marketable securities

 

17

 

(69)

 

130

 

(142)

Other comprehensive gain (loss), net of tax

 

17

 

(69)

 

130

 

(142)

Comprehensive income (loss), net of tax

$

(19,084)

$

(28,487)

$

(67,949)

$

(78,567)

The Notes to Condensed Financial Statements are an integral part of these statements.

6

Applied Therapeutics Inc.

Condensed Statements of Stockholders’ Equity

(in thousands, except share and per share data)

(Unaudited)

 

Common Stock

 

 

 

 

$0.0001

 

Additional

 

Accumulated Other

Total

 

Par Value

Paid-in

Accumulated

Comprehensive

Stockholders’

    

Shares

    

Amount

    

Capital

    

Deficit

    

Income (Loss)

Equity

BALANCE, January 1, 2021

22,493,661

$

2

$

242,780

$

(160,731)

$

(112)

$

81,939

Issuance of common stock upon secondary public offering, net of issuance costs of $203

3,450,000

1

74,386

74,387

Exercise of options for common stock issued under Equity Incentive Plan

37,400

67

67

Exercise of options for common stock not yet issued

(465)

(1)

(1)

Restricted Stock Unit released for common stock issued under Equity Incentive Plan

1,988

Exercise of warrants for common stock

27,855

69

69

Stock-based compensation expense

2,981

2,981

Net loss

(24,179)

(24,179)

Other comprehensive income (loss)

(42)

(42)

BALANCE, March 31, 2021

26,010,439

3

320,282

(184,910)

(154)

135,221

Secondary public offering issuance costs

35

35

Issuance of common stock for options exercised in prior periods under Equity Incentive Plan

465

1

1

Exercise of options for common stock issued under Equity Incentive Plan

82,668

341

341

Exercise of options for common stock not yet issued

(920)

(1)

(1)

Restricted Stock Unit released for common stock issued under Equity Incentive Plan

37,884

Stock-based compensation expense

2,702

2,702

Net loss

(25,828)

(25,828)

Other comprehensive income (loss)

(31)

(31)

BALANCE, June 30, 2021

26,130,536

3

323,360

(210,738)

(185)

112,440

Secondary public offering issuance costs

Issuance of common stock for options exercised in prior periods under Equity Incentive Plan

920

1

1

Exercise of options for common stock issued under Equity Incentive Plan

70,368

103

103

Exercise of options for common stock not yet issued

(115)

(1)

(1)

Restricted Stock Unit released for common stock issued under Equity Incentive Plan

12,690

Stock-based compensation expense

2,645

2,645

Net loss

(28,418)

(28,418)

Other comprehensive income (loss)

(69)

(69)

BALANCE, September 30, 2021

26,214,399

3

326,108

(239,156)

(254)

86,701

7

 

Common Stock

 

 

 

 

$0.0001

 

Additional

Accumulated Other

 

Total

 

Par Value

Paid-in

Accumulated

Comprehensive

Stockholders’

    

Shares

    

Amount

    

Capital

    

Deficit

    

Income (Loss)

    

Equity

BALANCE, January 1, 2022

26,215,514

$

3

$

328,958

$

(266,315)

$

(107)

$

62,539

Restricted Stock Unit released for common stock issued under Equity Incentive Plan

21,417

Restricted Stock Units released for common stock not yet issued

(21,417)

Stock-based compensation expense

2,077

2,077

Issuance of options in-lieu of bonus

441

441

Net loss

(23,121)

(23,121)

Other comprehensive income (loss)

27

27

BALANCE, March 31, 2022

26,215,514

$

3

$

331,476

$

(289,436)

$

(80)

$

41,963

Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of issuance costs of $96

20,000,000

2

5,966

5,968

Exercise of pre-funded warrants for common stock

1,750,000

1,417

1,417

Exercise of pre-funded warrants for common stock not yet issued

(1,750,000)

Issuance of common stock for Restricted Stock released in prior periods under Equity Incentive Plan

21,417

Restricted Stock Units released for common issued under Equity Incentive Plan

16,593

Stock-based compensation expense

2,231

2,231

Net loss

(25,857)

(25,857)

Other comprehensive income (loss)

86

86

BALANCE, June 30, 2022

46,253,524

5

341,090

(315,293)

6

25,808

Issuance of common stock for pre-funded warrants exercised in prior periods

1,750,000

Exercise of options for common stock issued under Equity Incentive Plan

47,602

49

49

Restricted Stock Units released for common issued under Equity Incentive Plan

7,830

Stock-based compensation expense

2,856

2,856

Net loss

(19,101)

(19,101)

Other comprehensive income (loss)

17

17

BALANCE, September 30, 2022

48,058,956

$

5

$

343,995

$

(334,394)

$

23

$

9,629

8

Applied Therapeutics, Inc.

Condensed Statements of Cash Flows

(in thousands)

(Unaudited)

Nine Months Ended

September 30, 

    

2022

    

2021

OPERATING ACTIVITIES:

  

  

Net loss

$

(68,079)

$

(78,425)

Adjustments to reconcile net loss to net cash used in operating activities:

 

Stock-based compensation expense

 

7,164

8,328

Issuance of options in-lieu of bonus

441

Amortization of insurance premium

2,806

3,163

Amortization of operating lease right-of-use assets

328

308

Amortization of leasehold improvements

1

1

Change in operating lease liability

(327)

(299)

Change in fair value of warrant liability

4,321

Changes in operating assets and liabilities:

 

Financed insurance premium

(3,105)

(4,434)

Prepaid expenses

 

(262)

(1,107)

Accounts payable

 

(2,488)

8,530

Accrued expenses and other current liabilities

 

(3,000)

149

Net cash used in operating activities

 

(62,200)

 

(63,786)

INVESTING ACTIVITIES:

Purchase of available-for-sale securities

(36,911)

(109,119)

Proceeds from sale of available-for-sale securities

5,539

Proceeds from maturities of available-for-sale securities

56,986

104,206

Net cash provided by investing activities

20,075

626

FINANCING ACTIVITIES:

 

  

 

  

Proceeds from June Offering issuance of shares and pre-funded warrants

27,811

Proceeds from February Offering, net of cash issuance costs of $165

 

74,420

Proceeds from financed insurance premium

3,105

4,434

Repayments of short-term borrowings

(2,340)

(3,534)

Exercise of stock options for common stock under Equity Incentive Plan

 

49

512

Exercise of Warrants

69

Net cash provided by financing activities

 

28,625

 

75,901

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

 

(13,500)

12,741

Cash and cash equivalents at beginning of period

 

53,888

57,466

Cash and cash equivalents at end of period

$

40,388

$

70,207

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

 

  

 

  

Initial measurement of warrant liability

$

21,835

$

Conversion of warrant liability to equity for warrant exercises

$

1,417

$

Unrealized gain (loss) on marketable securities

$

130

$

(142)

Offering costs still in accrued expense

$

8

$

The Notes to Condensed Financial Statements are an integral part of these statements.

9

Applied Therapeutics, Inc.

Notes to Condensed Financial Statements (Unaudited)

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Operations and Business

Applied Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. In particular, the Company is currently targeting treatments for rare metabolic diseases such as Galactosemia, Sorbitol Dehydrogenase (“SORD”) deficiency, and diabetic complications including diabetic cardiomyopathy. The Company was incorporated in Delaware on January 20, 2016 and is headquartered in New York, New York.

On January 28, 2020, the Company completed its secondary public offering (the “Secondary Public Offering”), pursuant to which it issued and sold 2,741,489 shares of common stock at a public offering price of $45.50 per share, with an additional 411,223 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering, after deducting underwriting discounts and commissions and offering costs, were $134.1 million.

On June 4, 2020, the Company filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”) under which the Company may, from time to time, sell securities in one or more offerings having an aggregate offering price of up to $300.0 million. The Shelf Registration Statement was declared effective as of June 15, 2020.

On June 12, 2020, the Company entered into an equity distribution agreement (the “Goldman Equity Distribution Agreement”) with Goldman Sachs & Co. LLC (“Goldman”), as a sales agent to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100 million. Goldman may act as an agent on the Company’s behalf or purchase shares of the Company’s common stock as a principal. The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.

In February 2021, the Company completed an underwritten public offering of 3,450,000 shares of common stock (the “February Offering”), including the exercise in full of the underwriters’ option to purchase 450,000 additional shares of common stock, which option closed on February 19, 2021. The shares were offered at a price to the public of $23.00 per share, resulting in aggregate net proceeds of approximately $74.4 million, after deducting underwriting discounts and commissions and offering expenses.

On January 26, 2022, the Company entered into an equity distribution agreement (the “Cowen Equity Distribution Agreement) with Cowen and Company, LLC (“Cowen”), as a sales agent, to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has not sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.

On June 27, 2022, the Company completed an underwritten public offering (the “June Offering”) of 20,000,000 shares of common stock, par value $0.0001 per share, 10,000,000 pre-funded warrants to purchase shares of common stock (the “Pre-Funded Warrants”), and accompanying warrants to purchase up to 30,000,000 shares of common stock (the “Common Warrants”). The shares and accompanying Common Warrants were offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price

10

to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.

The accompanying unaudited condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2021 included in the Annual Report, filed with the SEC on March 10, 2022 (the “Annual Report”).

The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments which are necessary for a fair presentation of the Company’s financial position as of September 30, 2022, results of operations for the three and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

Liquidity and Going Concern

The Company has incurred, and expects to continue to incur, significant operating losses for the foreseeable future as it continues to develop its drug candidates. To date, the Company has not generated any revenue, and it does not expect to generate revenue unless and until it successfully completes development and obtains regulatory approval for one of its product candidates.

Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. We are actively pursuing several potential financing options. While we continue to explore opportunities to raise additional equity capital in the public markets, this has proven to be challenging in the biotech sector recently. Other options for structured finance which we continue to explore include a PIPE, debt, convertible debt, and synthetic royalty financing. Synthetic royalty financing, in particular, has become a favorable option for many companies for funding ongoing clinical development in late-stage and pre-approval programs. We have engaged an investment bank and we are specifically exploring this option in the near term. Additionally, we are in active dialogue with several potential partners regarding business development opportunities related to one or more of our programs.

11

There can be no assurances that our discussions with any of the current counterparties will be successful, and the Company expects to continue to pursue additional opportunities.

As reflected in the accompanying financial statements, the Company has a net loss of $68.1 million for the nine months ended September 30, 2022 and has an accumulated deficit of $334.4 million as of September 30, 2022. The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. While we believe that our cash and cash equivalents and short-term investments of $47.4 million at September 30, 2022 will be sufficient to fund our operations through June 30, 2023, given our planned expenditures for the next several years, we have concluded and our independent registered public accounting firm has agreed with our conclusion that there is still a substantial doubt regarding our ability to continue as a going concern within one year after the date this Quarterly Report on Form 10-Q is issued.

Risks and Uncertainties

The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Significant Accounting Policies

The significant accounting policies and estimates used in preparation of the condensed financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2022.

Recent Accounting Pronouncements

Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

2. LICENSE AGREEMENT

Columbia University

In October 2016, the Company entered into a license agreement (the “2016 Columbia Agreement”) with the Trustees of Columbia University (“Columbia University”) to obtain an exclusive royalty-bearing sublicensable license in respect to certain patents. As part of the consideration for entering into the 2016 Columbia Agreement, the Company issued to Columbia University shares equal to 5% of its outstanding common stock on a fully diluted basis at the time of issue. The common stock had a fair value of $0.5 million at the time of issuance. The Company will be required to make further payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual net sales, in each case in connection with products covered by the 2016 Columbia Agreement. The Company will also be required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages

12

on the Company’s, its affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent upon the approval of the licensed products, in the mid-six figures beginning on the 10th anniversary of the effective date of the 2016 Columbia Agreement. The Company has not granted any sublicenses under the 2016 Columbia Agreement. However, if the Company sublicenses the rights granted under the 2016 Columbia Agreement to one or more third parties, it will be required to pay Columbia University a portion of the net sublicensing revenue received from such third parties, at percentages between 10% and 20%, depending on the stage of development at the time such revenue is received from such third parties.

The 2016 Columbia Agreement will terminate upon the expiration of all the Company’s royalty payment obligations in all countries. The Company may terminate the 2016 Columbia Agreement for convenience upon 90 days’ written notice to Columbia University. At its election, Columbia University may terminate the 2016 Columbia Agreement, or convert the licenses granted to the Company into non-exclusive, non-sublicensable licenses, in the case of (a) the Company’s uncured material breach upon 30 days’ written notice (which shall be extended to 90 days if the Company is diligently attempting to cure such material breach), (b) the Company’s failure to achieve the specified development and funding milestone events, or (c) the Company’s insolvency.

In January 2019, the Company entered into a second license agreement with Columbia University (the “2019 Columbia Agreement”). Pursuant to the 2019 Columbia Agreement, Columbia University granted the Company a royalty-bearing, sublicensable license that is exclusive with respect to certain patents, and non-exclusive with respect to certain know-how, in each case to develop, manufacture and commercialize PI3k inhibitor products. The license grant is worldwide. Under the 2019 Columbia Agreement, the Company is obligated to use commercially reasonable efforts to research, discover, develop and market licensed products for commercial sale in the licensed territory, and to comply with certain obligations to meet specified development and funding milestones within defined time periods. Columbia University retains the right to conduct, and grant third parties the right to conduct, non-clinical academic research using the licensed technology; provided that such research is not funded by a commercial entity or for-profit entity or results in rights granted to a commercial or for-profit entity. As consideration for entering into the 2019 Columbia Agreement, the Company made a nominal upfront payment to Columbia University. The Company will be required to make further payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual net sales, in each case in connection with products covered by the 2019 Columbia Agreement. The Company will also be required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages on the Company’s, its affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent upon the approval of the licensed products, in the mid-six figures beginning on the tenth anniversary of the effective date of the 2019 Columbia Agreement.

In March 2019, and in connection with the 2016 Columbia Agreement, the Company entered into a research services agreement (the “2019 Columbia Research Agreement”) with Columbia University with the purpose of analyzing structural and functional changes in brain tissue in an animal model of Galactosemia, and the effects of certain compounds whose intellectual property rights were licensed to the Company as part of the 2016 Columbia Agreement on any such structural and functional changes. The 2019 Columbia Research Agreement had a term of 12 months from its effective date and expired in accordance with its terms.

On October 3, 2019, and in connection with the 2019 Columbia Agreement, the Company entered into a research services agreement (the “PI3k Columbia Research Agreement” and collectively with the 2016 Columbia Agreement, 2019 Columbia Agreement and 2019 Columbia Research Agreement, the “Columbia Agreements”) with Columbia University with the purpose of analyzing PI3k inhibitors for the treatment of lymphoid malignancies. The PI3k Columbia Research Agreement had a term of 18 months from its effective date and expired in accordance with its terms.

During the three and nine months ended September 30, 2022, the Company recorded $0 and $0 in research and development expenses, respectively; and $0.1 million and $0.2 million in general and administrative expense, respectively, related to the Columbia Agreements. During the three and nine months ended September 30, 2021, the

13

Company recorded $0 and $0, respectively, in research and development expense and $46,000 and $0.2 million, respectively, in general and administrative expense related to the Columbia Agreements. In aggregate, the Company has incurred $2.6 million in expense from the execution of the Columbia Agreements through September 30, 2022.

As of September 30, 2022, the Company had $0.1 million due to Columbia University included in accrued expenses and $0 included in accounts payable. As of December 31, 2021, the Company had $12,000 due to Columbia University included in accrued expenses and $0.1 million included in accounts payable.

Due to regulatory changes impacting development of the PI3K inhibitor class of compounds, the company has determined that it will discontinue its early stage preclinical PI3K program. On July 15, 2022, the Company notified Columbia University that it is terminating the 2019 Columbia Agreement, effective in 90 days according to the terms of the 2019 Columbia Agreement, or at an earlier date agreed by the parties.

The Company and Columbia entered into an agreement terminating the 2019 Columbia Agreement (the “2022 Columbia Termination Agreement”) as of July 25, 2022. Under the terms of the 2022 Columbia Termination Agreement, the Company assigned certain regulatory documents regarding the preclinical PI3k inhibitor AT-104 to Columbia and granted Columbia a non-exclusive royalty free license (with rights to sublicense any future Columbia licensee) under certain know-how, technical information and data relating to AT-104 that was developed by the Company during the term of the 2019 Columbia Agreement.

University of Miami

2020 Miami License Agreement

On October 28, 2020, the Company entered into a license agreement with the University of Miami (the “2020 Miami License Agreement”) relating to certain technology that is co-owned by the University of Miami (UM), the University of Rochester (UR) and University College London (UCL). UM was granted an exclusive agency from UR and UCL to license each of their rights in the technology. Pursuant to the 2020 Miami License Agreement, UM, on behalf of itself and UR and UCL, granted the Company a royalty-bearing, sublicensable license that is exclusive with respect to certain patent applications and patents that may grant from the applications, and non-exclusive with respect to certain know-how, in each case to research, develop, make, have made, use, sell and import products for use in treating and/or detecting certain inherited neuropathies, in particular those caused by mutation in the sorbitol dehydrogenase (SORD) gene. The license grant is worldwide. Under the 2020 Miami License Agreement, the Company is obligated to use commercially reasonable efforts to develop, manufacture, market and sell licensed products in the licensed territory, and to comply with certain obligations to meet specified development milestones within defined time periods. UM retains for itself, UR, and UCL the right to use the licensed patent rights and licensed technology for their internal non-commercial educational, research and clinical patient care purposes, including in sponsored research and collaboration with commercial entities.

Under the terms of the 2020 Miami License Agreement, the Company was obligated to pay UM an up-front non-refundable license fee of $1.1 million, and a second non-refundable license fee of $0.5 million due on the first anniversary of the date of the license. The Company will be required to make further payments to UM of up to an aggregate $2.2 million for the achievement of specified patenting and development milestones, and up to an aggregate of $4.1 million for achievement of late stage regulatory milestones. The Company will also be required to pay royalties ranging from 0.88% - 5% on the Company’s, the Company’s affiliates’ and the Company’s sublicensees’ net sales of licensed products. If the Company sublicenses the rights granted under the 2020 Miami License Agreement to one or more third parties, the Company will be required to pay to UM a portion of the non-royalty sublicensing revenue received from such third parties ranging from 15% – 25%.

The 2020 Miami License Agreement terminates upon the later of the expiration of all issued patents and filed patent applications or 10 years after the first commercial sale of the last product or process for which a royalty is due, unless earlier terminated. In addition, the 2020 Miami License Agreement may be terminated by the Company at any time upon 60 days prior written notice to UM, and may be terminated by either the Company or UM upon material breach of an obligation if action to cure the breach is not initiated within 60 days of receipt of written notice.

14

During the three and nine months ended September 30, 2022 the company recorded $25,000 and $75,000, respectively, in research and development expense related to the Miami License Agreement.  During the three and nine months ended September 30, 2021 the Company recorded $0.2 million in research and development expense related to the 2020 Miami License Agreement. During the three and nine months ended September 30, 2022, the Company recorded $0 and $2,000, respectively, in general and administrative expense related to the 2020 Miami License Agreement. There were no general and administrative expense recorded during the three and nine months ended September 30, 2021. In aggregate, the Company has incurred $2.4 million in expense from execution of the 2020 Miami License Agreement through September 30, 2022.

The Company had $0.2 million and $0.3 million due to UM included in accrued expenses as of September 30, 2022 and December 31, 2021, respectively, relating to the 2020 Miami License Agreement.

2020 Miami Option Agreement

On October 28, 2020, the Company entered into an option agreement with the University of Miami (the “2020 Miami Option Agreement”) concerning certain research activities and technology relating to SORD neuropathy that may be pursued and developed by UM. Under the 2020 Miami Option Agreement, if UM conducts such research activities, then UM is obligated to grant the Company certain option rights to access and use the research results and to obtain licenses to any associated patent rights upon the Company making specified payments to UM within specified time limits. If the Company elects to obtain option rights the Company will be required to make payments to UM in the low-six figures to the low-seven figures, depending upon the rights the Company elects to obtain, and the Company will be obligated to make certain milestone payments in the high-six figures to mid-seven figures if UM conducts and completes certain research activities within specified time periods and the Company elects to receive rights to use the results of that research.

2020 Miami Sponsored Research Agreement

On December 14, 2020, the Company entered into a research agreement with the University of Miami (the “2020 Miami Research Agreement”), under which the University of Miami will conduct a research study relating to SORD neuropathy and deliver a final report on the study to the Company. The term of the research agreement is from December 14, 2020 through December 30, 2021, and was extended through August 31, 2022, whereby the research study was completed. The total consideration for the 2020 Miami Research Agreement was $0.3 million.

During the three and nine months ended September 30, 2022, the Company recorded $0 and $0.1 million, respectively, in research and development expense in relation to the 2020 Miami Research Agreement. During the three and nine months ended September 30, 2021, the Company recorded $0.1 million and $0.2 million, respectively, in research and development expense in relation to the 2020 Miami Research Agreement. The Company had $0.1 million and $0.2 million as of September 30, 2022 and December 31, 2021, respectively, in accrued expense in relation to the 2020 Miami Research Agreement.

Bayh-Dole Act

Some of the intellectual property rights the Company has licensed, including certain rights licensed in the agreements described above, may have been generated through the use of U.S. government funding. As a result, the U.S. government may have certain rights to intellectual property embodied in the Company’s current or future product candidates under the Bayh-Dole Act of 1980, or Bayh-Dole Act, including the grant to the government of a non-exclusive, worldwide, freedom to operate license under any patents, and the requirement, absent a waiver, to manufacture products substantially in the United States.  To the extent any of the Company’s current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.

15

3. FAIR VALUE MEASUREMENTS

The following tables summarize, as of September 30, 2022, the Company’s financial assets and liabilities that are measured at fair value on a recurring basis, according to the fair value hierarchy described in the significant accounting policies in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report.

As of September 30, 2022

(in thousands)

Level 1

Level 2

Level 3

Total

Cash

$

7,880

$

$

$

7,880

Money market funds

32,508

32,508

Total cash and cash equivalents

$

40,388

$

$

$

40,388

U.S. government agency debt securities

6,990

6,990

Total marketable securities

$

$

6,990

$

$

6,990

Total financial assets measured at fair value on a recurring basis

$

40,388

$

6,990

$

$

47,378

Warrant liabilities - Common Warrants

24,739

24,739

Total financial liabilities measured at fair value on a recurring basis

$

$

$

24,739

$

24,739

Investments in U.S. government agency debt securities have been classified as Level 2 as they are valued using quoted prices in less active markets or other directly or indirectly observable inputs. Fair values of U.S. government agency debt securities were derived from a consensus or weighted average price based on input of market prices from multiple sources at each reporting period. During the period ended September 30, 2022, there were no transfers of financial assets between Level 1 and Level 2.

On June 27, 2022 the Company issued Common Warrants exercisable for 30,000,000 shares of common stock and Pre-Funded Warrants exercisable for 10,000,000 shares of common stock in connection with the June Offering (see note 1 and note 8 for more information on the June Offering). The Common Warrants were accounted for as liabilities under ASC 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”), as these warrants provide for a settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. The Pre-Funded Warrants were recorded at fair value as a liability as the Company could be required to settle the Pre-Funded Warrants in cash under certain circumstances. These warrant liabilities were measured at fair value at inception and are then subsequently measured on a recurring basis, with changes in fair value recognized in other income (expense) within the Company’s statement of operations.

The Company uses a Black-Scholes option pricing model to estimate the fair value of the Common and Pre-Funded Warrants, which utilizes certain unobservable inputs and is therefore considered a Level 3 fair value measurement. Certain inputs used in this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of the Company’s control, including a potential change in control outside of the Company’s control. A significant change in one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the Company’s warrant liabilities, which could also result in material non-cash gains or losses being reported in the Company’s consolidated statement of operations.

The Common and Pre-Funded Warrants were initially valued and remeasured using a Black-Scholes option pricing model with a range of assumptions as follows:

Expected term (in years)

    

3.7

 

Volatility

 

91.53

%

Risk-free interest rate

 

4.11

%

Dividend yield

0.00

%

16

The Company utilized a probability-weighted approach that considered the probability of a change in control at the Company in the Black-Scholes option pricing model, whereby a 10% probability of change in control was used for each of the five years in the term of the agreements.

The following table provides a roll forward of the aggregate fair values of the Company’s warrant liability, for which fair value is determined using Level 3 inputs (in thousands):

    

Warrant Liability

Common Warrant

Pre-Funded Warrant

Balance as of January 1, 2022

$

$

Initial fair value of Warrant Liability

 

13,734

 

8,101

Warrants exercised

(1,417)

Change in fair value

 

3,331

 

990

Balance as of September 30, 2022

$

17,065

$

7,674

The inputs utilized by management to value the warrant liability for Common and Pre-Funded Warrants are highly subjective. The assumptions used in calculating the fair value of the warrant liability for Common and Pre-Funded Warrants represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the fair value of the warrant liability for Common and Pre-Funded Warrants may be materially different in the future.

4. INVESTMENTS

Marketable Securities

Marketable securities, which the Company classifies as available-for-sale securities, primarily consist of U.S. government debt obligations. Marketable securities with remaining effective maturities of twelve months or less from the balance sheet date are classified as short-term; otherwise, they are classified as long-term on the balance sheets.

The following tables provide the Company’s marketable securities by security type (in thousands):

As of September 30, 2022

As of December 31, 2021

Gross

Gross

 

Gross

Gross

 

    

Unrealized

    

Unrealized

    

Estimated

    

    

Unrealized

    

Unrealized

    

Estimated

(in thousands)

Cost

Gains

Losses

Fair Value

Cost

Gains

Losses

Fair Value

US government agency debt security

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

Total

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

As of September 30, 2022, the Company’s investment portfolio reported no unrealized loss. Based on its evaluations, the Company determined that a credit loss allowance is not required since the decline was not related to underlying credit issues of the counterparties. The counterparties to these investments have high credit quality with investment grade ratings of at least AA+ or above, along with a history of no defaults. No single investment in the portfolio had an individually material unrealized loss and in the aggregate. In addition, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost bases. Accordingly, based on the foregoing evaluation, the Company did not record any credit losses during the nine months ended September 30, 2022. Unrealized gains are also reflected, net of tax, as other comprehensive income (loss) in the Statements of Comprehensive Loss.

17

Contractual maturities of the Company’s marketable securities are summarized as follows:

As of September 30, 2022

As of December 31, 2021

Gross

Gross

 

Gross

Gross

 

Unrealized

Unrealized

    

Estimated

Unrealized

Unrealized

    

Estimated

(in thousands)

Cost

    

Gains

    

Losses

    

Fair Value

    

Cost

    

Gains

    

Losses

    

Fair Value

Due in one year or less

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

Due in one through two years

Total

$

6,967

$

23

  

$

$

6,990

$

27,042

$

1

  

$

(108)

$

26,935

At September 30, 2022, the Company had $23,000 of gross unrealized gains and $0 of gross unrealized losses primarily due to fluctuations in the fair value of certain U.S. government agency debt securities.

During the three and nine months ended September 30, 2022, the Company recorded gross realized losses of $3,000 and $0.2 million, respectively, and no gross realized gains of from the sale of marketable securities.

The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September 30, 2022 are as follows:

As of September 30, 2022

Securities in an unrealized loss position less than 12 months

Securities in an unrealized loss position greater than 12 months

Total

Unrealized

    

Estimated

    

Unrealized

    

Estimated

    

Unrealized

    

Estimated

(in thousands)

Losses

Fair Value

Losses

Fair Value

Losses

Fair Value

US government agency debt security

$

$

$

$

$

$

Total

$

$

$

$

$

$

The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December 31, 2021 are as follows:

As of December 31, 2021

Securities in an unrealized loss position less than 12 months

Securities in an unrealized loss position greater than 12 months

Total

Unrealized

    

Estimated

    

Unrealized

    

Estimated

    

Unrealized

    

Estimated

(in thousands)

Losses

Fair Value

Losses

Fair Value

Losses

Fair Value

US government agency debt security

$

(108)

$

17,696

$

$

$

(108)

$

17,696

Total

$

(108)

$

17,696

$

$

$

(108)

$

17,696

5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

    

September 30, 

    

December 31,

(in thousands)

2022

2021

Prepaid research and development expenses

$

4,996

$

4,483

Insurance premium asset

1,914

1,616

Prepaid rent expenses

 

86

 

117

Prepaid insurance expenses

 

89

 

105

Prepaid commercial and patient advocacy

167

254

Research and development tax credit receivable

 

252

 

502

Interest receivable

24

23

Other prepaid expenses and current assets

604

471

Total prepaid expenses & other current assets

$

8,132

$

7,571

18

6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following:

    

September 30, 

    

December 31,

(in thousands)

2022

2021

Accrued pre-clinical and clinical expenses

$

8,836

$

9,912

Short-term insurance financing note

1,554

789

Accrued professional fees

 

837

 

419

Accrued compensation and benefits

 

1,484

 

2,779

Accrued commercial expenses

849

1,394

Accrued patent expenses

 

314

 

279

Other

 

458

 

987

Total accrued expenses & other current liabilities

$

14,332

$

16,559

7. STOCK-BASED COMPENSATION

Equity Incentive Plans

In May 2019, the Company’s board of directors (the “Board”) adopted its 2019 Equity Incentive Plan (“2019 Plan”), which was subsequently approved by its stockholders and became effective on May 13, 2019. As a result, no additional awards under the Company’s 2016 Equity Incentive Plan, as amended (the “2016 Plan”) will be granted and all outstanding stock awards granted under the 2016 Plan that are repurchased, forfeited, expired, or are cancelled will become available for grant under the 2019 Plan in accordance with its terms. The 2016 Plan will continue to govern outstanding equity awards granted thereunder.

The 2019 Plan provides for the issuance of incentive stock options (“ISOs”) to employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other forms of stock awards to the Company’s employees, officers, and directors, as well as non- employees, consultants, and affiliates to the Company. Under the terms of the 2019 Plan, stock options may not be granted at an exercise price less than fair market value of the Company’s common stock on the date of the grant. The 2019 Plan is administered by the Compensation Committee of the Company’s Board.

Initially, subject to adjustments as provided in the 2019 Plan, the maximum number of the Company’s common stock that may be issued under the 2019 Plan was 4,530,000 shares, which is the sum of (i) 1,618,841 new shares, plus (ii) the number of shares (not to exceed 2,911,159 shares) that remained available for the issuance of awards under the 2016 Plan, at the time the 2019 Plan became effective, and (iii) any shares subject to outstanding stock options or other stock awards granted under the 2016 Plan that are forfeited, expired, or reacquired. The 2019 Plan provides that the number of shares reserved and available for issuance under the 2019 Plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Board. Subject to certain changes in capitalization of the Company, the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of ISOs shall be equal to 13,000,000 shares of common stock. Stock options awarded under the 2019 Plan expire 10 years after grant and typically vest over four years.

On August 2, 2022, the Board took action in accordance with its authority under the terms of the 2019 Plan to reset the per-share exercise price of all stock options previously granted under the 2019 Plan to $1.05 per share (the "Options Repricing"), which is equal to the closing price of a share of the Company’s common stock on August 1, 2022. The Options Repricing was deemed to be a Type I modification event under ASC 718, Compensation-Stock Compensation. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the Options Repricing, 1,797,517 vested and 1,380,917 unvested stock options outstanding as of August 2, 2022, with original exercise prices ranging from $1.22 to $49.60, were repriced. The Options Repricing resulted in incremental

19

stock-based compensation expense of $1.4 million, of which $0.9 million related to vested stock option awards and was expensed on the repricing date, and $0.5 million of which related to unvested stock option awards and is being amortized on a ratable basis over the remaining weighted-average vesting period of those awards being approximately 2.4 years.

As of September 30, 2022, there were 1,331,659 shares of common stock available for issuance under the 2019 Plan.

Stock-Based Compensation Expense

Total stock-based compensation expense recorded for employees, directors and non-employees (in thousands):

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

(in thousands)

    

2022

    

2021

    

2022

    

2021

Research and development

$

1,178

$

642

$

2,822

$

1,974

General and administrative

 

1,678

 

2,003

 

4,342

 

6,354

Total stock-based compensation expense

$

2,856

$

2,645

$

7,164

$

8,328

Stock Option Activity

During the nine months ended September 30, 2022 the Company granted 767,913 options to shares of common stock. For the three and nine months ended September 30, 2022, amortization of stock compensation of options amounted to $2.5 million and $6.2 million, respectively, and for the three and nine months ended September 30, 2021, amortization of stock compensation of options amounted to $2.2 million and $7.0 million, respectively. As of September 30, 2022 and 2021, the total unrecognized stock-based compensation balance for unvested options was $9.9 million and $20.2 million, respectively, which is expected to be recognized over 2.3 years and 2.5 years, respectively. The weighted-average fair value per share of options granted during the nine months ended September 30, 2022 and 2021 was $1.79 and $10.01, respectively.

The following table summarizes the information about options outstanding at September 30, 2022:

    

    

    

Weighted-Average

    

 

 

Weighted-

 

Remaining

 

Aggregate

Options

 

Average

 

Contractual

 

Intrinsic

(in thousands, except for share data)

Outstanding

Exercise Price

 

Term (in years)

Value

Outstanding at December 31, 2021

 

4,704,888

$

13.29

7.7

$

10,305

Options granted

 

767,913

2.80

Options exercised

 

(47,602)

1.04

21

Forfeited

 

(357,833)

20.93

Expired

 

(141,688)

31.65

Outstanding at September 30, 2022

 

4,925,678

$

1.99

7.2

$

Exercisable at September 30, 2022

 

3,711,517

$

2.30

6.7

$

Nonvested at September 30, 2022

 

1,214,161

$

1.05

8.5

$

20

Valuation of Stock Options Granted to Employees that Contain Service Conditions Only

The fair value of each option award granted with service-based vesting is estimated on the date of the grant using the Black-Scholes option valuation model based on the weighted average assumptions noted in the table below for those options granted in the nine months ended September 30, 2022 and 2021.

Nine Months Ended

 

September 30, 

    

2022

 

2021

Expected term (in years)

5.7

5.6

Volatility

 

75.83

%

70.99

%

Risk-free interest rate

 

2.13

%

0.91

%

Dividend yield

%

%

Restricted Stock Unit Activity

During the nine months ended September 30, 2022, the Company granted 305,600 RSUs to shares of common stock. For the three months ended September 30, 2022 and 2021, amortization of stock compensation of RSUs amounted to $0.4 million and $0.5 million, respectively. For the nine months ended September 30, 2022 and 2021, amortization of stock compensation of RSU’s amounted to $0.9 million and $1.3 million, respectively. As of September 30, 2022 and 2021, the unamortized compensation costs associated with non-vested restricted stock awards were $3.9 million and $5.1 million, respectively, with a weighted-average remaining amortization period of 3.1 and 2.9 years, respectively.

The following table summarizes the information about restricted stock units outstanding at September 30, 2022:

 

 

Weighted-Average

 

 

Grant Date

 

Aggregate

(in thousands, except for share data)

Shares

 

Fair Value

Intrinsic Value

Outstanding at December 31, 2021

 

469,485

$

18.05

$

4,202

Awarded

 

305,600

3.78

Released

 

(45,840)

25.57

Forfeited

 

(196,131)

18.36

Outstanding at September 30, 2022

 

533,114

$

9.10

$

496

Nonvested at September 30, 2022

 

528,712

$

9.06

$

492

Weighted Average Remaining Recognition Period (in years)

3.1

2019 Employee Stock Purchase Plan

In May 2019, the Company’s Board and its stockholders approved the 2019 Employee Stock Purchase Plan (the “ESPP”), which became effective as of May 13, 2019. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 180,000 shares. The ESPP provides for an annual increase on the first day of each year beginning in 2020 and ending in 2029, in each case subject to the approval of the Board, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the calendar month before the date of the automatic increase and (ii) 360,000 shares; provided that prior to the date of any such increase, the Board may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of September 30, 2022, no shares of common stock had been issued under the ESPP. The first offering period has not yet been decided by the Board.

21

8. STOCKHOLDERS’ EQUITY

As of September 30, 2022, and December 31, 2021, the authorized capital stock of the Company consists of 100,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share.

Common Stock

Goldman Equity Distribution Agreement

In June 2020, the Company entered into the Goldman Equity Distribution Agreement to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. The issuance and sale of shares of common stock by the Company pursuant to the Goldman Equity Distribution Agreement is deemed an “at-the-market” offering under the Securities Act of 1933, as amended, or the Securities Act. Goldman is entitled to compensation for its services equal to up to 3.0% of the gross offering proceeds of all shares of the Company’s common stock sold through it as a sales agent pursuant to the Goldman Equity Distribution Agreement. The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.

Cowen Equity Distribution Agreement

On January 26, 2022, the Company entered into the Cowen Equity Distribution Agreement to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has not sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.

June 2022 Offering

On June 27, 2022, the Company completed the June Offering, an underwritten public offering of 20,000,000 shares of common stock, par value $0.0001 per share, 10,000,000 Pre-Funded Warrants, and accompanying Common Warrants to purchase up to 30,000,000 shares of common stock. The shares and accompanying Common Warrants were offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate

22

purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.

9. WARRANTS

Warrants Issued with Series A Preferred Stock

On January 26, 2017, in connection with the sale and issuance of the Series A Preferred Stock, the Company issued equity-classified warrants to purchase 309,389 shares of common stock (the “2017 Warrants”), valued at $0.2 million, and included in the issuance costs of the Series A Preferred Stock. The warrants vested immediately and have an exercise price of $2.49 per share and expire on March 13, 2027.

The fair value of warrants issued was estimated using the Black-Scholes option pricing model with the following assumptions for the 2017 Warrants.

Contractual term (in years)

    

10.0

 

Volatility

 

74.48

%

Risk-free interest rate

 

3.20

%

Dividend yield

 

0.00

%

On February 5, 2021, a warrantholder exercised 27,855 warrants on a cash basis and received 27,855 shares of common stock. The Company received $69,000 in cash proceeds for the exercise of these warrants.

Warrants Issued with the 2018 Notes

On January 18, 2018, the Company entered into a placement agent agreement through which it became obligated to issue common stock warrants in connection with the issuance of convertible promissory notes, issued on February 5, 2018 (the “2018 Notes”). The obligation to issue the 2018 Notes Warrants was recorded as a liability at its fair value, (see Note 3), which was initially $0.1 million, and was included in the issuance costs of the 2018 Notes. On November 5, 2018, in connection with the extinguishment of the 2018 Notes into shares of Series B Preferred Stock, the Company issued the 2018 Notes Warrants, which were equity-classified warrants upon issuance, to purchase 76,847 shares of common stock, valued at $0.3 million. The 2018 Notes Warrants vested immediately upon issuance and have an exercise price of $6.59 per share and expire on November 4, 2028.

Warrants Issued with Series B Preferred Stock

In November and December 2018, in connection with the sale and issuance of the Series B Preferred Stock, the Company was obligated to issue equity-classified warrants to purchase 72,261 shares of common stock (collectively the “2018 Warrants”), valued in the aggregate at $0.2 million, which was included in the issuance costs for the Series B Preferred Stock. The warrants vest immediately upon issuance, have an exercise price of $8.24 per share and expire 10 years from the date of issuance.

The fair value of the 2018 Warrants was estimated using the Black-Scholes option pricing model with the following assumptions:

Contractual term (in years)

    

10.0

 

Volatility

 

73.22

%

Risk-free interest rate

 

2.70

%

Dividend yield

 

0.00

%

In February 2019, in connection with the sale and issuance of the Series B Preferred Stock, the Company was obligated to issue warrants to purchase 23,867 shares of common stock (collectively the “2019 Warrants”), valued in the

23

aggregate at $0.1 million, which was included in the issuance costs for the Series B Preferred Stock. The warrants vested immediately upon issuance, have an exercise price of $8.24 per share and expire 10 years from the date of issuance.

The fair value of the 2019 Warrants was estimated using the Black-Scholes option pricing model with the following assumptions:

Contractual term (in years)

    

10.0

 

Volatility

 

73.22

%

Risk-free interest rate

 

2.70

%

Dividend yield

 

0.00

%

The inputs utilized by management to value the warrants are highly subjective. The assumptions used in calculating the fair value of the warrants represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the fair value of the warrants may be materially different in the future.

Warrants Issued with June 2022 Offering

On June 27, 2022, in connection with the sale and issuance common stock as part of the June Offering, the Company issued 10,000,000 Pre-Funded Warrants at an exercise price of $0.0001 per share, and 30,000,000 accompanying Common Warrants at an exercise price of $1.00 per share. Each share of common stock and accompanying Common Warrant was sold at a public offering price of $1.00, less underwriting discounts and commissions, and each Pre-Funded Warrant and accompanying Common Warrant was sold at a public offering price of $0.9999, less underwriting discounts and commissions, as described in the prospectus supplement, dated June 22, 2022, filed with the Securities and Exchange Commission on June 24, 2022.

The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled.

On June 28, 2022, a warrantholder exercised 1,750,000 Pre-Funded Warrants on a cash basis and received 1,750,000 shares of common stock. The Company received $175 in cash proceeds for the exercise of these Pre-Funded Warrants.

As of September 30, 2022, the Company had 8,250,000 Pre-Funded Warrants outstanding with a weighted average exercise price of $0.0001 per share and an average contractual life of 5 years. As of September 30, 2022, the Company had 30,000,000 Common Warrants outstanding with a weighted average exercise price of $1.00 per share and an average contractual life of 5 years.

The Common Warrants were accounted for as liabilities under ASC 815-40, as these warrants provide for a settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. These warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the

24

statement of operations. The Pre-Funded Warrants were recorded at fair value as a liability as the Company could be required to settle the Pre-Funded Warrants in cash in the event of an acquisition of the Company under certain circumstances.

The fair value of the Common and Pre-Funded Warrants were estimated using the Black-Scholes option pricing model with the following assumptions:

Expected term (in years)

    

3.7

 

Volatility

 

91.53

%

Risk-free interest rate

 

4.11

%

Dividend yield

0.00

%

A summary of the Company’s outstanding common stock warrants as of September 30, 2022 is as follows:

Warrants

Outstanding as of December 31, 2021

125,618

Warrants granted and issued

 

40,000,000

Warrants exercised

 

(1,750,000)

Warrants exchanged

 

Outstanding as of September 30, 2022

38,375,618

10. LEASES

The following table summarizes the Company’s lease related costs for the nine months ended September 30, 2022 and 2021:

Operating
(in thousands)

Lease Cost

Statement of Operations Location

2022

2021

Operating Lease Cost

General and administrative

$

126

$

126

Total Lease Cost

$

126

$

126

Average lease terms and discount rates for the Company’s operating leases were as follows:

Nine Months Ended

September 30, 

September 30, 

Other Information

    

2022

2021

Weighted-average remaining lease term

Operating leases

2.1 years

3.0 years

Weighted-average discount rate

Operating leases

5.69%

5.69%

25

The following table summarizes the maturities of lease liabilities as of September 30, 2022:

    

Operating

Year

(in thousands)

2022

$

128

2023

515

2024

426

Thereafter

Total lease payments

1,069

Less: interest

63

Total lease liabilities

$

1,006

11. INCOME TAXES

On March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to provide certain relief as a result of the Covid-19 pandemic. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of social security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property and the creation of certain refundable employee retention credits. The CARES Act did not have a material impact on our financial statements for the three and nine months ended September 30, 2022. The Company continues to monitor any effects that may result from the CARES Act.

During the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future.

12. BENEFIT PLANS

The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code in 2018. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company’s board of directors. The Company made approximately $0.4 million and $0.2 million in matching contributions to the plan during the nine months ended September 30, 2022 and 2021, respectively.

13. NET LOSS PER COMMON SHARE

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.

Diluted net loss per common share is computed by giving the effect of all potential shares of common stock, including stock options, preferred shares, warrants and instruments convertible into common stock, to the extent dilutive. Basic and diluted net loss per common share was the same for the three and nine months ended September 30, 2022 and 2021, as the inclusion of all potential common shares outstanding would have been anti-dilutive.

26

The following tables set forth the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended

 

September 30, 

(in thousands, except for share data)

    

2022

    

2021

Numerator:

 

Net loss

$

(19,101)

$

(28,418)

Denominator:

 

Weighted-average common stock outstanding

 

48,000,183

26,177,079

Net loss per share attributable to common stockholders - basic and diluted

$

(0.40)

$

(1.09)

Nine Months Ended

 

September 30, 

    

2022

    

2021

Numerator:

 

  

 

  

Net loss

$

(68,079)

$

(78,425)

Denominator:

 

Weighted-average common stock outstanding

 

33,785,386

25,472,590

Net loss per share attributable to common stockholders - basic and diluted

$

(2.02)

$

(3.08)

The Company’s potentially dilutive securities, which include restricted stock units, stock options, and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding for the nine months ended September 30, 2022 and 2021, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:

As of

September 30, 

    

2022

    

2021

Options to purchase common stock

 

4,925,678

4,542,353

Restricted stock units

533,114

222,693

Warrants to purchase common stock

 

38,375,618

125,618

14. RELATED PARTIES

In December 2018, the Company entered into an agreement (the “LaunchLabs Agreement”) with ARE-LaunchLabs NYC LLC (“Alexandria LaunchLabs”), a subsidiary of Alexandria Real Estate Equities, Inc. for use of specified premises within the Alexandria LaunchLabs space on a month-to-month basis. A member of the Company’s board of directors is the founder and executive chairman of Alexandria Real Estate Equities, Inc. During the three and nine months ended September 30, 2022, the Company made payments to Alexandria LaunchLabs of approximately $23,000, and $70,000, respectively, and during the three and nine months ended September 30, 2021, the Company made the same payments of approximately $23,000 and $70,000 respectively, under the LaunchLabs Agreement, which was recognized in research and development expenses. As of September 30, 2022, there were no amounts due to Alexandria LaunchLabs under the LaunchLabs Agreement.

15. SUBSEQUENT EVENTS

On October 26, 2022, at a Special Meeting of Stockholders (the “Special Meeting”), the stockholders of Applied Therapeutics, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Company’s Amended

27

and Restated Certificate of Incorporation to increase the number of shares of the Company’s common stock authorized for issuance from 100,000,000 shares to 200,000,000 shares (the “Authorized Shares Increase Proposal”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware on October 26, 2022.

28

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in the Annual Report. In addition, this discussion and analysis contains forward-looking statements and involves numerous risks and uncertainties, including, but not limited to, those described under “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in this report, and in other reports we file with the SEC, that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

We are a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. We focus on molecules and pathways whose role in the disease process is well known based on prior research, but have previously failed to yield successful products due to poor efficacy and tolerability. Our unique approach to drug development leverages recent technological advances to design improved drugs, employs early use of biomarkers to confirm biological activity and focuses on abbreviated regulatory pathways. Our first molecular target is aldose reductase, or AR, an enzyme that converts glucose to sorbitol under oxidative stress conditions, and is implicated in multiple diseases. Prior attempts to inhibit this enzyme were hindered by nonselective, nonspecific inhibition, which resulted in limited efficacy and significant off-target safety effects. The detrimental consequences of AR activation have been well established by decades of prior research. Our AR program currently includes three small molecules, which are all potent and selective inhibitors of AR, but are engineered to have unique tissue permeability profiles to target different disease states, including diabetic complications, heart disease and rare metabolic diseases. The result of this unique multifaceted approach to drug development is a portfolio of highly specific and selective product candidates that we believe are significantly de-risked and can move quickly through the development process.

29

AT-007 is a novel central nervous system, or CNS, penetrant ARI that we are developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency. Galactosemia is a devastating rare pediatric metabolic disease that affects how the body processes a simple sugar called galactose, and for which there is no known cure or approved treatment available. The U.S. Food and Drug Administration, or FDA, has granted both orphan drug designation and rare pediatric disease designation to AT-007 for the treatment of Galactosemia and in June 2021, the FDA granted Fast Track Designation to AT-007 for the treatment of Galactosemia. We have completed an adult study in healthy volunteers and Galactosemia patients, demonstrating that AT-007 is safe and well tolerated, and significantly reduces plasma galactitol levels vs. placebo. Galactitol is a toxic metabolite of galactose, which is formed in Galactosemia patients by aberrant activity of aldose reductase when galactose is present at high levels. A pediatric study is underway in children with Galactosemia, assessing the impact of AT-007 vs. placebo on safety, biomarker reduction of galactitol, and long-term functional outcomes. On April 13, 2021, we presented data featuring a cross-sectional analysis of nineteen pediatric patients with Classic Galactosemia, providing meaningful insight on the progressive worsening of the central nervous system phenotype with age. On October 18, 2021, we reported biomarker data from the pediatric ACTION-Galactosemia Kids study. The results demonstrate a substantial reduction in plasma galactitol of approximately 40%, which was statistically significant (p<0.001) vs. placebo. We previously reported a baseline analysis of the 47 children enrolled in the study which demonstrated a clear correlation between baseline galactitol levels and baseline clinical functional outcomes. The long-term functional outcomes portion of the pediatric study is ongoing, and the outcomes are assessed every 6 months by a fire-walled data monitoring committee (DMC). When the study reaches statistical significance in the active treated arm vs. the placebo arm, the DMC will alert the Company and the trial will be unblinded. Statistical modelling suggests that this should occur at approximately the 18-month outcome assessment, based on currently available predictive information. In April 2022, the Company met with the FDA to discuss the design of the ongoing pediatric study prior to the first 6-month outcomes assessment by the DMC. The FDA confirmed that the pediatric study as it is currently designed would support an NDA submission if statistical significance is reached, and there is alignment between the FDA and the Company on the potential path forward to approval. The 12-month clinical outcomes were assessed by the fire-walled DMC, and as expected the data did not yet reach statistical significance, but demonstrated a trend in clinical outcomes favoring AT-007 vs. placebo. A safety analysis showed that AT-007 continued to be safe and well tolerated. The Company is exploring a potential submission for conditional approval based on existing data with the European Medicines Agency (EMA).

AT-007 is also being studied in a rare disease caused by deficiency in the enzyme Sorbitol Dehydrogenase. Aldose Reductase is the first enzyme in the polyol pathway, converting glucose to sorbitol. AR is then followed by Sorbitol Dehydrogenase, which converts sorbitol to fructose. Patients with SORD deficiency accumulate very high levels of sorbitol in their cells and tissues as a result of the enzyme deficiency, which results in tissue toxicities such as peripheral neuropathy and motor neuron disease. Recent research in drosophila and cell models of SORD deficiency demonstrated that treatment with an ARI that blocks sorbitol production may provide benefit in this disease. Preclinical studies on AT-007 have demonstrated significant reduction in sorbitol levels in fibroblasts from SORD deficient patients. Treatment with AT-007 in the drosophila model of SORD prevented the disease phenotype and protected from neuronal degeneration. On October 25, 2021, we reported data from a pilot open-label study in 8 SORD Deficiency patients. AT-007 reduced blood sorbitol levels by approximately 66% from baseline through 30 days of treatment. AT-007 was safe and well tolerated in all treated patients. In December 2021, we initiated a Phase 2/3 registrational study in patients with SORD Deficiency, which is ongoing at multiple clinical sites in the US and Europe. We are in the process of discussing regulatory requirements for approval in SORD deficiency and plan to advance AT-007 towards registration for this indication.

We also plan to initiate a clinical development program on AT-007 in another pediatric rare disease, called PMM2-CDG. PMM2-CDG is a glycosylation disorder caused by deficiencies in the enzyme phosphomannomutase 2, which leads to CNS symptoms similar to galactosemia, including low IQ, tremor, and speech and motor problems. Aldose Reductase is over-activated in this disease as a compensatory consequence of PMM2 deficiency, and a CNS penetrant ARI may be a compelling clinical option. Initial data in fibroblast cell lines derived from PMM2-CDG patients demonstrates that AT-007 treatment increases phosphomannomutase 2 activity. A young child with PMM2-CDG is being treated in a single-patient investigator initiated trial with AT-007 at the University of North Carolina School of Medicine. Data has been presented at medical conferences in 2022 supporting a favorable treatment effect of AT-007

30

on biomarkers and organ function in this patient. The FDA has granted pediatric rare disease designation and orphan designation for AT-007 in PMM2-CDG.

AT-001 is a novel ARI with broad systemic exposure and peripheral nerve permeability that we are developing for the treatment of diabetic cardiomyopathy, or DbCM, a fatal fibrosis of the heart, for which no treatments are available. We completed a Phase 1/2 clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. In September 2019, we announced the initiation of a Phase 3 registrational trial of AT-001 in DbCM. The study, called ARISE-HF, is designed to evaluate AT-001’s ability to improve or prevent the decline of functional capacity in patients with DbCM at high risk of progression to overt heart failure. Although we did experience enrollment delays in 2020 associated with the Covid-19 pandemic, modifications were made to the trial to include additional sites and geographies to address Covid-19-related issues. The trial is now fully enrolled with 675 patients.

AT-003 is a novel ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy, or DR. DR is an ophthalmic disease that occurs in diabetic patients and for which treatments are currently limited to high-cost biologics requiring intravitreal administration. DR has been linked to AR activity, including elevations in sorbitol and subsequent changes in retinal blood vessels, which distorts vision and leads to permanent blindness.

AT-104 is a preclinical dual selective PI3K inhibitor. Due to recent regulatory changes impacting development of the PI3K inhibitor class of compounds, the company has discontinued its early stage preclinical PI3K program and further development of AT-104. The compound and all rights associated with the technology were returned to Columbia University.

As we advance our product candidates forward in additional indications, such as SORD deficiency, PMM2-CDG and retinopathy, we anticipate potential moderate growth in our clinical development and operations teams to support the additional clinical trials, as well as addition of a medical affairs team to support the late stage indications and preparations for commercialization.

Since inception in 2016, our operations have focused on developing our product candidates, organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and conducting clinical trials. We do not have any product candidates approved for sale and have not generated any revenue.

We have incurred significant operating losses since inception in 2016. Our ability to generate product revenue sufficient to achieve profitability will depend on the successful development and commercialization of one or more of our product candidates. Our net loss was $68.1 million for the nine months ended September 30, 2022. As of September 30, 2022, we had an accumulated deficit of $334.4 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future in connection with our ongoing activities. Furthermore, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. As of September 30, 2022, we had cash and cash equivalents and short-term investments of $47.4 million.

February 2021 Secondary Public Offering

In February 2021, we issued and sold 3,000,000 shares of common stock at a public offering price of $23.00 per share, with an additional 450,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares in the February Offering. We received aggregate net proceeds, net of underwriting discounts and commissions and offering costs of $74.4 million.

June 2022 Offering

On June 27, 2022, the Company completed the June Offering, an underwritten public offering of 20,000,000 shares of common stock, par value $0.0001 per share, 10,000,000 Pre-Funded Warrants, and accompanying Common Warrants to purchase up to 30,000,000 shares of common stock. The shares and accompanying Common Warrants were

31

offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.

Components of Our Results of Operations

Revenue

Since inception, we have not generated any revenue and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for our product candidates are successful and result in regulatory approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements.

Operating Expenses

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts and the development of our product candidates, and include:

employee-related expenses, including salaries, related benefits and stock-based compensation expense for employees engaged in research and development functions;
fees paid to consultants for services directly related to our product development and regulatory efforts;
expenses incurred under agreements with contract research organizations, or CROs, as well as contract manufacturing organizations, or CMOs, and consultants that conduct and provide supplies for our preclinical studies and clinical trials;
costs associated with preclinical activities and development activities;
costs associated with our technology and our intellectual property portfolio; and
costs related to compliance with regulatory requirements.

32

We expense research and development costs as incurred. Costs for external development activities are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our financial statements as prepaid or accrued research and development expenses.

Research and development costs also include costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we will record any milestone payments in Identifiable intangible assets, commence amortization and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.

Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we continue clinical development for our product candidates and continue to discover and develop additional product candidates. If any of our product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. Historically, we have incurred research and development expenses that primarily relate to the development of AT-007, AT-001 and our ARI program. As we advance our product candidates, we expect to allocate our direct external research and development costs across each of the indications or product candidates.

The following table summarizes our research and development expenses for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

(in thousands)

    

2022

    

2021

2022

    

2021

Product pipeline research and development expenses

AT-001

$

5,058

$

4,925

$

16,926

$

17,614

AT-007

 

5,326

10,547

 

18,383

22,985

Personnel-related expenses

1,416

1,368

4,931

3,730

Stock-based compensation

1,178

642

2,822

1,974

Other expenses

 

138

115

 

480

543

Total research and development expenses

$

13,116

$

17,597

$

43,542

$

46,846

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in our executive, finance, and commercial functions. General and administrative expenses also include professional fees for legal, accounting, auditing, tax and consulting services; travel expenses; and facility-related expenses, which include allocated expenses for rent and maintenance of facilities and other operating costs.

Commercial expenses consist of payroll expense for commercial personnel, as well as marketing, market research, market access, and other focused investments to support launch of drug candidates and generate evidence of commercial potential and value proposition. Commercial expenses are included in general and administrative expenses.

We expect that our general and administrative expenses will increase in the future as we increase our general and administrative headcount to support our continued research and development and potential commercialization of our product candidates. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax compliance services; director and officer insurance costs; and investor and public relations costs.

33

Other Income (Expense), Net

Other income (expense), net consists of interest income (expense), net, and other income (expense), net. Interest income (expense), net consists primarily of our interest income on our cash and cash equivalents and marketable securities. Other income (expense), net consists primarily of realized gains and losses on sales of marketable securities.

Results of Operations

Three Months Ended September 30, 2022 and 2021

The following table summarizes our results of operations for the three months ended September 30, 2022 and 2021:

(Unaudited)

Three Months Ended

 

September 30, 

(in thousands)

2022

    

2021

Operating expenses:

  

 

  

Research and development

$

13,116

$

17,597

General and administrative

 

6,240

10,833

Total operating expenses

 

19,356

28,430

Loss from operations

 

(19,356)

(28,430)

Other income (expense), net:

 

Interest income (expense), net

227

76

Change in fair value of warrant liabilities

36

Other income (expense)

(8)

(64)

Other income (expense), net

255

12

Net loss

$

(19,101)

$

(28,418)

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended September 30, 2022 and 2021:

Three Months Ended

 

September 30, 

(in thousands)

2022

    

2021

    

Increase/(Decrease)

Clinical and pre-clinical

$

10,035

$

11,778

$

(1,743)

Drug manufacturing and formulation

 

236

3,172

 

(2,936)

Personnel expenses

 

1,416

1,368

 

48

Stock-based compensation

1,178

642

536

Regulatory and other

 

251

637

 

(386)

Total research and development expenses

$

13,116

$

17,597

$

(4,481)

Research and development expenses for the three months ended September 30, 2022 were $13.1 million, compared to $17.6 million for the three months ended September 30, 2021. For the three months ended September 30, 2022, the decrease of $4.5 million was primarily related to:

a decrease in clinical and pre-clinical expense of $1.7 million, primarily due to reduced clinical trial spend on the AT-007 ACTION-Galactosemia Kids pediatric registrational study and AT-007 ACTION-Galactosemia long-term extension adult study;
a decrease in drug manufacturing and formulation costs of $2.9 million primarily related to the completion and release of AT-007 drug product batches and purchase of raw materials in the three months ended September 30, 2021;

34

an increase in personnel expenses of $48,000 due to the increase in headcount in support of our clinical program pipeline;
an increase in stock-based compensation of $0.5 million due to new stock option and restricted stock grants and due to the incremental stock-based compensation expense recognized as a result of the Options Repricing; and
a decrease in regulatory and other expenses of $0.4 million.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the three months ended September 30, 2022 and 2021:

Three Months Ended

 

September 30, 

(in thousands)

    

2022

    

2021

    

Increase/(Decrease)

Legal and professional fees

$

1,341

$

1,511

$

(170)

Commercial expenses

315

3,111

(2,796)

Personnel expenses

 

1,157

1,653

 

(496)

Stock-based compensation

1,678

2,003

(325)

Insurance expenses

810

1,152

(342)

Other expenses

 

939

1,403

 

(464)

Total general and administrative expenses

$

6,240

$

10,833

$

(4,593)

General and administrative expenses were $6.2 million for the three months ended September 30, 2022, compared to $10.8 million for the three months ended September 30, 2021. For the three months ended September 30, 2022, the decrease of $4.6 million was primarily related to:

a decrease in legal and professional fees of $0.2 million due to lower external legal fees;
a decrease in commercial expenses of $2.8 million related to a decrease in spend for commercial operations;
a decrease in personnel expenses of $0.5 million related to a decrease in headcount;
a decrease in stock-based compensation of $0.3 million relating to options being forfeited during the current period as well as decrease in headcount;
a decrease in insurance expenses of $0.3 million related to decreased insurance costs; and
a decrease in other expenses of $0.5 million relating to decreased costs of other office expenses.

Interest Income, Net

Interest income was $0.2 million for the three months ended September 30, 2022, as compared to $0.1 million for the three months ended September 30, 2021. Interest income is derived from our marketable securities and increased due to higher interest rates in the current period.

Change in Fair Value of Warrant Liabilities

The change in the fair value of our warrant liabilities for the three months ended September 30, 2022 resulted in a $36,000 gain recognized in the period primarily due to changes in our common share price. There were no warrant liabilities for the three months ended September 30, 2021.

35

Other Income (Expense)

Other expense was $8,000 for the three months ended September 30, 2022, compared to $0.1 million for the three months ended September 30, 2021. Other expense was primarily related to the realized loss of $8,000 related to the sale and or maturities of marketable securities during the three months ended September 30, 2022, compared to a realized loss of $0.1 million on the sale and or maturities of marketable securities during the three months ended September 30, 2021.

Nine Months Ended September 30, 2022 and 2021

The following table summarizes our results of operations for the nine months ended September 30, 2022 and 2021:

Nine Months Ended

 

September 30, 

(in thousands)

    

2022

    

2021

Operating expenses:

 

  

 

  

Research and development

$

43,542

$

46,846

General and administrative

 

20,436

31,658

Total operating expenses

 

63,978

78,504

Loss from operations

 

(63,978)

(78,504)

Other income (expense), net:

 

Interest income (expense), net

414

321

Change in fair value of warrant liabilities

(4,321)

Other income (expense)

(194)

(242)

Other income (expense), net

(4,101)

79

Net loss

$

(68,079)

$

(78,425)

Research and Development Expenses

The following table summarizes our research and development expenses for the nine months ended September 30, 2022 and 2021:

Nine Months Ended

 

September 30, 

(in thousands)

    

2022

    

2021

    

Increase/(Decrease)

Clinical and pre-clinical

$

33,965

$

28,404

$

5,561

Drug manufacturing and formulation

 

603

11,308

 

(10,705)

Personnel expenses

 

4,931

3,730

 

1,201

Stock-based compensation

2,822

1,974

848

Regulatory and other

 

1,221

1,430

 

(209)

Total research and development expenses

$

43,542

$

46,846

$

(3,304)

Research and development expenses for the nine months ended September 30, 2022 were $43.5 million, compared to $46.8 million for the nine months ended September 30, 2021. For the nine months ended September 30, 2022, the decrease of $3.3 million was primarily related to:

a decrease in drug manufacturing and formulation costs of $10.7 million primarily related to the completion and release of AT-001 and AT-007 drug product batches in the nine months ended September 30, 2021;

36

a decrease in regulatory and other expenses of $0.2 mllion;
an increase in clinical and pre-clinical expense of $5.6 million, primarily related to the progression of the SORD Phase 2/3 registrational study, progression of the AT-007 ACTION-Galactosemia long-term extension adult study, and progression of the AT-007 ACTION-Galactosemia Kids pediatric registrational study;
an increase in personnel expenses of $1.2 million due to the increase in headcount in support of our clinical program pipeline; and
an increase in stock-based compensation of $0.8 million due to new stock option and restricted stock grants and due to the incremental stock-based compensation expense recognized as of the Options Repricing.

General and Administrative Expenses

The following table summarizes our general and administrative expenses for the nine months ended September 30, 2022 and 2021:

Nine Months Ended

 

September 30, 

(in thousands)

    

2022

    

2021

    

Increase/(Decrease)

Legal and professional fees

$

4,319

$

5,108

$

(789)

Commercial expenses

1,845

7,738

(5,893)

Personnel expenses

4,219

4,922

(703)

Stock-based compensation

4,342

6,354

(2,012)

Insurance expenses

2,881

3,246

(365)

Other expenses

 

2,830

4,290

 

(1,460)

Total general and administrative expenses

$

20,436

$

31,658

$

(11,222)

General and administrative expenses were $20.4 million for the nine months ended September 30, 2022, compared to $31.7 million for the nine months ended September 30, 2021. For the nine months ended September 30, 2022, the decrease of $11.2 million was primarily related to:

a decrease in legal and professional fees of $0.8 million due to lower external legal fees;
a decrease in commercial expenses of $5.9 million related to a decrease in spend relating to commercial operations;
a decrease in stock-based compensation of $2.0 million relating to options being forfeited during the current period;
a decrease in personnel expenses of $0.7 million related to an decrease in headcount;
a decrease in insurance expenses of $0.4 million related to decreased insurance costs; and
a decrease in other expenses of $1.5 million relating to decreased costs of other office expenses.

Interest Income, Net

Interest income was $0.4 million for the nine months ended September 30, 2022, as compared to $0.3 million for the nine months ended September 30, 2021. The increase of $0.1 million in interest income period over period is due to rising interest rates during 2022. Interest income is derived from our marketable securities and the increase of $0.1 million was due to higher interest rates when compared to the prior period.

37

Change in Fair Value of Warrant Liabilities

The change in the fair value of our warrant liabilities for the nine months ended September 30, 2022 resulted in a $4.3 million expense recognized in the period. There were no warrant liabilities for the nine months ended September 30, 2021.

Other Income (Expense)

Other expense was $0.2 million for the nine months ended September 30, 2022, compared to other expense of $0.2 for the nine months ended September 30, 2021. Other expense remained relatively consistent period over period, and primarily related to the realized loss of $0.2 million related to the sale and or maturities of marketable securities during 2022. During the nine months ended September 30, 2021, there was a net realized loss of $0.2 million related to the sale and or maturities of marketable securities.

Liquidity and Capital Resources

Since our inception through September 30, 2022, we have not generated any revenue and have incurred significant operating losses and negative cash flows from our operations. The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. While we believe that our cash and cash equivalents of $47.4 million at September 30, 2022 will be sufficient to fund our operations through June 30, 2023, given our planned expenditures for the next several years, we have concluded and our independent registered public accounting firm has agreed with our conclusion that there is still a substantial doubt regarding our ability to continue as a going concern.

Cash Flows

The following table summarizes our cash flows for each of the periods presented:

Nine Months Ended

 

September 30, 

(in thousands)

    

2022

    

2021

Net cash used in operating activities

$

(62,200)

$

(63,786)

Net cash provided by/(used in) investing activities

 

20,075

626

Net cash provided by financing activities

 

28,625

75,901

Net increase (decrease) in cash and cash equivalents

$

(13,500)

$

12,741

Operating Activities

Net cash used in operating activities for the nine months ended September 30, 2022, was $62.2 million primarily due to our net losses of $68.1 million, a decrease in operating lease liability of $0.3 million, a decrease in accounts payable of $2.5 million, a decrease of $3.0 million in accrued expense, a $0.3 million decrease in prepaid expenses, and a decrease of $3.1 million in financed insurance premium. This is partially offset by increases of $7.2 million in non-cash stock-based compensation expense, $0.4 million in options issued in lieu of bonus, $2.8 million of amortization of insurance premium, a $4.3 million increase in change in fair value of warrant liabilities, and $0.3 million in amortization of operating lease right-of-use assets.

Net cash used in operating activities for the nine months ended September 30, 2021, was $63.8 million primarily due to our net losses of $78.4 million, a decrease in operating lease liability of $0.3 million, a decrease in financed insurance premium of $4.4 million, and a decrease in prepaid expenses of $1.1 million. This is partially offset by increases of $8.5 million in accounts payable, $8.3 million in non-cash stock-based compensation expense, $3.2 million of amortization of insurance premium, $0.1 million in accrued expense and $0.3 million in amortization of operating lease right-of-use assets.

38

Investing Activities

Net cash provided by investing activities for the nine months ended September 30, 2022 was $20.1 million relating to our purchase of available-for-sale securities for $36.9 million, offset by the proceeds from the maturities of available-for-sale securities of $57.0 million.

Net cash provided by investing activities for the nine months ended September 30, 2021 was $0.6 million relating to our purchase of available-for-sale securities for $109.1 million, offset by the proceeds from the sale and maturities of available-for-sale securities of $5.5 million and $104.2 million, respectively.

Financing Activities

During the nine months ended September 30, 2022, net cash provided by financing activities was $28.6 million, primarily from the proceeds from the issuance of shares and Pre-Funded Warrants of $27.8 million as part of the June Offering, proceeds from financed insurance premium of $3.1 million, offset by repayment of short-term borrowings of $2.3 million and exercise of stock options for common stock under the Equity Incentive Plan of $49,000.

In June 2020, we entered into the Goldman Equity Distribution Agreement to sell shares of our common stock, from time to time, having an aggregate offering price of up to $100 million. The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.

On January 26, 2022, the Company entered into the Cowen Equity Distribution Agreement to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has not sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.

On June 27, 2022, the Company completed the June Offering, an underwritten public offering of 20,000,000 shares of common stock, par value $0.0001 per share, 10,000,000 Pre-Funded Warrants, and accompanying Common Warrants to purchase up to 30,000,000 shares of common stock. The shares and accompanying Common Warrants were offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate purposes, which may include research and development costs, including the conduct of clinical trials and process

39

development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.

During the nine months ended September 30, 2021, net cash provided by financing activities was $75.9 million, primarily from the cash proceeds from the February Offering of $74.4 million, $0.5 million from the exercise of stock options for common stock under the 2019 Plan, and $69,000 from the exercise of warrants for common stock, and $4.4 million from the proceeds from financed insurance premium. This was partially offset by the repayment of short-term borrowings of $3.5 million.

Funding Requirements

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. We expect that our expenses will increase significantly if and as we:

continue the ongoing and planned development of our product candidates;
initiate, conduct and complete any ongoing, anticipated or future preclinical studies and clinical trials for our current and future product candidates;
seek marketing approvals for any product candidates that successfully complete clinical trials;
establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any current or future product candidate for which we may obtain marketing approval;
seek to discover and develop additional product candidates;
continue to build a portfolio of product candidates through the acquisition or in-license of drugs, product candidates or technologies;
maintain, protect and expand our intellectual property portfolio;
hire additional clinical, regulatory and scientific personnel; and
add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.

Furthermore, we have and expect to continue to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses.

Due to the numerous risks and uncertainties associated with the development of our product candidates and programs, and because the extent to which we may enter into collaborations with third parties for development of our product candidates is unknown, we are unable to estimate the timing and amounts of increased capital outlays and operating expenses associated with completing the research and development of our product candidates. Our future funding requirements, both near and long-term, will depend on many factors, including:

the initiation, scope, progress, timing, costs and results of our ongoing and planned clinical trials for our product candidates;
the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities;

40

the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights;
the cost of defending potential intellectual property disputes, including patent infringement actions;
the achievement of milestones or occurrence of other developments that trigger payments under the Columbia Agreements, the 2020 Miami License Agreement, the 2020 Miami Research Agreement, the 2020 Miami Option Agreement, or other agreements we may enter into;
the extent to which we are obligated to reimburse, or entitled to reimbursement of, clinical trial costs under future collaboration agreements, if any;
the effect of competing technological and market developments;
the cost and timing of completion of clinical or commercial-scale manufacturing activities;
the costs of operating as a public company;
the extent to which we in-license or acquire other products and technologies;
our ability to establish and maintain collaborations on favorable terms, if at all;
the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions where we choose to commercialize our product candidates, if approved; and
the initiation, progress, timing and results of the commercialization our product candidates, if approved, for commercial sale.

A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate.

Until such time, if ever, that we can generate product revenue sufficient to achieve profitability, we expect to finance our cash needs through offerings of securities, PIPE, debt financings, collaborations or other strategic transactions. The terms of financing may adversely affect the holdings or the rights of our stockholders. Funding may not be available to us on acceptable terms, or at all. If we are unable to obtain funding, we may be required to delay, limit, reduce or terminate some or all of our research and product development, product portfolio expansion or future commercialization efforts. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations as of September 30, 2022:

Payments Due By Period

Less Than

More Than

(in thousands)

    

Total

    

1 Year

    

1 to 3 Years

    

4 to 5 Years

    

5 Years

Operating lease commitments(1)

$

1,069

$

515

$

554

$

$

Total

$

1,069

$

515

$

554

$

$

(1)Represents future minimum lease payments under our operating leases for office space.

41

Except as disclosed in the table above, we have no long-term debt or capital leases and no material non-cancelable purchase commitments with service providers, as we have generally contracted on a cancelable, purchase-order basis. We enter into contracts in the normal course of business with CROs, CMOs and other third parties for clinical trials, preclinical research studies and testing and manufacturing services. These contracts are cancelable by us upon prior notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation. These payments are not included in the preceding table as the amount and timing of such payments are not known.

We may incur potential contingent payments upon our achievement of clinical, regulatory, and commercial milestones, as applicable, or royalty payments that we may be required to make under the 2016 and 2019 Columbia Agreements, the 2020 Miami License Agreement, the 2020 Miami Option Agreement, and the 2020 Miami Research Agreement, pursuant to which we have in-licensed certain intellectual property. Due to the uncertainty of the achievement and timing of the events requiring payment under these agreements, the amounts to be paid by us are not fixed or determinable at this time and are excluded from the table above.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

There have been no significant changes to our critical accounting policies from those described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the Annual Report.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.

Recently Issued Accounting Pronouncements

Refer to Note 1, in the accompanying notes to our condensed financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for a discussion of recent accounting pronouncements.

Emerging Growth Company Status

The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected to “opt out” of this provision and, as a result, we will comply with new or revised accounting standards when they are required to be adopted by public companies that are not emerging growth companies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities and foreign currency sensitivities.

42

Interest Rate Sensitivity

Our exposure to market risk relates to our cash, cash equivalents and short-term investments of $47.4 million. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. Some of the financial instruments in which we invest could be subject to market risk where the interest rates may cause the value of the instruments to fluctuate. To minimize this risk, we intend to maintain a portfolio which may include cash, cash equivalents and short-term investment securities available-for-sale in a variety of securities.

The securities in our investment portfolio are not leveraged and are classified as available-for-sale. These available-for-sale securities are short-term in nature and subject to minimal interest rate risk. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. A change of 50 to 100 basis points would result in a change of $2,000 to $4,000, respectively, on the value of our investment portfolio.

We do not believe that our cash has significant risk of default or illiquidity. While we believe our cash and cash equivalents does not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value. In addition, we maintain significant amounts of cash at one or more financial institutions that are in excess of federally insured limits. Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented.

As of September 30, 2022, we had cash and cash equivalents of $47.4 million. Our exposure to interest rate sensitivity is impacted by changes in the underlying U.S. bank interest rates. Our surplus cash has been invested in interest-bearing savings accounts from time to time. We have not entered into investments for trading or speculative purposes. A change of 50 to 100 basis points would result in a change of $0.5 million to $0.5 million, respectively, on the value of our portfolio.

Foreign Currency Sensitivity

Our primary operations are transacted in U.S. Dollars, however, certain service agreements with third parties are denominated in currencies other than the U.S. Dollar, primarily the Euro. As such, we are subject to foreign exchange risk and therefore, fluctuations in the value of the U.S. Dollar against the Euro may impact the amounts reported for expenses and obligations incurred under such agreements. We do not participate in any foreign currency hedging activities and we do not have any other derivative financial instruments. We did not recognize any significant exchange rate gain or loss during the nine months ended September 30, 2022. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have a material impact on our financial condition or results of operations.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures.

As of September 30, 2022, our management, with the participation of our principal executive officer and our principal financial officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, our principal

43

executive officer and principal financial officer concluded that, as of September 30, 2022, the design and operation of our disclosure controls and procedures were effective at a reasonable assurance level.

Changes in Internal Control over Financial Reporting.

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended September 30, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors.

An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following information about these risks described below, together with other information appearing elsewhere in this Quarterly Report on Form 10-Q, including our financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment.

Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock.

Risk Factor Summary

The following is a summary of the risk factors included in this Item 1A and is qualified entirely by the disclosure included in the rest of this Item 1A:

Risks Related to Our Financial Position and Capital Needs

We have incurred and expect to continue to incur substantial operating losses and our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.
Our operating history makes evaluating our business and future viability more difficult.
We will require substantial additional funding to finance our operations, and may suffer consequences to our development programs upon failure to do so.
Raising additional capital may cause adverse effects.

Risks Related to the Development and Commercialization of Our Product Candidates

Our success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates and may be adversely affected upon failure to do so.
Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and our results may not be sufficient for the necessary regulatory approvals.

44

Clinical drug development involves a lengthy and expensive process and the development of additional product candidates is risky and uncertain.
We may be unable to obtain/maintain or receive the benefits of regulatory approval, rare pediatric disease designation/exclusivity, accelerated registration pathways, breakthrough therapy designations or fast track designations for our product candidates, as applicable.
Clinical trials are expensive, time consuming and subject to factors outside our control.
Our product candidates may cause undesirable side effects, affecting regulatory approval, commercial potential or result in significant negative consequences following any potential marketing approval.
Interim, “top line” and preliminary data from our clinical trials may be subject to change.
The market opportunities for our product candidates may be smaller than we believe or approval we obtain may narrow our patient population.
We may face substantial competition.
We may face risks related to strategic collaborations to develop our product candidates
Our product candidates may fail to achieve market acceptance necessary for commercial success.
We may face risks related to any potential international operations.
We may be adversely affected by product liability lawsuits.
Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.

Risks Related to Regulatory Compliance

We are subject to healthcare laws and regulations, which carry substantial penalties for noncompliance.
Coverage and adequate reimbursement may not be available for our product candidates.
Healthcare reform measures may have a negative impact on our business and results of operations.

Risks Related to Our Dependence on Third Parties

Third-parties may conduct our preclinical studies and clinical trials in an unsatisfactory manner.
We intend to rely on third parties to produce supplies of our product candidates.
We and our third-party affiliates are subject to environmental, health and safety laws and regulations.

Risks Related to Our Intellectual Property

Breaches of our license agreements may result in the adverse effects to our ability to continue the development and commercialization of our product candidates.
Insufficient patent protection could allow our competitors to develop and commercialize products and technology similar or identical to ours.
Obtaining and maintaining our patent rights is expensive, complicated and labor intensive and patent terms may be inadequate to protect our competitive position on our product candidates.
We may be subject to claims alleging violations of intellectual property rights.
Changes in patent law could impair our ability to protect our product candidates.
We may be unable to protect our intellectual property rights.
Intellectual property rights do not necessarily address all potential threats to our business.

Risks Related to Our Business Operations, Employee Matters and Managing Growth

We are highly dependent on the services of our current executive officers.
We may experience difficulties resulting from the expansion of our organization.
We may be subject to security breaches in our information technology systems.
Our employees and the third-parties we deal with may engage in misconduct or improper activities.
Our business may be adversely affected by the coronavirus outbreak.

45

Risks Related to Ownership of Our Common Stock

The market price of our common stock is volatile and has fluctuated substantially.
Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.
We do not anticipate paying any cash dividends on our capital stock in the foreseeable future.
Failure to regain compliance with the continued listing requirements of Nasdaq could result in our common stock being delisted and the price of our common stock could be negatively impacted.

General Risk Factors

We may be affected by unfavorable research or reports.
We may use our cash and cash equivalents ineffectively or in ways with which you do not agree.
We are subject to risks as an “emerging growth company” and a public company.
We may avail ourselves of defensive and forum selection provisions in our governing documents and under Delaware law.

Risks Related to Our Financial Position and Capital Needs

We have incurred significant operating losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or maintain profitability.

Since inception in January 2016, we have incurred significant operating losses. Our net loss was $105.6 million and $94.0 million for the years ended December 31, 2021 and 2020, respectively and $68.1 million and $78.4 million for the nine months ended September 30, 2022, and 2021, respectively. As of September 30, 2022, we had an accumulated deficit of $334.4 million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Since inception, we have devoted substantially all of our efforts to research and preclinical and clinical development of our product candidates, organizing and staffing our company, business planning, raising capital, establishing our intellectual property portfolio and conducting clinical trials. To date, we have never obtained regulatory approval for, or commercialized, any drugs. It could be several years, if ever, before we have a commercialized drug. The net losses we incur may fluctuate significantly from quarter to quarter and year-to-year. We anticipate that our expenses will increase substantially if, and as, we:

continue the ongoing and planned development of our product candidates;
initiate, conduct and complete any ongoing, anticipated or future preclinical studies and clinical trials for our current and future product candidates;
seek marketing approvals for any product candidates that successfully complete clinical trials;
establish a sales, marketing, manufacturing and distribution infrastructure to commercialize any current or future product candidate for which we may obtain marketing approval;
seek to discover and develop additional product candidates;
continue to build a portfolio of product candidates through the acquisition or in-license of drugs, product candidates or technologies;
maintain, protect and expand our intellectual property portfolio;
meet the requirements and demands of being a public company;
defend against any product liability claims or other lawsuits related to our products;
hire additional clinical, regulatory and scientific personnel; and
add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts.

Furthermore, we have incurred additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses.

46

To become and remain profitable, we must succeed in developing and eventually commercializing drugs that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our current and future product candidates, obtaining regulatory approval, procuring commercial-scale manufacturing, marketing and selling any products for which we obtain regulatory approval (including through third parties), as well as discovering or acquiring and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are sufficient to offset our expenses and achieve profitability.

Because of the numerous risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.

Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our common stock could also cause you to lose all or part of your investment.

The report of our independent registered public accounting firm included a “going concern” explanatory paragraph.

The report of our independent registered public accounting firm on our Financial Statements for the year ended December 31, 2021 includes an explanatory paragraph regarding the existence of substantial doubt about our ability to continue as a going concern. While we believe that our cash and cash equivalents and investments of $47.4 million at September 30, 2022 will be sufficient to fund our operations through June 30, 2023, given our planned expenditures for the next several years, we have concluded and our independent registered public accounting firm has agreed with our conclusion that there is still a substantial doubt regarding our ability to continue as a going concern. Any such inability to continue as a going concern may result in our stockholders losing their entire investment. There is no guarantee that we will become profitable or secure additional financing on acceptable terms.

Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.

We are a clinical-stage company with limited operational history, and our operations to date have been largely focused on raising capital, organizing and staffing our company, identifying and developing our product candidates, and undertaking preclinical and clinical development for our product candidates. As an organization, we have not yet demonstrated an ability to successfully complete clinical development, obtain regulatory approvals, manufacture a commercial-scale product or conduct sales and marketing activities necessary for successful commercialization, or arrange for a third party to conduct these activities on our behalf. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.

We have encountered, and may continue to encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.

Additionally, we expect our financial condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.

47

We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.

As of September 30, 2022, our cash, cash equivalents and marketable securities was $47.4 million. Based on our current operating and research and development plans, we do not believe that our existing cash, cash equivalents, and marketable securities as of September 30, 2022 will be sufficient to fund our projected operations through at least the next 12 months from the date the financial statements were issued. We will need to obtain substantial additional funding in connection with our continuing operations and planned research and clinical development activities. Our future capital requirements will depend on many factors, including:

the timing, progress and results of our ongoing preclinical studies and clinical trials of our product candidates;
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other product candidates that we may pursue;
our ability to establish collaborations on favorable terms, if at all;
the costs, timing and outcome of regulatory review of our product candidates;
the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
the cost of any milestone and royalty payments with respect to any approved product candidates;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
the costs of operating as a public company; and
the extent to which we acquire or in-license other product candidates and technologies.

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of drugs that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. We may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

In addition, our ability to access additional capital has been affected by overall macroeconomic trends, among other things, including rising interest rates, which have caused the price of our common stock to fluctuate significantly and/or decline. These macroeconomic trends have been exacerbated by recent hostilities between Russia and Ukraine, which have contributed to further economic instability in the global financial markets. As a result, adequate additional financing may not be available to us when needed or on attractive terms. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce, or altogether terminate our research and development programs or future commercialization efforts.

Raising additional capital may cause dilution to our stockholders and restrict our operations or require us to relinquish rights to our product candidates.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, including through the Cowen Equity Distribution Agreement, third party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest in our company may be diluted, and the terms of these securities may include liquidation or other preferences that

48

adversely affect your rights as a stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.

If we raise additional capital through future collaborations, strategic alliances or third party licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our drug development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.

Our ability to use our net operating losses to offset future taxable income may be subject to certain limitations.

We have incurred substantial losses since inception and do not expect to become profitable in the near future, if ever. In general, under Section 382 of the United States Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of subsequent changes in our stock ownership (some of which shifts are outside our control). As a result, if, and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations.

For NOLs arising in tax years beginning after December 31, 2017, the Code limits a taxpayer’s ability to utilize NOL carryforwards to 80% of taxable income. In addition, NOLs arising in tax years ending after December 31, 2017 can be carried forward indefinitely, but carryback is generally prohibited. NOLs generated in tax years beginning before January 1, 2018 will not be subject to the taxable income limitation, and NOLs generated in tax years ending before January 1, 2018 will continue to have a two-year carryback and 20-year carryforward period. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The limitations in the carryforward/carryback periods, as well as the limitation on use of NOLs for NOLs arising in tax years beginning after December 31, 2017 may significantly impact our ability to utilize our NOLs to offset taxable income in the future.

In order to realize the future tax benefits of our NOL carryforwards, we must generate taxable income, of which there is no assurance. Accordingly, we have provided a full valuation allowance for deferred tax assets as of September 30, 2022 and December 31, 2021.

Risks Related to the Development and Commercialization of Our Product Candidates

Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.

We have invested a significant portion of our time and financial resources in the development of AT-007, AT-001 and AT-003. Our business is dependent on our ability to successfully complete development of, obtain regulatory approval for, and, if approved, successfully commercialize our product candidates in a timely manner. We may face unforeseen challenges in our drug development strategy, and we can provide no assurances that our drug design will prove to be effective, that we will be able to take advantage of expedited regulatory pathways for any of our product candidates, or that we will ultimately be successful in our future clinical trials.

We have not obtained regulatory approval for any product candidate, and it is possible that any product candidates we may seek to develop in the future will not obtain regulatory approval. Neither we nor any future collaborator is permitted to market any product candidates in the United States or abroad until we receive regulatory

49

approval from the FDA or applicable foreign regulatory agency. The time required to obtain approval or other marketing authorizations by the FDA and comparable foreign regulatory authorities is unpredictable and typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions.

Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program, requiring their alteration.

Of the large number of products in development, only a small percentage successfully complete the FDA or comparable foreign regulatory authorities approval processes and are commercialized. The lengthy approval or marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval or marketing authorization to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects.

Even if we eventually complete clinical testing and receive approval of a new drug application, or NDA, or foreign marketing for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.

In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.

Furthermore, even if we obtain regulatory approval for our product candidates, we will still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third party and government payors, including government health administration authorities. If we are unable to successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business.

The development of additional product candidates is risky and uncertain, and we can provide no assurances that we will be able to replicate our approach to drug development for other disease indications.

Efforts to identify, acquire or in-license, and then develop, product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development, approved products or commercial revenues for many reasons, including the following:

the methodology used may not be successful in identifying potential product candidates;
competitors may develop alternatives that render any product candidates we develop obsolete;

50

any product candidates we develop may be covered by third parties’ patents or other exclusive rights;
a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
a product candidate may not be accepted as safe and effective by physicians, patients, the medical community or third party payors.

We have limited financial and management resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we may not be successful in replicating our approach to drug development for other disease indications. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business may be harmed.

Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals.

Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Preclinical studies and Phase 1 clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules. Success in preclinical studies and earlier clinical trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through earlier clinical trials.

In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.

Clinical drug development involves a lengthy and expensive process. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.

We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval from the FDA or other comparable regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome.

A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product

51

candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.

We may experience numerous unforeseen events prior to, during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including the following:

delays in reaching a consensus with regulatory authorities on the design or implementation of our clinical trials;
regulators or institutional review boards, or IRBs, may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites;
the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate or fail to return for post-treatment follow-up or we may fail to recruit suitable patients to participate in a trial;
clinical trials of our product candidates may produce negative or inconclusive results;
imposition of a clinical hold by regulatory authorities as a result of a serious adverse event, concerns with a class of product candidates or after an inspection of our clinical trial operations, trial sites or manufacturing facilities;
occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;
changes in regulatory requirements and guidance that require amending or submitting new clinical protocols; or
we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs.

Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future drug sales or other sources. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing drugs to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.

Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:

be delayed in obtaining marketing approval, or not obtain marketing approval at all;
obtain approval for indications or patient populations that are not as broad as intended or desired;
obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including in the form of a risk evaluation and mitigation strategy, or REMS;
be subject to additional post-marketing testing requirements;
be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements;
have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified REMS;
be subject to the addition of labeling statements, such as warnings or contraindications;
be sued; or
experience damage to our reputation.

52

Our product development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.

Further, we, the FDA or an IRB may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA’s current Good Clinical Practice, or GCP, regulations, that we are exposing participants to unacceptable health risks, or if the FDA finds deficiencies in our investigational new drug applications, or INDs, or the conduct of these trials. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenues from our product candidates may be delayed.

All of our current product candidates that have proceeded to clinical trials target inhibition of aldose reductase. There can be no assurance that aldose reductase inhibitors will ever receive regulatory approval.

All of our current product candidates that have proceeded to clinical trials target inhibition of the aldose reductase enzyme. There are no currently approved aldose reductase inhibitors on the market outside of Japan, India and China, and there can be no assurance that aldose reductase inhibitors will ever receive regulatory approval in all other countries, including the United States. Prior attempts to inhibit this enzyme were hindered by nonselective, nonspecific inhibition, which resulted in limited efficacy and significant off-target safety effects. Our current product candidates, including AT-007, AT-001 and AT-003, may face similar or different challenges that prevent their successful commercialization.

We may not be able to obtain or maintain rare pediatric disease designation or exclusivity for our product candidates, which could limit the potential profitability of our product candidates.

We have obtained orphan drug designation and rare pediatric disease designation, from the FDA for AT-007 for the treatment of galactosemia and PMM2-CDG. The FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is defined as a disease or condition that either affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals, there is no reasonable expectation that sales of the drug in the United States will be sufficient to offset the costs of developing and making the drug available in the United States. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

For the purposes of the rare pediatric disease program, a “rare pediatric disease” is a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years or a rare disease or conditions within the meaning of the Orphan Drug Act. Under the FDA’s rare pediatric disease priority review voucher, or RPD-PRV, program, upon the approval of an NDA for the treatment of a rare pediatric disease, the sponsor of such application would be eligible for an RPD-PRV that can be used to obtain priority review for a subsequent NDA. The sponsor of the application may transfer (including by sale) the RPD-PRV to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. Congress has extended the RPD-PRV program until September 30, 2024, with potential for vouchers to be granted until 2026. This program has been subject to criticism, including by the FDA. As such it is possible that even though we have obtained qualification for a RPD-PRV, the program may no longer be in effect at the time of approval. Also, although priority review vouchers may be sold or transferred to third parties, there is no guaranty that we will be able to realize any value if we obtained, and subsequently were able to sell a priority review voucher. The RPD-PRV program is currently scheduled to sunset as of September 30, 2026.

53

A breakthrough therapy designation by the FDA for a product candidate may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the product candidate will receive marketing approval.

We may seek a breakthrough therapy designation for one or more product candidates. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the NDA.

Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.

We have sought, and may in the future seek, fast track designation from the FDA for our product candidates. Even if granted, fast track designation may not actually lead to a faster development, regulatory review or approval process.

If a product candidate is intended for the treatment of a serious or life-threatening condition and demonstrates the potential to address unmet needs for this condition, the sponsor may apply for FDA fast track designation. If fast track designation is obtained, the FDA may prioritize interactions with the sponsor concerning the designated development program and initiate review of sections of an NDA before the application is complete, known as “rolling review.” Fast track designation would not ensure that we would experience a faster development, regulatory review or approval process compared to conventional FDA procedures or that we would ultimately obtain regulatory approval. Additionally, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program.

54

We intend to seek approval from the FDA through the use of accelerated registration pathways. If we are unable to obtain approval under an accelerated pathway, we may be required to conduct additional preclinical studies or clinical trials, which could increase the expense of obtaining, reduce the likelihood of obtaining and/or delay the timing of obtaining, necessary marketing approvals. Even if we receive approval from the FDA to utilize an accelerated registration pathway, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.

We intend to seek an accelerated approval development pathway for our product candidates. Under the accelerated approval provisions of the Federal Food, Drug, and Cosmetic Act, or the FDCA, and the FDA’s implementing regulations, the FDA may grant accelerated approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval development pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical profile or risks and benefits for accelerated approval. The FDA may require that any such confirmatory studies be initiated or substantially underway prior to the submission of an application for accelerated approval. If such post-approval studies fail to confirm the drug’s clinical profile or risks and benefits, the FDA may withdraw its approval of the drug. Because we are still in early stages of our clinical trials, we can provide no assurances that our biomarker-based approach will be successful in demonstrating a causal link to the relevant outcomes we are evaluating. If our approach is not successful, we may be required to conduct longer clinical trials.

If we choose to pursue accelerated approval, we intend to seek feedback from the FDA or will otherwise evaluate our ability to seek and receive such accelerated approval. There can be no assurance that, after our evaluation of the feedback from the FDA or other factors, we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Furthermore, even if we submit an application for accelerated approval, there can be no assurance that the application will be accepted or that approval will be granted on a timely basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting approval of any type. We might not be able to fulfill the FDA’s requirements in a timely manner, which would cause delays, or approval might not be granted because our submission is deemed incomplete by the FDA. A failure to obtain accelerated approval or any other form of expedited development, review or approval for a product candidate would result in a longer time period to commercialize such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

Even if we receive accelerated approval from the FDA, we will be subject to rigorous post-marketing requirements, including the completion of confirmatory post-market clinical trial(s) to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their dissemination. The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required post-market study with due diligence, a post-market study does not confirm the predicted clinical benefit, other evidence shows that the product is not safe or effective under the conditions of use, or we disseminate promotional materials that are found by the FDA to be false or misleading.

A failure to obtain accelerated approval or any other form of expedited development, review or approval for a product candidate that we may choose to develop would result in a longer time period prior to commercializing such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.

55

Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.

Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial. Because our focus includes rare disorders, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. Accordingly, enrollment of our clinical trials could take significantly longer than projected, which would delay any potential approval of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials.

Our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. Any negative results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to ensure their actual performance.

For additional information regarding delays in enrollment and retention of patients, see “Risks Related to Our Business Operations, Employee Matters and Managing Growth—Our business may be adversely affected by the recent coronavirus outbreak.”

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.

During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm these determinations, if they occur.

In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects or patients. Many times, side effects are only detectable after investigational drugs are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, prospects, operating results and financial condition.

Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publish interim, “top-line” or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or “top-line” data also

56

remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.

The incidence and prevalence for target patient populations of our product candidates have not been established with precision. If the market opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer.

We currently focus our drug development on product candidates for the treatment of diseases with high unmet medical need. Our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidates. Our estimates of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on our beliefs and analyses. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be receptive to treatment with our product candidates, and new patients may become increasingly difficult to identify or access. If the market opportunities for our product candidates are smaller than we estimate, we may not be able to achieve our forecast revenue, which could hinder our business plan and adversely affect our business and results of operations.

We may face substantial competition, which may result in others developing or commercializing drugs before or more successfully than us.

The development and commercialization of new drugs is highly competitive. We may face potential competition with respect to our current product candidates and may face competition with respect to any other product candidates that we may seek to develop or commercialize in the future from pharmaceutical and biotechnology companies, academic institutions, government agencies and other public and private research institutions.

Our competitors may have an advantage over us due to their greater size, resources and institutional experience. In particular, these companies have greater experience and expertise in securing reimbursement, government contracts and relationships with key opinion leaders, conducting testing and clinical trials, obtaining and maintaining regulatory approvals and distribution relationships to market products and marketing approved drugs. These companies also have significantly greater research and marketing capabilities than we do. If we are not able to compete effectively against existing and potential competitors, our business and financial condition may be harmed.

As a result of these factors, our competitors may obtain regulatory approval of their drugs before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful than we are in manufacturing and marketing their drugs. These advantages could render our product candidates obsolete or non-competitive before we can recover the costs of such product candidates’ development and commercialization.

Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third-parties compete with us in recruiting and retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

57

We may explore strategic collaborations that may never materialize or we may be required to relinquish important rights to and control over the development and commercialization of our product candidates to any future collaborators.

Over time, our business strategy includes acquiring or in-licensing additional product candidates for treatments of diseases with high unmet medical need. As a result, we intend to periodically explore a variety of possible strategic collaborations in an effort to gain access to additional product candidates or resources. These strategic collaborations may include partnerships with large strategic partners, particularly for the development of DPN treatments using AT-001. At the current time however, we cannot predict what form such a strategic collaboration might take. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any strategic collaborations because of the numerous risks and uncertainties associated with establishing them.

Future collaborations could subject us to a number of risks, including:

we may be required to undertake the expenditure of substantial operational, financial and management resources;
we may be required to issue equity securities that would dilute our stockholders’ percentage ownership of our company;
we may be required to assume substantial actual or contingent liabilities;
we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates;
strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so;
strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing;
strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs;
strategic collaborators may not commit adequate resources to the marketing and distribution of our product candidates, limiting our potential revenues from these products;
disputes may arise between us and our strategic collaborators that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management’s attention and consumes resources;
strategic collaborators may experience financial difficulties;
strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation;
business combinations or significant changes in a strategic collaborator’s business strategy may adversely affect a strategic collaborator’s willingness or ability to complete its obligations under any arrangement;
strategic collaborators could decide to move forward with a competing product candidate developed either independently or in collaboration with others, including our competitors; and
strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates.

Even if any product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third party payors or others in the medical community necessary for commercial success.

Even if any product candidates receive marketing approval, they may fail to gain market acceptance by physicians, patients, third party payors and others in the medical community. If such product candidates do not achieve an adequate level of acceptance, we may not generate significant drug revenue and may not become profitable. The

58

degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:

the convenience and ease of administration compared to alternative treatments and therapies;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the efficacy and potential advantages compared to alternative treatments and therapies;
the effectiveness of sales and marketing efforts;
the strength of our relationships with patient communities;
the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments;
our ability to offer such drug for sale at competitive prices;
the strength of marketing and distribution support;
the availability of third party coverage and adequate reimbursement;
the prevalence and severity of any side effects; and
any restrictions on the use of the drug together with other medications.

Our efforts to educate physicians, patients, third-party payors and others in the medical community on the benefits of our product candidates may require significant resources and may never be successful. Such efforts may require more resources than are typically required due to the complexity and uniqueness of our product candidates. Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business.

Even if we obtain regulatory approvals for our product candidates, they will remain subject to ongoing regulatory oversight.

Even if we obtain regulatory approvals for our product candidates, such approvals will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record keeping and submission of safety and other post-market information. Any regulatory approvals that we receive for our product candidates may also be subject to a REMS, limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 trials, and surveillance to monitor the quality, safety and efficacy of the drug. Such regulatory requirements may differ from country to country depending on where we have received regulatory approval.

In addition, drug manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, requirements and adherence to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a drug, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug is manufactured or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing.

If we fail to comply with applicable regulatory requirements following approval of our product candidates, a regulatory authority may, among other actions:

issue an untitled letter or warning letter asserting that we are in violation of the law;
seek an injunction or impose administrative, civil or criminal penalties or monetary fines;
suspend or withdraw regulatory approval;
suspend any ongoing clinical trials;
refuse to approve a pending NDA or comparable foreign marketing application or any supplements thereto submitted by us or our partners;
restrict the marketing or manufacturing of the drug;

59

seize or detain the drug or otherwise require the withdrawal of the drug from the market;
refuse to permit the import or export of product candidates; or
refuse to allow us to enter into supply contracts, including government contracts.

Moreover, the FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant civil, criminal and administrative penalties.

Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and harm our business, financial condition, results of operations and prospects.

The FDA’s and other regulatory authorities’ policies may change and additional laws or government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are not able to maintain regulatory compliance with the FDCA, Cures Act, or other applicable requirements, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.

In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the U.S. administration may impact our business and industry. It is difficult to predict how executive actions, including executive orders, may be implemented and the extent to which they will affect the FDA’s ability to exercise its regulatory authority. If legislative, administrative or executive actions impose constraints on the FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing them, if and when they are approved.

To successfully commercialize any product candidate that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any drug launch. Moreover, we cannot be certain that we will be able to successfully develop this capability. We may seek to enter into collaborations with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate sufficient revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval outside the United States, which would limit our market opportunities.

Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory

60

authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for our product candidates in the European Union from the European Commission following the opinion of the European Medicines Agency, or the EMA, if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the EMA may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.

Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.

If we commercialize our product candidates outside the United States, a variety of risks associated with international operations could harm our business.

We intend to seek approval to market our product candidates outside the United States, and may do so for future product candidates. If we market approved products outside the United States, we expect that we will be subject to additional risks in commercialization, including:

different regulatory requirements for approval of therapies in foreign countries;
reduced protection for intellectual property rights;
unexpected changes in tariffs, trade barriers and regulatory requirements;
economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;
foreign reimbursement, pricing and insurance regimes;
workforce uncertainty in countries where labor unrest is more common than in the United States;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
business interruptions resulting from geopolitical actions, including war and terrorism, international hostilities, or natural disasters including earthquakes, typhoons, floods and fires.

We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their products in foreign countries to be challenging.

Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.

We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot

61

successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

decreased demand for any product candidate that we may develop;
loss of revenue;
substantial monetary awards to trial participants or patients;
significant time and costs to defend the related litigation;
withdrawal of clinical trial participants;
increased insurance costs;
the inability to commercialize any product candidate that we may develop; and
injury to our reputation and significant negative media attention.

Any such outcomes could negatively impact our business, financial condition, results of operations and prospects.

Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.

Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. We have observed rapidly changing conditions in the insurance markets relating to nearly all areas of traditional corporate insurance. Such conditions have resulted in higher premium costs, higher policy deductibles, and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.

Risks Related to Regulatory Compliance

Our relationships with customers, physicians, and third party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.

Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute, the federal civil and criminal false claims laws and the law commonly referred to as the Physician Payments Sunshine Act and regulations.

Ensuring that our business arrangements with third-parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.

If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions

62

from government-funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.

Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell profitably, if approved.

Market acceptance and sales of any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor’s determination to provide coverage for a drug does not assure that other payors will also provide coverage, and adequate reimbursement, for the drug. Additionally, a third-party payor’s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its formulary it will be placed. The position on a payor’s list of covered drugs, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our product candidates, if approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.

Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any drug for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize any product candidates that we develop.

Healthcare reform measures may have a negative impact on our business and results of operations.

In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes, as well as judicial challenges, regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.

63

Further, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or, collectively, the PPACA, was passed, which substantially changed the way healthcare is financed by both governmental and private payors in the United States. Some of the provisions of the PPACA have yet to be fully implemented, while certain provisions have been subject to executive, judicial and Congressional challenges. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, which is commonly referred to as the “individual mandate.” Additionally, on January 22, 2018, then-President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain PPACA-mandated fees, including the so-called “Cadillac” tax on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the PPACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the “donut hole.” In July 2018, CMS published a final rule permitting further collections and payments to and from certain PPACA-qualified health plans and health insurance issuers under the PPACA adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate was a critical and inseverable feature of the PPACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the PPACA were invalid as well. In December 2019, the U.S. Court of Appeals for the Fifth Circuit upheld the lower court decision, which was then appealed to the U.S. Supreme Court. The U.S. Supreme Court heard arguments in the case in November 2020 and issued its decision in June 2021, ruling that the plaintiffs lacked the standing to challenge the individual mandate provision. In so holding, the Supreme Court did not consider larger constitutional questions about the validity of this provision or the validity of the PPACA in its entirety. Another case challenging the PPACA’s requirement that insurers cover certain preventative services is currently pending before the same U.S. District Court Judge in the Northern District of Texas who ruled against the individual mandate in 2018. In September 2022, the judge held that certain preventative services violated the U.S. Constitution and set a schedule for additional briefing that will expand into January 2023. It is unclear how this or any potential future litigation and other efforts to repeal and replace the PPACA will impact the PPACA. Congress may consider additional legislation to repeal or repeal and replace other elements of the PPACA. We continue to evaluate the effect that the PPACA and its possible repeal and replacement may have on our business and the potential profitability of our product candidates.

Other legislative changes have been proposed and adopted since the PPACA was enacted. These changes include aggregate reductions to Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, including the BBA, which will remain in effect through 2027 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

Additional changes that may affect our business include the expansion of programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015. At this time, the full impact of the introduction of the Medicare quality payment program on overall physician reimbursement is unclear.

Further, in the United States there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs. While some of the proposed measures will require authorization through additional legislation to become effective, the U.S. Congress have indicated that they will continue to seek new legislative and/or administrative measures to control drug costs. For example, on April 21, 2021, the Lower Costs, More Cures Act of 2021 was introduced, a bill intended to reduce Medicare and Medicaid prescription drug prices, including by restructuring the Medicare Part B reimbursement and Medicare Part D benefit and modifying aspects of the Medicaid Drug Rebate Program. An even more restrictive bill, the Lower Drug Costs Now Act, was introduced in the House of

64

Representatives on September 19, 2019, and re-introduced on April 22, 2021, and would require the U.S. Department of Health and Human Services (HHS) to directly negotiate drug prices with manufacturers. The Biden Administration’s Prescription Drug Pricing Plan as part of the House-passed Build Back Better Act also seeks to reduce prescription drug costs by, among other provisions, allowing Medicare to negotiate prices for certain high-cost prescription drugs in Medicare Parts B and D, imposing an excise tax on pharmaceutical manufacturers that refuse to negotiate pricing with Medicare, requiring inflation rebates to limit annual drug price increases in Medicare and private insurance, redesigning the Medicare Part D formula, and limiting cost-sharing for insulin products. It is unclear whether such measures will be acted, and if enacted, what effect they would have on our business. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current or any future product candidates or additional pricing pressures. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

Further, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.

We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved drug, which could have an adverse effect on demand for our product candidates if they are approved. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.

Risks Related to Our Dependence on Third Parties

We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.

We do not own or operate facilities for drug manufacturing, storage and distribution, or testing. We are dependent on third parties to manufacture the clinical supplies of our current and any future product candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the cGMP requirements, for manufacture of both active drug substance and finished drug product. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.

We also intend to rely on third-party manufacturers to supply us with sufficient quantities of our product candidates to be used, if approved, for commercialization. We do not yet have a commercial supply agreement for

65

commercial quantities of drug substance or drug product. If we are not able to meet market demand for any approved product, it would negatively impact our ability to generate revenue, harm our reputation, and could have an adverse effect on our business and financial condition.

Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including:

inability to meet our product specifications and quality requirements consistently;
delay or inability to procure or expand sufficient manufacturing capacity;
issues related to scale-up of manufacturing;
costs and validation of new equipment and facilities required for scale-up;
our third party manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately;
our third party manufacturers may fail to comply with cGMP requirements and other inspections by the FDA or other comparable regulatory authorities;
our inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all;
breach, termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us;
reliance on single sources for drug components;
lack of qualified backup suppliers for those components that are currently purchased from a sole or single-source supplier;
our third party manufacturers may not devote sufficient resources to our product candidates;
we may not own, or may have to share, the intellectual property rights to any improvements made by our third party manufacturers in the manufacturing process for our product candidates;
operations of our third party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; and
carrier disruptions or increased costs that are beyond our control.

In addition, if we enter into a strategic collaboration with a third party for the commercialization of our current or any future product candidates, we will not be able to control the amount of time or resources that they devote to such efforts. If any strategic collaborator does not commit adequate resources to the marketing and distribution of our product candidates, it could limit our potential revenues.

Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize our current or any future product candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production.

Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.

Our research and development activities and our third-party manufacturers’ and suppliers’ activities involve the generation, storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds and wastes. We and our manufacturers and suppliers are subject to environmental, health and safety laws and regulations governing, among other matters, the use, manufacture, generation, storage, handling, transportation, discharge and disposal of these hazardous materials and wastes and worker health and safety. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities pending their use and disposal. We cannot eliminate the risk of contamination or injury, which could result in an interruption of our commercialization efforts, research and development efforts and business operations, damages and significant cleanup costs and liabilities under applicable environmental, health and safety laws and regulations. We also cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these

66

materials and wastes generally comply with the standards prescribed by these laws and regulations. We may be held liable for any resulting damages, costs or liabilities, which could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Failure to comply with these environmental, health and safety laws and regulations may result in substantial fines, penalties or other sanctions. We do not currently carry environmental insurance coverage.

We rely on third-parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.

We do not currently have the ability to independently conduct any clinical trials. We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of our CROs’ activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.

We and our CROs are required to comply with the good laboratory practices, or GLPs, and GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.

Our reliance on third parties to conduct clinical trials will result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Such parties may:

have staffing difficulties;
fail to comply with contractual obligations;
experience regulatory compliance issues; or
undergo changes in priorities or become financially distressed.

These factors may adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond our control. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or fail to comply with regulatory requirements, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. While we will have agreements governing their activities, our CROs will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our business. We face the risk of potential unauthorized disclosure or

67

misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology.

If our relationship with any of these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. While we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition and prospects.

In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates.

Risks Related to Our Intellectual Property

Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. If we breach our license agreements with Columbia University or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the related product.

The licensing of intellectual property is of critical importance to our business and to our current and future product candidates, and we expect to enter into additional such agreements in the future. In particular, our current product candidates AT-007, AT-001 and AT-003 are dependent on our license agreement with The Trustees of Columbia University in the City of New York, or Columbia University. Pursuant to that license agreement with Columbia University, or the 2016 Columbia Agreement, Columbia University granted us an exclusive license under two important patent families, and a nonexclusive license to certain know-how, owned by Columbia University to develop, manufacture or commercialize certain compounds, including AT-001, AT-003 and AT-007, for the diagnosis and treatment of human and animal diseases and conditions. The license grant is worldwide, with the exception of the patent family that covers AT-001 and AT-003. The license grant for the patent family that covers AT-001 and AT-003 excludes patent rights in China, Taiwan, Hong Kong and Macao, which Columbia University has exclusively licensed to a third party. We cannot prevent Columbia University’s third party licensee from developing, manufacturing or commercializing certain compounds, including AT-001 and AT-003, but not including AT-007, in China, Taiwan, Hong Kong and Macao, and we cannot develop, manufacture or commercialize AT-001 or AT-003 in these territories, which could have a negative effect on our business.

We do not have the right to control the preparation, filing, prosecution and maintenance of patents and patent applications covering the technology that we license under either of the Columbia Agreements. Therefore, we cannot always be certain that these patents and patent applications will be prepared, filed, prosecuted and maintained in a manner consistent with the best interests of our business. Although we have a right to have our comments considered in connection with the prosecution process, if Columbia University fails to prosecute and maintain such patents, or loses rights to those patents or patent applications as a result of its control of the prosecution activities, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our product candidates that are the subject of such licensed rights could be adversely affected.

If we fail to meet our obligations under the Columbia Agreement in any material respect and fail to cure such breach in a timely fashion, then Columbia University may terminate such Columbia Agreement. If either Columbia Agreement is terminated, and we lose our intellectual property rights under such Columbia Agreement, this may result in complete termination of our product development and any commercialization efforts for the product candidates that are

68

subject to such agreement, including AT-007, AT-001, and AT-003. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the Columbia Agreement, we may not be able to do so in a timely manner, at an acceptable cost or at all.

Furthermore, license agreements we enter into in the future may not provide exclusive rights to use intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.

If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.

Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and our technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and our technology that are important to our business.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by such third party, or by the U.S. Patent and Trademark Office, or USPTO, itself, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.

The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.

Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development,

69

testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.

Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various government patent agencies outside the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from marketing products that are the same as or similar to our product candidates, which would have an adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.

In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent owner.

Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.

Given the amount of time required for the development, testing and regulatory review of product candidates such as AT-007, AT-001, and AT-003, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the

70

patent; provided that the patent is not enforceable for more than 14 years from the date of drug approval, which is limited to the approved indication (or any additional indications approved during the period of extension). Furthermore, only one patent per approved product can be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their drug earlier than might otherwise be the case.

Third-parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.

Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, post grant review and inter partes review before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could have a negative impact on our ability to commercialize our current and any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this is a high burden and requires us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Moreover, given the vast number of patents in our field of technology, we cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. Other companies and research institutions have filed, and may file in the future, patent applications related to AR inhibitors and their therapeutic use. Some of these patent applications have already been allowed or issued, and others may issue in the future. While we may decide to initiate proceedings to challenge the validity of these or other patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold the validity of any such patent. Furthermore, because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed, we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes that our product candidate infringes its patent, the patent holder may sue us even if we have received patent protection for our technology. Moreover, we may face patent infringement claims from nonpracticing entities that have no relevant drug revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the drug or product candidate that is the subject of the actual or threatened suit.

If we are found to infringe a third party’s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all.

71

The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have an adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third-parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. In addition, we could be found liable for monetary damages, including treble damages and attorneys’ fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time-consuming and would divert management’s attention from our core business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.

Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.

We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.

Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.

72

We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third-party to bring counterclaims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.

We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, or if the license offered as a result is not on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.

We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.

Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current and any future product candidates.

Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the America

73

Invents Act, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. The America Invents Act also includes a number of significant changes that affect the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business, financial condition, results of operations, and prospects.

In addition, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce patents that we own, have licensed or might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.

We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.

Filing, prosecuting and defending patents covering our current and any future product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.

74

Reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Since we rely on third parties to help us discover, develop and manufacture our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business and results of operations.

In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets. Despite our efforts to protect our trade secrets, we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators, or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into nondisclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees, advisors and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.

Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or

75

those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.

We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.

Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.

We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. We have selected trademarks for some of our later stage product candidates and filed applications to register those trademarks for our current or any future product candidates. For other earlier stage product candidates, we have not yet selected trademarks or begun the process of applying to register trademarks. Our pending trademark applications, and any future trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.

In addition, any proprietary name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.

Intellectual property rights do not necessarily address all potential threats to our business.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:

others may be able to make compounds or formulations that are similar to our product candidates but that are not covered by the claims of any patents, should they issue, that we own or license;
we or our licensors might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or license;
we or our licensors might not have been the first to file patent applications covering certain of our inventions;
others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
it is possible that our pending patent applications will not lead to issued patents;
issued patents that we own or license may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;
our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;

76

we may not develop additional proprietary technologies that are patentable; and
the patents of others may have an adverse effect on our business.

Risks Related to Our Business Operations, Employee Matters and Managing Growth

We are highly dependent on the services of our Chief Executive Officer and Chairman, Dr. Shoshana Shendelman, and our Chief Medical Officer, Dr. Riccardo Perfetti, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.

We are highly dependent on our Chief Executive Officer and Chairman, Dr. Shoshana Shendelman, and our Chief Medical Officer, Dr. Riccardo Perfetti. Each of them may currently terminate their employment with us at any time. The loss of the services of either of these persons could impede the achievement of our research, development and commercialization objectives.

Recruiting and retaining other senior executives, qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.

Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations. Additionally, we do not currently maintain “key person” life insurance on the lives of our executives or any of our employees.

We expect to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.

As of September 30, 2022, we had 26 full-time employees. As the clinical development of our product candidates progresses, we also expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, drug development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

77

Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a significant disruption of our product development programs and our ability to operate our business effectively, and adversely affect our business and operating results.

Our internal computer systems, cloud-based computing services and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage or interruption from computer viruses, data corruption, cyber-based attacks (including phishing attempts, denial of service attacks, and malware or ransomware incidents), unauthorized access, natural disasters, terrorism, war, international hostilities and telecommunication and electrical failures. While we have not experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Furthermore, federal, state and international laws and regulations, such as the European Union’s General Data Protection Regulation, which took effect in May 2018, can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts fail. In addition, our software systems include cloud-based applications that are hosted by third-party service providers with security and information technology systems subject to similar risks. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.

Risks of unauthorized access and cyber-attacks have increased as most of our personnel, and the personnel of many third-parties with which we do business, have adopted remote working arrangements as a result of the Covid-19 pandemic, and may increase as a result of recent hostilities between Russia and Ukraine. Improper or inadvertent employee behavior, including data privacy breaches by employees, contractors and others with permitted access to our systems, may also pose a risk that sensitive data may be exposed to unauthorized persons or to the public. If a system failure or security breach occurs and interrupts our operations or the operations at one of our third-party vendors, it could result in intellectual property and other proprietary or confidential information being lost or stolen or a material disruption of our drug development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate disclosure of confidential or proprietary information, including protected health information or personal data of employees or former employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks by hackers or other malfeasance. This type of breach of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or reputation or result in legal or regulatory proceedings. In addition, if a ransomware attack or other cyber-attack occurs, either internally or at our third-party vendors, we could be prevented from accessing our systems or data, which may cause interruptions or delays in our business, cause us to incur remediation costs or subject us to demands to pay ransom, or adversely affect our business reputation.

Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in other jurisdictions, provide accurate information to the FDA and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of

78

clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.

Any future acquisitions or strategic collaborations may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and/or subject us to other risks.

From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses, as deemed appropriate to carry out our business plan. Any potential acquisition or strategic partnership may entail numerous risks, including:

increased operating expenses and cash requirements;
the assumption of additional indebtedness or contingent or unknown liabilities;
assimilation of operations, intellectual property and drugs of an acquired company, including difficulties associated with integrating new personnel;
the diversion of our management’s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;
retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;
risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or product candidates and regulatory approvals; and
our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.

In addition, if we engage in future acquisitions or strategic partnerships, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses, and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to technology or drugs that may be important to the development of our business.

Our business may be adversely affected by the coronavirus outbreak.

The Covid-19 pandemic, (“Covid-19”) has had and may continue to have a material impact on our operations. Infections and deaths related to Covid-19 continue to disrupt the United States’ healthcare and healthcare regulatory systems. Such disruptions could divert healthcare resources away from, or materially delay FDA approval with respect to, our clinical trials. In addition, other known and unknown factors caused by Covid-19 could materially delay our clinical trials, including our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to Covid-19. For example, with respect to our trials related to AT-001 for the treatment of Diabetic Cardiomyopathy, we have experienced, and continued to experience, delays in patient enrollment. Furthermore, we may experience additional delays in patient enrollment that we may not be able to mitigate. In addition, we have partnered with clinical research organizations, or CROs, to conduct clinical studies in jurisdictions, such as the EU, that have been affected by the spread of Covid-19. There is a possibility that such CROs may become unavailable or that the clinical trials they manage may be delayed due to Covid-19 or containment efforts associated with it. Such events may lead to termination of our relationship with affected CROs, affecting the development and study of our product candidates. Any elongation or de-prioritization of our clinical trials or delay in regulatory review resulting from such disruptions could materially affect the development and study of our product candidates, and increase the

79

costs related to such development. While Covid-19 vaccines have become available both domestically and internationally, the effects of Covid-19, including the impacts described above may last longer than expected, extending such impacts, and materially impacting our business, financial condition, and results of operations. 

Risks Related to Ownership of Our Common Stock

The market price of our common stock is volatile and has fluctuated substantially, which could result in substantial losses for purchasers of our common stock.

The stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the price at which you purchased it. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this Quarterly Report, the market price for our common stock has been, and is likely to continue to be influenced by the following:

the commencement, enrollment, results of , or any delays in our planned or future clinical trials of our product candidates or those of our competitors;
the success of competitive drugs or therapies;
regulatory or legal developments in the United States and other countries;
the success of competitive products or technologies;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the recruitment or departure of key personnel;
the level of expenses related to our product candidates or clinical development programs;
the results of our efforts to discover, develop, acquire or in-license additional product candidates;
actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
our inability to obtain or delays in obtaining adequate drug supply for any approved drug or inability to do so at acceptable prices;
disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
the potential impact of the Covid-19 pandemic on the timing and progress of our ongoing clinical trials, our business, results of operations, liquidity, and operations and our ability to mitigate those potential impacts;
significant lawsuits, including patent or stockholder litigation;
variations in our financial results or those of companies that are perceived to be similar to us;
changes in the structure of healthcare payment systems, including coverage and adequate reimbursement for any approved drug;
market conditions in the pharmaceutical and biotechnology sectors;
general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad; and
investors’ general perception of us and our business.

These and other market and industry factors have caused the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock. Furthermore, we believe our stock has been, and may in the future be, adversely affected as a result of actions by third parties. Short sellers and others, some of whom post anonymously on social media, may be positioned to profit if our stock declines and their activities can negatively affect our stock price.

Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our management’s attention and our

80

resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock.

Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.

Based upon shares of our common stock outstanding as of September 30, 2022, and after giving effect to the February Offering and the June Offering, our executive officers, directors, and stockholders who owned more than 10% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately 44.4% of our outstanding common stock. If our executive officers, directors and stockholders who owned more than 10% of our outstanding common stock acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree.

Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.

You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. Investors seeking cash dividends should not purchase our common stock.

Future sales of common stock by holders of our common stock, or the perception that such sales may occur, could depress the market price of our common stock.

Sales of a substantial number of shares of our common stock in the public market could occur at any time, subject to certain restrictions described below. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. As of September 30, 2022, we had outstanding 48,058,956 shares of common stock. A substantial number of such shares are currently restricted as a result of securities laws or lock-up agreements but will be able to be sold in the future.

We further have registered all shares of common stock that we may issue in the future or have issued to date under our equity compensation plans. These shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and certain lock-up agreements. Sales of a large number of the shares issued under these plans in the public market could have an adverse effect on the market price of our common stock.

If we fail to regain compliance with the continued listing requirements of Nasdaq, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted. 

 

On November 3, 2022, we received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market, or Nasdaq, notifying us that, for the last 30 consecutive business days, the bid price for our common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market, referred to as the minimum bid price rule. In accordance with Nasdaq Listing Rules, we have an initial period of 180 calendar days, or until May 2, 2023, to regain compliance with the minimum bid price rule. If at any time before May 2, 2023 the bid price for our common stock closes at $1.00 or more per share for a minimum of 10 consecutive business days, the Nasdaq Listing Qualifications Department staff will provide written notification to us that we are in compliance with the minimum bid price rule, unless the staff exercises its discretion to extend this 10-day period pursuant to the Nasdaq Listing Rules.  If we do not regain compliance with the minimum bid price rule by May 2, 2023, we may be eligible for an additional 180 calendar day compliance period.  We intend to monitor the closing bid

81

price of our common stock and may, if appropriate, consider available options to regain compliance with the minimum bid price rule.

 

There are many factors that may adversely affect our minimum bid price, including those described throughout this section titled “Risk Factors.” Many of these factors are outside of our control. As a result, we may not be able to sustain compliance with the minimum bid price rule in the long term. Any potential delisting of our common stock from the Nasdaq Global Market would likely result in decreased liquidity and increased volatility for our common stock and would adversely affect our ability to raise additional capital or to enter into strategic transactions. Any potential delisting of our common stock from the Nasdaq Global Market would also make it more difficult for our stockholders to sell our common stock in the public market.

General Risk Factors

If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.

The trading market for our common stock will be influenced by the research and reports that industry or financial analysts publish about us or our business. Equity research analysts may discontinue research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. We do not have any control over the analysts, or the content and opinions included in their reports. The price of our shares could decline if one or more equity research analysts downgrade our shares or issue other unfavorable commentary or research about us. If one or more equity research analysts cease coverage of us or fail to publish reports on us regularly, demand for our shares could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.

We have broad discretion in the use of our cash and cash equivalents and may use them ineffectively, in ways with which you do not agree or in ways that do not increase the value of your investment.

Our management has broad discretion in the application of our cash and cash equivalents and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in additional operating losses that could have a negative impact on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.

We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.

We are an “emerging growth company,” or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of some of the exemptions from reporting requirements that are applicable to other public companies that are not EGCs, including:

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;
not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;
reduced disclosure obligations regarding executive compensation; and
not being required to hold a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

82

We cannot predict whether investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile. We currently take advantage of some or all of these reporting exemptions until we are no longer an EGC. We will remain an EGC until the earlier of (i) December 31, 2024, (ii) the last day of the fiscal year in which we have total annual gross revenue of at least $1.07 billion, (iii) the last day of the first fiscal year in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30th, and (iv) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

In addition, under Section 107(b) of the JOBS Act, EGCs can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not EGCs.

We have incurred increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.

As a public company, and particularly after we are no longer an EGC, we incur and will continue to incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules subsequently implemented by the SEC and The Nasdaq Stock Market LLC have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance.

Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we will be required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.

Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by

83

making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

establish a classified board of directors such that not all members of the board are elected at one time;
allow the authorized number of our directors to be changed only by resolution of our board of directors;
limit the manner in which stockholders can remove directors from the board;
establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;
require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;
limit who may call stockholder meetings;
authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a stockholder rights plan, or so-called “poison pill,” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and
require the approval of the holders of at least 662/3% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of our charter or bylaws.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock.

Our governing documents designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated certificate of incorporation provides that, with respect to any state actions or proceedings under Delaware statutory or common law, the Court of Chancery of the State of Delaware is the exclusive forum for:

any derivative action or proceeding brought on our behalf;
any action asserting a breach of fiduciary duty;
any action asserting a claim against us or any of our directors, officers, employees or agents arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws;
any action or proceeding to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws; and
any action asserting a claim against us or any of our directors, officers, employees or agents that is governed by the internal-affairs doctrine.

In addition, our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States are, to the fullest extent permitted by law, the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.

These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find an exclusive-forum provision in our amended and restated certificate of incorporation or our amended and restated bylaws to be inapplicable or unenforceable in an

84

action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could harm our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities.

Not applicable.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

On November 3, 2022, Applied Therapeutics, Inc. (the “Company”) received written notification (the “Notice”) from the Nasdaq Stock Market (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”).  The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market.  Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until May 2, 2023, to regain compliance with the Bid Price Requirement.  To regain compliance, the closing bid price of the Company’s common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive business days prior to May 2, 2023.

 

If the Company does not regain compliance by May 2, 2023, the Company may be eligible for an additional 180 calendar day grace period if it transfers the listing of its common stock to the Nasdaq Capital Market. 

 

The Company intends to monitor the closing bid price of its common stock and consider available options to regain compliance with the Bid Price Requirement, but no decisions about a response have been made at this time.  There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or will otherwise remain in compliance with other Nasdaq listing criteria.

85

Item 6. Exhibits.

Exhibit
Number

    

Description

31.1

Rule 13a-14(a)/15d-14(a) Certification under the Exchange Act by Shoshana Shendelman, President and Chief Executive Officer (Principal Executive Officer).

31.2

Rule 13a-14(a)/15d-14(a) Certification under the Exchange Act by Chids Mahadevan, Senior Vice President of Finance (Interim Principal Financial Officer).

32.1*

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Section 1350 Certifications.

32.2*

Certification of Interim Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Section 1350 Certifications.

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

XBRL Schema Document.

101.CAL

XBRL Calculation Linkbase Document.

101.DEF

XBRL Definition Linkbase Document.

101.LAB

XBRL Label Linkbase Document.

101.PRE

XBRL Presentation Linkbase Document.

104

Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

*     Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

86

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

    

APPLIED THERAPEUTICS, INC.

Date: November 9, 2022

By:

/s/ Shoshana Shendelman, Ph.D.

Shoshana Shendelman, Ph.D.

President and Chief Executive Officer

(Principal Executive Officer)

Date: November 9, 2022

By:

/s/ Chids Mahadevan

Chids Mahadevan

Senior Vice President of Finance

(Interim Principal Financial Officer)

87

EX-31.1 2 aplt-20220930xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Shoshana Shendelman, certify that:

1.           I have reviewed this Form 10-Q of Applied Therapeutics, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)         Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2022

By:

/s/ Shoshana Shendelman

Name:

Shoshana Shendelman, Ph.D.

Title:

Chief Executive Officer
(Principal Executive Officer)


EX-31.2 3 aplt-20220930xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Chids Mahadevan, certify that:

1.           I have reviewed this Form 10-Q of Applied Therapeutics, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)          Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)          Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)          Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)          Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)          All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)         Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2022

By:

/s/ Chids Mahadevan

Name:

Chids Mahadevan

Title:

Senior Vice President of Finance
(Interim Principal Financial Officer)


EX-32.1 4 aplt-20220930xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), the undersigned hereby certifies that, to the best of their knowledge:

1.

The Quarterly Report on Form 10-Q of Applied Therapeutics, Inc. (the “Company”) for the period ended September 30, 2022, to which this Certification is attached as Exhibit 32.1 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 9, 2022

By:

/s/ Shoshana Shendelman

Name:

Shoshana Shendelman, Ph.D.

Title:

Chief Executive Officer
(Principal Executive Officer)


EX-32.2 5 aplt-20220930xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), the undersigned hereby certifies that, to the best of their knowledge:

1.

The Quarterly Report on Form 10-Q of Applied Therapeutics, Inc. (the “Company”) for the period ended September 30, 2022, to which this Certification is attached as Exhibit 32.2 (the “Quarterly Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.

The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 9, 2022

By:

/s/ Chids Mahadevan

Name:

Chids Mahadevan

Title:

Senior Vice President of Finance
(Interim Principal Financial Officer)


EX-101.SCH 6 aplt-20220930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Condensed Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - FAIR VALUE MEASUREMENTS - FV hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - INVESTMENTS - By type (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - INVESTMENTS - By contractual maturity (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - INVESTMENTS - By contractual maturity (Details) (calc 2) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - INVESTMENTS - Unrealized losses and fair values of available-for-sale securities (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 41003 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 41004 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) (calc 2) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00405 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00505 - Statement - Condensed Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - STOCK BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock issued (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - LICENSE AGREEMENT - Columbia (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - LICENSE AGREEMENT - Miami University (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - FAIR VALUE MEASUREMENTS - Transfers (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - FAIR VALUE MEASUREMENTS - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - FAIR VALUE MEASUREMENTS - Warrants Valuation (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Values of Company's Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - INVESTMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - INVESTMENTS - Realized gains and losses (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - STOCK BASED COMPENSATION - Plans (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - STOCK BASED COMPENSATION - Options (Details) link:presentationLink link:calculationLink link:definitionLink 40705 - Disclosure - STOCK BASED COMPENSATION - Valuation assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40706 - Disclosure - STOCK BASED COMPENSATION - RSUs (Details) link:presentationLink link:calculationLink link:definitionLink 40707 - Disclosure - STOCK BASED COMPENSATION - 2019 Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - STOCKHOLDERS' EQUITY - Authorized stock (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock and Equity Distribution Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - STOCKHOLDERS' EQUITY - June 2022 Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - WARRANTS - Issued with Series A Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - WARRANTS - Issued with the 2018 Notes (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - WARRANTS - Issued with Series B Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - WARRANTS - Issued with June 2022 Offering (Details) link:presentationLink link:calculationLink link:definitionLink 40905 - Disclosure - WARRANTS - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - LEASES - Lease Cost (Details) link:presentationLink link:calculationLink link:definitionLink 41302 - Disclosure - NET LOSS PER COMMON SHARE - Anti-dilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - RELATED PARTIES (Details) link:presentationLink link:calculationLink link:definitionLink 41501 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - LICENSE AGREEMENT link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - STOCK BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - NET LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - RELATED PARTIES link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 31003 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - NET LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details) link:presentationLink link:calculationLink link:definitionLink 40704 - Disclosure - STOCK BASED COMPENSATION - Options activity (Details) link:presentationLink link:calculationLink link:definitionLink 41002 - Disclosure - LEASES - Lease terms and discount rates (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - BENEFIT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - NET LOSS PER COMMON SHARE - EPS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 aplt-20220930_cal.xml EX-101.CAL EX-101.DEF 8 aplt-20220930_def.xml EX-101.DEF EX-101.LAB 9 aplt-20220930_lab.xml EX-101.LAB EX-101.PRE 10 aplt-20220930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2022
Nov. 08, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 001-38898  
Entity Registrant Name Applied Therapeutics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-3405262  
Entity Address, Address Line One 545 Fifth Avenue  
Entity Address, Address Line Two Suite 1400  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10017  
City Area Code 212  
Local Phone Number 220-9226  
Title of 12(b) Security Common Stock  
Trading Symbol APLT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   48,058,956
Entity Central Index Key 0001697532  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Cash and cash equivalents $ 40,388 $ 53,888
Investments 6,990 26,935
Prepaid expenses and other current assets 8,132 7,571
Total current assets 55,510 88,394
Operating lease right-of-use asset 970 1,298
Security deposits and leasehold improvements 199 200
TOTAL ASSETS 56,679 89,892
CURRENT LIABILITIES:    
Current portion of operating lease liabilities 470 442
Accounts payable 6,973 9,461
Accrued expenses and other current liabilities 14,332 16,559
Warrant liability 24,739  
Total current liabilities 46,514 26,462
NONCURRENT LIABILITIES:    
Noncurrent portion of operating lease liabilities 536 891
Total noncurrent liabilities 536 891
Total liabilities 47,050 27,353
STOCKHOLDERS' EQUITY:    
Common stock, $0.0001 par value; 100,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 48,058,956 shares issued and outstanding as of September 30, 2022 and 26,215,514 shares issued and outstanding as of December 31, 2021 5 3
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021
Additional paid-in capital 343,995 328,958
Accumulated other comprehensive gain/(loss) 23 (107)
Accumulated deficit (334,394) (266,315)
Total stockholders' equity 9,629 62,539
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 56,679 $ 89,892
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
Condensed Balance Sheets    
Common Stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common Stock, authorized (in shares) 100,000,000 100,000,000
Common Stock, issued (in shares) 48,058,956 26,215,514
Common stock, outstanding (in shares) 48,058,956 26,215,514
Preferred Stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred Stock, authorized (in shares) 10,000,000 10,000,000
Preferred Stock, issued (in shares) 0 0
Preferred Stock, outstanding (in shares) 0 0
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
OPERATING EXPENSES:        
Research and development $ 13,116 $ 17,597 $ 43,542 $ 46,846
General and administrative 6,240 10,833 20,436 31,658
Total operating expenses 19,356 28,430 63,978 78,504
LOSS FROM OPERATIONS (19,356) (28,430) (63,978) (78,504)
OTHER INCOME (EXPENSE), NET:        
Interest income 227 76 414 321
Change in fair value of warrant liabilities 36   (4,321)  
Other expense (8) (64) (194) (242)
Total other income (expense), net 255 12 (4,101) 79
Net loss (19,101) (28,418) (68,079) (78,425)
Net loss attributable to common stockholders-basic (19,101) (28,418) (68,079) (78,425)
Net loss attributable to common stockholders-diluted $ (19,101) $ (28,418) $ (68,079) $ (78,425)
Net loss per share attributable to common stockholders-basic (in dollars per share) $ (0.40) $ (1.09) $ (2.02) $ (3.08)
Net loss per share attributable to common stockholders-diluted (in dollars per share) $ (0.40) $ (1.09) $ (2.02) $ (3.08)
Weighted-average common stock outstanding-basic (in shares) 48,000,183 26,177,079 33,785,386 25,472,590
Weighted-average common stock outstanding-diluted (in shares) 48,000,183 26,177,079 33,785,386 25,472,590
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Condensed Statements of Comprehensive Income (Loss)        
Net Loss $ (19,101) $ (28,418) $ (68,079) $ (78,425)
Other comprehensive income (loss)        
Unrealized gain (loss) on marketable securities 17 (69) 130 (142)
Other comprehensive gain (loss), net of tax 17 (69) 130 (142)
Comprehensive income (loss), net of tax $ (19,084) $ (28,487) $ (67,949) $ (78,567)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Total
Balance at Dec. 31, 2020 $ 2 $ 242,780 $ (160,731) $ (112) $ 81,939
Balance (in shares) at Dec. 31, 2020 22,493,661        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock $ 1 74,386     74,387
Issuance of common stock (in shares) 3,450,000        
Exercise of options for common stock issued under Equity Incentive Plan   67     67
Exercise of options for common stock issued under Equity Incentive Plan (in shares) 37,400        
Exercise of options for common stock not yet issued   (1)     (1)
Exercise of options for common stock not yet issued (in shares) (465)        
Restricted Stock Units released for common stock issued under Equity Incentive Plan (in shares) 1,988        
Exercise of warrants of common stock   69     69
Exercise of warrants of common stock (in shares) 27,855        
Stock-based compensation expense   2,981     2,981
Net loss     (24,179)   (24,179)
Other comprehensive income (loss)       (42) (42)
Balance at Mar. 31, 2021 $ 3 320,282 (184,910) (154) 135,221
Balance (in shares) at Mar. 31, 2021 26,010,439        
Balance at Dec. 31, 2020 $ 2 242,780 (160,731) (112) 81,939
Balance (in shares) at Dec. 31, 2020 22,493,661        
Increase (Decrease) in Stockholders' Equity          
Net loss         (78,425)
Balance at Sep. 30, 2021 $ 3 326,108 (239,156) (254) 86,701
Balance (in shares) at Sep. 30, 2021 26,214,399        
Balance at Mar. 31, 2021 $ 3 320,282 (184,910) (154) 135,221
Balance (in shares) at Mar. 31, 2021 26,010,439        
Increase (Decrease) in Stockholders' Equity          
Secondary public offering issuance costs   35     35
Issuance of common stock for options exercised in prior periods under Equity Incentive Plan   1     1
Issuance of common stock for options exercised in prior periods under Equity Incentive Plan (in shares) 465        
Exercise of options for common stock issued under Equity Incentive Plan   341     341
Exercise of options for common stock issued under Equity Incentive Plan (in shares) 82,668        
Exercise of options for common stock not yet issued   (1)     (1)
Exercise of options for common stock not yet issued (in shares) (920)        
Restricted Stock Units released for common stock issued under Equity Incentive Plan (in shares) 37,884        
Stock-based compensation expense   2,702     2,702
Net loss     (25,828)   (25,828)
Other comprehensive income (loss)       (31) (31)
Balance at Jun. 30, 2021 $ 3 323,360 (210,738) (185) 112,440
Balance (in shares) at Jun. 30, 2021 26,130,536        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock for options exercised in prior periods under Equity Incentive Plan   1     1
Issuance of common stock for options exercised in prior periods under Equity Incentive Plan (in shares) 920        
Exercise of options for common stock issued under Equity Incentive Plan   103     103
Exercise of options for common stock issued under Equity Incentive Plan (in shares) 70,368        
Exercise of options for common stock not yet issued   (1)     (1)
Exercise of options for common stock not yet issued (in shares) (115)        
Restricted Stock Units released for common stock issued under Equity Incentive Plan (in shares) 12,690        
Stock-based compensation expense   2,645     2,645
Net loss     (28,418)   (28,418)
Other comprehensive income (loss)       (69) (69)
Balance at Sep. 30, 2021 $ 3 326,108 (239,156) (254) 86,701
Balance (in shares) at Sep. 30, 2021 26,214,399        
Balance at Dec. 31, 2021 $ 3 328,958 (266,315) (107) 62,539
Balance (in shares) at Dec. 31, 2021 26,215,514        
Increase (Decrease) in Stockholders' Equity          
Restricted Stock Units released for common stock issued under Equity Incentive Plan (in shares) 21,417        
Restricted Stock Units released for common stock not yet issued (in shares) (21,417)        
Stock-based compensation expense   2,077     2,077
Issuance of options in-lieu of bonus   441     441
Net loss     (23,121)   (23,121)
Other comprehensive income (loss)       27 27
Balance at Mar. 31, 2022 $ 3 331,476 (289,436) (80) 41,963
Balance (in shares) at Mar. 31, 2022 26,215,514        
Balance at Dec. 31, 2021 $ 3 328,958 (266,315) (107) $ 62,539
Balance (in shares) at Dec. 31, 2021 26,215,514        
Increase (Decrease) in Stockholders' Equity          
Exercise of options for common stock issued under Equity Incentive Plan (in shares)         47,602
Net loss         $ (68,079)
Balance at Sep. 30, 2022 $ 5 343,995 (334,394) 23 9,629
Balance (in shares) at Sep. 30, 2022 48,058,956        
Balance at Mar. 31, 2022 $ 3 331,476 (289,436) (80) 41,963
Balance (in shares) at Mar. 31, 2022 26,215,514        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of issuance costs $ 2 5,966     5,968
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of issuance costs (in shares) 20,000,000        
Exercise of prefunded warrants for common stock   1,417     1,417
Exercise of prefunded warrants for common stock (in shares) 1,750,000        
Exercise of prefunded warrants for common stock not yet issued (in shares) (1,750,000)        
Issuance of common stock for Restricted Stock released in prior periods under Equity Incentive Plan (in shares) 21,417        
Restricted Stock Units released for common stock issued under Equity Incentive Plan (in shares) 16,593        
Stock-based compensation expense   2,231     2,231
Net loss     (25,857)   (25,857)
Other comprehensive income (loss)       86 86
Balance at Jun. 30, 2022 $ 5 341,090 (315,293) 6 25,808
Balance (in shares) at Jun. 30, 2022 46,253,524        
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock for pre-funded warrants exercised in prior periods (in shares) 1,750,000        
Exercise of options for common stock issued under Equity Incentive Plan   49     49
Exercise of options for common stock issued under Equity Incentive Plan (in shares) 47,602        
Restricted Stock Units released for common stock issued under Equity Incentive Plan (in shares) 7,830        
Stock-based compensation expense   2,856     2,856
Net loss     (19,101)   (19,101)
Other comprehensive income (loss)       17 17
Balance at Sep. 30, 2022 $ 5 $ 343,995 $ (334,394) $ 23 $ 9,629
Balance (in shares) at Sep. 30, 2022 48,058,956        
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Stockholders' Equity (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2022
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Increase (Decrease) in Stockholders' Equity        
Common Stock, par value (in dollars per share)     $ 0.0001  
Stock issuance costs $ 96 $ 203    
Common Stock        
Increase (Decrease) in Stockholders' Equity        
Common Stock, par value (in dollars per share)     $ 0.0001 $ 0.0001
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
OPERATING ACTIVITIES:    
Net loss $ (68,079) $ (78,425)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 7,164 8,328
Issuance of options in-lieu of bonus 441  
Amortization of insurance premium 2,806 3,163
Amortization of operating lease right-of-use assets 328 308
Amortization of leasehold improvements 1 1
Change in operating lease liability (327) (299)
Change in fair value of warrant liability 4,321  
Changes in operating assets and liabilities:    
Financed insurance premium (3,105) (4,434)
Prepaid expenses (262) (1,107)
Accounts payable (2,488) 8,530
Accrued expenses and other current liabilities (3,000) 149
Net cash used in operating activities (62,200) (63,786)
INVESTING ACTIVITIES:    
Purchase of available-for-sale securities (36,911) (109,119)
Proceeds from sale of available-for-sale securities   5,539
Proceeds from maturities of available-for-sale securities 56,986 104,206
Net cash provided by investing activities 20,075 626
FINANCING ACTIVITIES:    
Proceeds from June Offering issuance of shares and pre-funded warrants 27,811  
Proceeds from February Offering, net of cash issuance costs of $165   74,420
Proceeds from financed insurance premium 3,105 4,434
Repayments of short-term borrowings (2,340) (3,534)
Exercise of stock options for common stock under Equity Incentive Plan 49 512
Exercise of Warrants   69
Net cash provided by financing activities 28,625 75,901
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (13,500) 12,741
Cash and cash equivalents at beginning of period 53,888 57,466
Cash and cash equivalents at end of period 40,388 70,207
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:    
Initial measurement of warrant liability 21,835  
Conversion of warrant liability to equity for warrant exercises 1,417  
Unrealized gain (loss) on marketable securities 130 $ (142)
Offering costs still in accrued expense $ 8  
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Statements of Cash Flows (Parenthetical)
$ in Thousands
9 Months Ended
Sep. 30, 2021
USD ($)
Condensed Statements of Cash Flows  
Cash issuance costs, February Offering $ 165
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Sep. 30, 2022
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Operations and Business

Applied Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. In particular, the Company is currently targeting treatments for rare metabolic diseases such as Galactosemia, Sorbitol Dehydrogenase (“SORD”) deficiency, and diabetic complications including diabetic cardiomyopathy. The Company was incorporated in Delaware on January 20, 2016 and is headquartered in New York, New York.

On January 28, 2020, the Company completed its secondary public offering (the “Secondary Public Offering”), pursuant to which it issued and sold 2,741,489 shares of common stock at a public offering price of $45.50 per share, with an additional 411,223 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering, after deducting underwriting discounts and commissions and offering costs, were $134.1 million.

On June 4, 2020, the Company filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”) under which the Company may, from time to time, sell securities in one or more offerings having an aggregate offering price of up to $300.0 million. The Shelf Registration Statement was declared effective as of June 15, 2020.

On June 12, 2020, the Company entered into an equity distribution agreement (the “Goldman Equity Distribution Agreement”) with Goldman Sachs & Co. LLC (“Goldman”), as a sales agent to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100 million. Goldman may act as an agent on the Company’s behalf or purchase shares of the Company’s common stock as a principal. The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.

In February 2021, the Company completed an underwritten public offering of 3,450,000 shares of common stock (the “February Offering”), including the exercise in full of the underwriters’ option to purchase 450,000 additional shares of common stock, which option closed on February 19, 2021. The shares were offered at a price to the public of $23.00 per share, resulting in aggregate net proceeds of approximately $74.4 million, after deducting underwriting discounts and commissions and offering expenses.

On January 26, 2022, the Company entered into an equity distribution agreement (the “Cowen Equity Distribution Agreement) with Cowen and Company, LLC (“Cowen”), as a sales agent, to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has not sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.

On June 27, 2022, the Company completed an underwritten public offering (the “June Offering”) of 20,000,000 shares of common stock, par value $0.0001 per share, 10,000,000 pre-funded warrants to purchase shares of common stock (the “Pre-Funded Warrants”), and accompanying warrants to purchase up to 30,000,000 shares of common stock (the “Common Warrants”). The shares and accompanying Common Warrants were offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price

to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.

The accompanying unaudited condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2021 included in the Annual Report, filed with the SEC on March 10, 2022 (the “Annual Report”).

The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments which are necessary for a fair presentation of the Company’s financial position as of September 30, 2022, results of operations for the three and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

Liquidity and Going Concern

The Company has incurred, and expects to continue to incur, significant operating losses for the foreseeable future as it continues to develop its drug candidates. To date, the Company has not generated any revenue, and it does not expect to generate revenue unless and until it successfully completes development and obtains regulatory approval for one of its product candidates.

Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. We are actively pursuing several potential financing options. While we continue to explore opportunities to raise additional equity capital in the public markets, this has proven to be challenging in the biotech sector recently. Other options for structured finance which we continue to explore include a PIPE, debt, convertible debt, and synthetic royalty financing. Synthetic royalty financing, in particular, has become a favorable option for many companies for funding ongoing clinical development in late-stage and pre-approval programs. We have engaged an investment bank and we are specifically exploring this option in the near term. Additionally, we are in active dialogue with several potential partners regarding business development opportunities related to one or more of our programs.

There can be no assurances that our discussions with any of the current counterparties will be successful, and the Company expects to continue to pursue additional opportunities.

As reflected in the accompanying financial statements, the Company has a net loss of $68.1 million for the nine months ended September 30, 2022 and has an accumulated deficit of $334.4 million as of September 30, 2022. The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. While we believe that our cash and cash equivalents and short-term investments of $47.4 million at September 30, 2022 will be sufficient to fund our operations through June 30, 2023, given our planned expenditures for the next several years, we have concluded and our independent registered public accounting firm has agreed with our conclusion that there is still a substantial doubt regarding our ability to continue as a going concern within one year after the date this Quarterly Report on Form 10-Q is issued.

Risks and Uncertainties

The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Significant Accounting Policies

The significant accounting policies and estimates used in preparation of the condensed financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2022.

Recent Accounting Pronouncements

Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
LICENSE AGREEMENT
9 Months Ended
Sep. 30, 2022
LICENSE AGREEMENT  
LICENSE AGREEMENT

2. LICENSE AGREEMENT

Columbia University

In October 2016, the Company entered into a license agreement (the “2016 Columbia Agreement”) with the Trustees of Columbia University (“Columbia University”) to obtain an exclusive royalty-bearing sublicensable license in respect to certain patents. As part of the consideration for entering into the 2016 Columbia Agreement, the Company issued to Columbia University shares equal to 5% of its outstanding common stock on a fully diluted basis at the time of issue. The common stock had a fair value of $0.5 million at the time of issuance. The Company will be required to make further payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual net sales, in each case in connection with products covered by the 2016 Columbia Agreement. The Company will also be required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages

on the Company’s, its affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent upon the approval of the licensed products, in the mid-six figures beginning on the 10th anniversary of the effective date of the 2016 Columbia Agreement. The Company has not granted any sublicenses under the 2016 Columbia Agreement. However, if the Company sublicenses the rights granted under the 2016 Columbia Agreement to one or more third parties, it will be required to pay Columbia University a portion of the net sublicensing revenue received from such third parties, at percentages between 10% and 20%, depending on the stage of development at the time such revenue is received from such third parties.

The 2016 Columbia Agreement will terminate upon the expiration of all the Company’s royalty payment obligations in all countries. The Company may terminate the 2016 Columbia Agreement for convenience upon 90 days’ written notice to Columbia University. At its election, Columbia University may terminate the 2016 Columbia Agreement, or convert the licenses granted to the Company into non-exclusive, non-sublicensable licenses, in the case of (a) the Company’s uncured material breach upon 30 days’ written notice (which shall be extended to 90 days if the Company is diligently attempting to cure such material breach), (b) the Company’s failure to achieve the specified development and funding milestone events, or (c) the Company’s insolvency.

In January 2019, the Company entered into a second license agreement with Columbia University (the “2019 Columbia Agreement”). Pursuant to the 2019 Columbia Agreement, Columbia University granted the Company a royalty-bearing, sublicensable license that is exclusive with respect to certain patents, and non-exclusive with respect to certain know-how, in each case to develop, manufacture and commercialize PI3k inhibitor products. The license grant is worldwide. Under the 2019 Columbia Agreement, the Company is obligated to use commercially reasonable efforts to research, discover, develop and market licensed products for commercial sale in the licensed territory, and to comply with certain obligations to meet specified development and funding milestones within defined time periods. Columbia University retains the right to conduct, and grant third parties the right to conduct, non-clinical academic research using the licensed technology; provided that such research is not funded by a commercial entity or for-profit entity or results in rights granted to a commercial or for-profit entity. As consideration for entering into the 2019 Columbia Agreement, the Company made a nominal upfront payment to Columbia University. The Company will be required to make further payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual net sales, in each case in connection with products covered by the 2019 Columbia Agreement. The Company will also be required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages on the Company’s, its affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent upon the approval of the licensed products, in the mid-six figures beginning on the tenth anniversary of the effective date of the 2019 Columbia Agreement.

In March 2019, and in connection with the 2016 Columbia Agreement, the Company entered into a research services agreement (the “2019 Columbia Research Agreement”) with Columbia University with the purpose of analyzing structural and functional changes in brain tissue in an animal model of Galactosemia, and the effects of certain compounds whose intellectual property rights were licensed to the Company as part of the 2016 Columbia Agreement on any such structural and functional changes. The 2019 Columbia Research Agreement had a term of 12 months from its effective date and expired in accordance with its terms.

On October 3, 2019, and in connection with the 2019 Columbia Agreement, the Company entered into a research services agreement (the “PI3k Columbia Research Agreement” and collectively with the 2016 Columbia Agreement, 2019 Columbia Agreement and 2019 Columbia Research Agreement, the “Columbia Agreements”) with Columbia University with the purpose of analyzing PI3k inhibitors for the treatment of lymphoid malignancies. The PI3k Columbia Research Agreement had a term of 18 months from its effective date and expired in accordance with its terms.

During the three and nine months ended September 30, 2022, the Company recorded $0 and $0 in research and development expenses, respectively; and $0.1 million and $0.2 million in general and administrative expense, respectively, related to the Columbia Agreements. During the three and nine months ended September 30, 2021, the

Company recorded $0 and $0, respectively, in research and development expense and $46,000 and $0.2 million, respectively, in general and administrative expense related to the Columbia Agreements. In aggregate, the Company has incurred $2.6 million in expense from the execution of the Columbia Agreements through September 30, 2022.

As of September 30, 2022, the Company had $0.1 million due to Columbia University included in accrued expenses and $0 included in accounts payable. As of December 31, 2021, the Company had $12,000 due to Columbia University included in accrued expenses and $0.1 million included in accounts payable.

Due to regulatory changes impacting development of the PI3K inhibitor class of compounds, the company has determined that it will discontinue its early stage preclinical PI3K program. On July 15, 2022, the Company notified Columbia University that it is terminating the 2019 Columbia Agreement, effective in 90 days according to the terms of the 2019 Columbia Agreement, or at an earlier date agreed by the parties.

The Company and Columbia entered into an agreement terminating the 2019 Columbia Agreement (the “2022 Columbia Termination Agreement”) as of July 25, 2022. Under the terms of the 2022 Columbia Termination Agreement, the Company assigned certain regulatory documents regarding the preclinical PI3k inhibitor AT-104 to Columbia and granted Columbia a non-exclusive royalty free license (with rights to sublicense any future Columbia licensee) under certain know-how, technical information and data relating to AT-104 that was developed by the Company during the term of the 2019 Columbia Agreement.

University of Miami

2020 Miami License Agreement

On October 28, 2020, the Company entered into a license agreement with the University of Miami (the “2020 Miami License Agreement”) relating to certain technology that is co-owned by the University of Miami (UM), the University of Rochester (UR) and University College London (UCL). UM was granted an exclusive agency from UR and UCL to license each of their rights in the technology. Pursuant to the 2020 Miami License Agreement, UM, on behalf of itself and UR and UCL, granted the Company a royalty-bearing, sublicensable license that is exclusive with respect to certain patent applications and patents that may grant from the applications, and non-exclusive with respect to certain know-how, in each case to research, develop, make, have made, use, sell and import products for use in treating and/or detecting certain inherited neuropathies, in particular those caused by mutation in the sorbitol dehydrogenase (SORD) gene. The license grant is worldwide. Under the 2020 Miami License Agreement, the Company is obligated to use commercially reasonable efforts to develop, manufacture, market and sell licensed products in the licensed territory, and to comply with certain obligations to meet specified development milestones within defined time periods. UM retains for itself, UR, and UCL the right to use the licensed patent rights and licensed technology for their internal non-commercial educational, research and clinical patient care purposes, including in sponsored research and collaboration with commercial entities.

Under the terms of the 2020 Miami License Agreement, the Company was obligated to pay UM an up-front non-refundable license fee of $1.1 million, and a second non-refundable license fee of $0.5 million due on the first anniversary of the date of the license. The Company will be required to make further payments to UM of up to an aggregate $2.2 million for the achievement of specified patenting and development milestones, and up to an aggregate of $4.1 million for achievement of late stage regulatory milestones. The Company will also be required to pay royalties ranging from 0.88% - 5% on the Company’s, the Company’s affiliates’ and the Company’s sublicensees’ net sales of licensed products. If the Company sublicenses the rights granted under the 2020 Miami License Agreement to one or more third parties, the Company will be required to pay to UM a portion of the non-royalty sublicensing revenue received from such third parties ranging from 15% – 25%.

The 2020 Miami License Agreement terminates upon the later of the expiration of all issued patents and filed patent applications or 10 years after the first commercial sale of the last product or process for which a royalty is due, unless earlier terminated. In addition, the 2020 Miami License Agreement may be terminated by the Company at any time upon 60 days prior written notice to UM, and may be terminated by either the Company or UM upon material breach of an obligation if action to cure the breach is not initiated within 60 days of receipt of written notice.

During the three and nine months ended September 30, 2022 the company recorded $25,000 and $75,000, respectively, in research and development expense related to the Miami License Agreement.  During the three and nine months ended September 30, 2021 the Company recorded $0.2 million in research and development expense related to the 2020 Miami License Agreement. During the three and nine months ended September 30, 2022, the Company recorded $0 and $2,000, respectively, in general and administrative expense related to the 2020 Miami License Agreement. There were no general and administrative expense recorded during the three and nine months ended September 30, 2021. In aggregate, the Company has incurred $2.4 million in expense from execution of the 2020 Miami License Agreement through September 30, 2022.

The Company had $0.2 million and $0.3 million due to UM included in accrued expenses as of September 30, 2022 and December 31, 2021, respectively, relating to the 2020 Miami License Agreement.

2020 Miami Option Agreement

On October 28, 2020, the Company entered into an option agreement with the University of Miami (the “2020 Miami Option Agreement”) concerning certain research activities and technology relating to SORD neuropathy that may be pursued and developed by UM. Under the 2020 Miami Option Agreement, if UM conducts such research activities, then UM is obligated to grant the Company certain option rights to access and use the research results and to obtain licenses to any associated patent rights upon the Company making specified payments to UM within specified time limits. If the Company elects to obtain option rights the Company will be required to make payments to UM in the low-six figures to the low-seven figures, depending upon the rights the Company elects to obtain, and the Company will be obligated to make certain milestone payments in the high-six figures to mid-seven figures if UM conducts and completes certain research activities within specified time periods and the Company elects to receive rights to use the results of that research.

2020 Miami Sponsored Research Agreement

On December 14, 2020, the Company entered into a research agreement with the University of Miami (the “2020 Miami Research Agreement”), under which the University of Miami will conduct a research study relating to SORD neuropathy and deliver a final report on the study to the Company. The term of the research agreement is from December 14, 2020 through December 30, 2021, and was extended through August 31, 2022, whereby the research study was completed. The total consideration for the 2020 Miami Research Agreement was $0.3 million.

During the three and nine months ended September 30, 2022, the Company recorded $0 and $0.1 million, respectively, in research and development expense in relation to the 2020 Miami Research Agreement. During the three and nine months ended September 30, 2021, the Company recorded $0.1 million and $0.2 million, respectively, in research and development expense in relation to the 2020 Miami Research Agreement. The Company had $0.1 million and $0.2 million as of September 30, 2022 and December 31, 2021, respectively, in accrued expense in relation to the 2020 Miami Research Agreement.

Bayh-Dole Act

Some of the intellectual property rights the Company has licensed, including certain rights licensed in the agreements described above, may have been generated through the use of U.S. government funding. As a result, the U.S. government may have certain rights to intellectual property embodied in the Company’s current or future product candidates under the Bayh-Dole Act of 1980, or Bayh-Dole Act, including the grant to the government of a non-exclusive, worldwide, freedom to operate license under any patents, and the requirement, absent a waiver, to manufacture products substantially in the United States.  To the extent any of the Company’s current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS
9 Months Ended
Sep. 30, 2022
FAIR VALUE MEASUREMENTS  
FAIR VALUE MEASUREMENTS

3. FAIR VALUE MEASUREMENTS

The following tables summarize, as of September 30, 2022, the Company’s financial assets and liabilities that are measured at fair value on a recurring basis, according to the fair value hierarchy described in the significant accounting policies in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report.

As of September 30, 2022

(in thousands)

Level 1

Level 2

Level 3

Total

Cash

$

7,880

$

$

$

7,880

Money market funds

32,508

32,508

Total cash and cash equivalents

$

40,388

$

$

$

40,388

U.S. government agency debt securities

6,990

6,990

Total marketable securities

$

$

6,990

$

$

6,990

Total financial assets measured at fair value on a recurring basis

$

40,388

$

6,990

$

$

47,378

Warrant liabilities - Common Warrants

24,739

24,739

Total financial liabilities measured at fair value on a recurring basis

$

$

$

24,739

$

24,739

Investments in U.S. government agency debt securities have been classified as Level 2 as they are valued using quoted prices in less active markets or other directly or indirectly observable inputs. Fair values of U.S. government agency debt securities were derived from a consensus or weighted average price based on input of market prices from multiple sources at each reporting period. During the period ended September 30, 2022, there were no transfers of financial assets between Level 1 and Level 2.

On June 27, 2022 the Company issued Common Warrants exercisable for 30,000,000 shares of common stock and Pre-Funded Warrants exercisable for 10,000,000 shares of common stock in connection with the June Offering (see note 1 and note 8 for more information on the June Offering). The Common Warrants were accounted for as liabilities under ASC 815-40, Derivatives and Hedging, Contracts in Entity’s Own Equity (“ASC 815-40”), as these warrants provide for a settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. The Pre-Funded Warrants were recorded at fair value as a liability as the Company could be required to settle the Pre-Funded Warrants in cash under certain circumstances. These warrant liabilities were measured at fair value at inception and are then subsequently measured on a recurring basis, with changes in fair value recognized in other income (expense) within the Company’s statement of operations.

The Company uses a Black-Scholes option pricing model to estimate the fair value of the Common and Pre-Funded Warrants, which utilizes certain unobservable inputs and is therefore considered a Level 3 fair value measurement. Certain inputs used in this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of the Company’s control, including a potential change in control outside of the Company’s control. A significant change in one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the Company’s warrant liabilities, which could also result in material non-cash gains or losses being reported in the Company’s consolidated statement of operations.

The Common and Pre-Funded Warrants were initially valued and remeasured using a Black-Scholes option pricing model with a range of assumptions as follows:

Expected term (in years)

    

3.7

 

Volatility

 

91.53

%

Risk-free interest rate

 

4.11

%

Dividend yield

0.00

%

The Company utilized a probability-weighted approach that considered the probability of a change in control at the Company in the Black-Scholes option pricing model, whereby a 10% probability of change in control was used for each of the five years in the term of the agreements.

The following table provides a roll forward of the aggregate fair values of the Company’s warrant liability, for which fair value is determined using Level 3 inputs (in thousands):

    

Warrant Liability

Common Warrant

Pre-Funded Warrant

Balance as of January 1, 2022

$

$

Initial fair value of Warrant Liability

 

13,734

 

8,101

Warrants exercised

(1,417)

Change in fair value

 

3,331

 

990

Balance as of September 30, 2022

$

17,065

$

7,674

The inputs utilized by management to value the warrant liability for Common and Pre-Funded Warrants are highly subjective. The assumptions used in calculating the fair value of the warrant liability for Common and Pre-Funded Warrants represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the fair value of the warrant liability for Common and Pre-Funded Warrants may be materially different in the future.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS
9 Months Ended
Sep. 30, 2022
INVESTMENTS  
INVESTMENTS

4. INVESTMENTS

Marketable Securities

Marketable securities, which the Company classifies as available-for-sale securities, primarily consist of U.S. government debt obligations. Marketable securities with remaining effective maturities of twelve months or less from the balance sheet date are classified as short-term; otherwise, they are classified as long-term on the balance sheets.

The following tables provide the Company’s marketable securities by security type (in thousands):

As of September 30, 2022

As of December 31, 2021

Gross

Gross

 

Gross

Gross

 

    

Unrealized

    

Unrealized

    

Estimated

    

    

Unrealized

    

Unrealized

    

Estimated

(in thousands)

Cost

Gains

Losses

Fair Value

Cost

Gains

Losses

Fair Value

US government agency debt security

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

Total

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

As of September 30, 2022, the Company’s investment portfolio reported no unrealized loss. Based on its evaluations, the Company determined that a credit loss allowance is not required since the decline was not related to underlying credit issues of the counterparties. The counterparties to these investments have high credit quality with investment grade ratings of at least AA+ or above, along with a history of no defaults. No single investment in the portfolio had an individually material unrealized loss and in the aggregate. In addition, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost bases. Accordingly, based on the foregoing evaluation, the Company did not record any credit losses during the nine months ended September 30, 2022. Unrealized gains are also reflected, net of tax, as other comprehensive income (loss) in the Statements of Comprehensive Loss.

Contractual maturities of the Company’s marketable securities are summarized as follows:

As of September 30, 2022

As of December 31, 2021

Gross

Gross

 

Gross

Gross

 

Unrealized

Unrealized

    

Estimated

Unrealized

Unrealized

    

Estimated

(in thousands)

Cost

    

Gains

    

Losses

    

Fair Value

    

Cost

    

Gains

    

Losses

    

Fair Value

Due in one year or less

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

Due in one through two years

Total

$

6,967

$

23

  

$

$

6,990

$

27,042

$

1

  

$

(108)

$

26,935

At September 30, 2022, the Company had $23,000 of gross unrealized gains and $0 of gross unrealized losses primarily due to fluctuations in the fair value of certain U.S. government agency debt securities.

During the three and nine months ended September 30, 2022, the Company recorded gross realized losses of $3,000 and $0.2 million, respectively, and no gross realized gains of from the sale of marketable securities.

The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September 30, 2022 are as follows:

As of September 30, 2022

Securities in an unrealized loss position less than 12 months

Securities in an unrealized loss position greater than 12 months

Total

Unrealized

    

Estimated

    

Unrealized

    

Estimated

    

Unrealized

    

Estimated

(in thousands)

Losses

Fair Value

Losses

Fair Value

Losses

Fair Value

US government agency debt security

$

$

$

$

$

$

Total

$

$

$

$

$

$

The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December 31, 2021 are as follows:

As of December 31, 2021

Securities in an unrealized loss position less than 12 months

Securities in an unrealized loss position greater than 12 months

Total

Unrealized

    

Estimated

    

Unrealized

    

Estimated

    

Unrealized

    

Estimated

(in thousands)

Losses

Fair Value

Losses

Fair Value

Losses

Fair Value

US government agency debt security

$

(108)

$

17,696

$

$

$

(108)

$

17,696

Total

$

(108)

$

17,696

$

$

$

(108)

$

17,696

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
PREPAID EXPENSES AND OTHER CURRENT ASSETS
9 Months Ended
Sep. 30, 2022
PREPAID EXPENSES AND OTHER CURRENT ASSETS  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

5. PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets consisted of the following:

    

September 30, 

    

December 31,

(in thousands)

2022

2021

Prepaid research and development expenses

$

4,996

$

4,483

Insurance premium asset

1,914

1,616

Prepaid rent expenses

 

86

 

117

Prepaid insurance expenses

 

89

 

105

Prepaid commercial and patient advocacy

167

254

Research and development tax credit receivable

 

252

 

502

Interest receivable

24

23

Other prepaid expenses and current assets

604

471

Total prepaid expenses & other current assets

$

8,132

$

7,571

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
9 Months Ended
Sep. 30, 2022
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following:

    

September 30, 

    

December 31,

(in thousands)

2022

2021

Accrued pre-clinical and clinical expenses

$

8,836

$

9,912

Short-term insurance financing note

1,554

789

Accrued professional fees

 

837

 

419

Accrued compensation and benefits

 

1,484

 

2,779

Accrued commercial expenses

849

1,394

Accrued patent expenses

 

314

 

279

Other

 

458

 

987

Total accrued expenses & other current liabilities

$

14,332

$

16,559

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION
9 Months Ended
Sep. 30, 2022
STOCK BASED COMPENSATION  
STOCK BASED COMPENSATION

7. STOCK-BASED COMPENSATION

Equity Incentive Plans

In May 2019, the Company’s board of directors (the “Board”) adopted its 2019 Equity Incentive Plan (“2019 Plan”), which was subsequently approved by its stockholders and became effective on May 13, 2019. As a result, no additional awards under the Company’s 2016 Equity Incentive Plan, as amended (the “2016 Plan”) will be granted and all outstanding stock awards granted under the 2016 Plan that are repurchased, forfeited, expired, or are cancelled will become available for grant under the 2019 Plan in accordance with its terms. The 2016 Plan will continue to govern outstanding equity awards granted thereunder.

The 2019 Plan provides for the issuance of incentive stock options (“ISOs”) to employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other forms of stock awards to the Company’s employees, officers, and directors, as well as non- employees, consultants, and affiliates to the Company. Under the terms of the 2019 Plan, stock options may not be granted at an exercise price less than fair market value of the Company’s common stock on the date of the grant. The 2019 Plan is administered by the Compensation Committee of the Company’s Board.

Initially, subject to adjustments as provided in the 2019 Plan, the maximum number of the Company’s common stock that may be issued under the 2019 Plan was 4,530,000 shares, which is the sum of (i) 1,618,841 new shares, plus (ii) the number of shares (not to exceed 2,911,159 shares) that remained available for the issuance of awards under the 2016 Plan, at the time the 2019 Plan became effective, and (iii) any shares subject to outstanding stock options or other stock awards granted under the 2016 Plan that are forfeited, expired, or reacquired. The 2019 Plan provides that the number of shares reserved and available for issuance under the 2019 Plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Board. Subject to certain changes in capitalization of the Company, the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of ISOs shall be equal to 13,000,000 shares of common stock. Stock options awarded under the 2019 Plan expire 10 years after grant and typically vest over four years.

On August 2, 2022, the Board took action in accordance with its authority under the terms of the 2019 Plan to reset the per-share exercise price of all stock options previously granted under the 2019 Plan to $1.05 per share (the "Options Repricing"), which is equal to the closing price of a share of the Company’s common stock on August 1, 2022. The Options Repricing was deemed to be a Type I modification event under ASC 718, Compensation-Stock Compensation. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the Options Repricing, 1,797,517 vested and 1,380,917 unvested stock options outstanding as of August 2, 2022, with original exercise prices ranging from $1.22 to $49.60, were repriced. The Options Repricing resulted in incremental

stock-based compensation expense of $1.4 million, of which $0.9 million related to vested stock option awards and was expensed on the repricing date, and $0.5 million of which related to unvested stock option awards and is being amortized on a ratable basis over the remaining weighted-average vesting period of those awards being approximately 2.4 years.

As of September 30, 2022, there were 1,331,659 shares of common stock available for issuance under the 2019 Plan.

Stock-Based Compensation Expense

Total stock-based compensation expense recorded for employees, directors and non-employees (in thousands):

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

(in thousands)

    

2022

    

2021

    

2022

    

2021

Research and development

$

1,178

$

642

$

2,822

$

1,974

General and administrative

 

1,678

 

2,003

 

4,342

 

6,354

Total stock-based compensation expense

$

2,856

$

2,645

$

7,164

$

8,328

Stock Option Activity

During the nine months ended September 30, 2022 the Company granted 767,913 options to shares of common stock. For the three and nine months ended September 30, 2022, amortization of stock compensation of options amounted to $2.5 million and $6.2 million, respectively, and for the three and nine months ended September 30, 2021, amortization of stock compensation of options amounted to $2.2 million and $7.0 million, respectively. As of September 30, 2022 and 2021, the total unrecognized stock-based compensation balance for unvested options was $9.9 million and $20.2 million, respectively, which is expected to be recognized over 2.3 years and 2.5 years, respectively. The weighted-average fair value per share of options granted during the nine months ended September 30, 2022 and 2021 was $1.79 and $10.01, respectively.

The following table summarizes the information about options outstanding at September 30, 2022:

    

    

    

Weighted-Average

    

 

 

Weighted-

 

Remaining

 

Aggregate

Options

 

Average

 

Contractual

 

Intrinsic

(in thousands, except for share data)

Outstanding

Exercise Price

 

Term (in years)

Value

Outstanding at December 31, 2021

 

4,704,888

$

13.29

7.7

$

10,305

Options granted

 

767,913

2.80

Options exercised

 

(47,602)

1.04

21

Forfeited

 

(357,833)

20.93

Expired

 

(141,688)

31.65

Outstanding at September 30, 2022

 

4,925,678

$

1.99

7.2

$

Exercisable at September 30, 2022

 

3,711,517

$

2.30

6.7

$

Nonvested at September 30, 2022

 

1,214,161

$

1.05

8.5

$

Valuation of Stock Options Granted to Employees that Contain Service Conditions Only

The fair value of each option award granted with service-based vesting is estimated on the date of the grant using the Black-Scholes option valuation model based on the weighted average assumptions noted in the table below for those options granted in the nine months ended September 30, 2022 and 2021.

Nine Months Ended

 

September 30, 

    

2022

 

2021

Expected term (in years)

5.7

5.6

Volatility

 

75.83

%

70.99

%

Risk-free interest rate

 

2.13

%

0.91

%

Dividend yield

%

%

Restricted Stock Unit Activity

During the nine months ended September 30, 2022, the Company granted 305,600 RSUs to shares of common stock. For the three months ended September 30, 2022 and 2021, amortization of stock compensation of RSUs amounted to $0.4 million and $0.5 million, respectively. For the nine months ended September 30, 2022 and 2021, amortization of stock compensation of RSU’s amounted to $0.9 million and $1.3 million, respectively. As of September 30, 2022 and 2021, the unamortized compensation costs associated with non-vested restricted stock awards were $3.9 million and $5.1 million, respectively, with a weighted-average remaining amortization period of 3.1 and 2.9 years, respectively.

The following table summarizes the information about restricted stock units outstanding at September 30, 2022:

 

 

Weighted-Average

 

 

Grant Date

 

Aggregate

(in thousands, except for share data)

Shares

 

Fair Value

Intrinsic Value

Outstanding at December 31, 2021

 

469,485

$

18.05

$

4,202

Awarded

 

305,600

3.78

Released

 

(45,840)

25.57

Forfeited

 

(196,131)

18.36

Outstanding at September 30, 2022

 

533,114

$

9.10

$

496

Nonvested at September 30, 2022

 

528,712

$

9.06

$

492

Weighted Average Remaining Recognition Period (in years)

3.1

2019 Employee Stock Purchase Plan

In May 2019, the Company’s Board and its stockholders approved the 2019 Employee Stock Purchase Plan (the “ESPP”), which became effective as of May 13, 2019. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 180,000 shares. The ESPP provides for an annual increase on the first day of each year beginning in 2020 and ending in 2029, in each case subject to the approval of the Board, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the calendar month before the date of the automatic increase and (ii) 360,000 shares; provided that prior to the date of any such increase, the Board may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of September 30, 2022, no shares of common stock had been issued under the ESPP. The first offering period has not yet been decided by the Board.

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY
9 Months Ended
Sep. 30, 2022
STOCKHOLDERS' EQUITY  
STOCKHOLDERS' EQUITY

8. STOCKHOLDERS’ EQUITY

As of September 30, 2022, and December 31, 2021, the authorized capital stock of the Company consists of 100,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share.

Common Stock

Goldman Equity Distribution Agreement

In June 2020, the Company entered into the Goldman Equity Distribution Agreement to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. The issuance and sale of shares of common stock by the Company pursuant to the Goldman Equity Distribution Agreement is deemed an “at-the-market” offering under the Securities Act of 1933, as amended, or the Securities Act. Goldman is entitled to compensation for its services equal to up to 3.0% of the gross offering proceeds of all shares of the Company’s common stock sold through it as a sales agent pursuant to the Goldman Equity Distribution Agreement. The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.

Cowen Equity Distribution Agreement

On January 26, 2022, the Company entered into the Cowen Equity Distribution Agreement to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has not sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.

June 2022 Offering

On June 27, 2022, the Company completed the June Offering, an underwritten public offering of 20,000,000 shares of common stock, par value $0.0001 per share, 10,000,000 Pre-Funded Warrants, and accompanying Common Warrants to purchase up to 30,000,000 shares of common stock. The shares and accompanying Common Warrants were offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate

purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS
9 Months Ended
Sep. 30, 2022
WARRANTS  
WARRANTS

9. WARRANTS

Warrants Issued with Series A Preferred Stock

On January 26, 2017, in connection with the sale and issuance of the Series A Preferred Stock, the Company issued equity-classified warrants to purchase 309,389 shares of common stock (the “2017 Warrants”), valued at $0.2 million, and included in the issuance costs of the Series A Preferred Stock. The warrants vested immediately and have an exercise price of $2.49 per share and expire on March 13, 2027.

The fair value of warrants issued was estimated using the Black-Scholes option pricing model with the following assumptions for the 2017 Warrants.

Contractual term (in years)

    

10.0

 

Volatility

 

74.48

%

Risk-free interest rate

 

3.20

%

Dividend yield

 

0.00

%

On February 5, 2021, a warrantholder exercised 27,855 warrants on a cash basis and received 27,855 shares of common stock. The Company received $69,000 in cash proceeds for the exercise of these warrants.

Warrants Issued with the 2018 Notes

On January 18, 2018, the Company entered into a placement agent agreement through which it became obligated to issue common stock warrants in connection with the issuance of convertible promissory notes, issued on February 5, 2018 (the “2018 Notes”). The obligation to issue the 2018 Notes Warrants was recorded as a liability at its fair value, (see Note 3), which was initially $0.1 million, and was included in the issuance costs of the 2018 Notes. On November 5, 2018, in connection with the extinguishment of the 2018 Notes into shares of Series B Preferred Stock, the Company issued the 2018 Notes Warrants, which were equity-classified warrants upon issuance, to purchase 76,847 shares of common stock, valued at $0.3 million. The 2018 Notes Warrants vested immediately upon issuance and have an exercise price of $6.59 per share and expire on November 4, 2028.

Warrants Issued with Series B Preferred Stock

In November and December 2018, in connection with the sale and issuance of the Series B Preferred Stock, the Company was obligated to issue equity-classified warrants to purchase 72,261 shares of common stock (collectively the “2018 Warrants”), valued in the aggregate at $0.2 million, which was included in the issuance costs for the Series B Preferred Stock. The warrants vest immediately upon issuance, have an exercise price of $8.24 per share and expire 10 years from the date of issuance.

The fair value of the 2018 Warrants was estimated using the Black-Scholes option pricing model with the following assumptions:

Contractual term (in years)

    

10.0

 

Volatility

 

73.22

%

Risk-free interest rate

 

2.70

%

Dividend yield

 

0.00

%

In February 2019, in connection with the sale and issuance of the Series B Preferred Stock, the Company was obligated to issue warrants to purchase 23,867 shares of common stock (collectively the “2019 Warrants”), valued in the

aggregate at $0.1 million, which was included in the issuance costs for the Series B Preferred Stock. The warrants vested immediately upon issuance, have an exercise price of $8.24 per share and expire 10 years from the date of issuance.

The fair value of the 2019 Warrants was estimated using the Black-Scholes option pricing model with the following assumptions:

Contractual term (in years)

    

10.0

 

Volatility

 

73.22

%

Risk-free interest rate

 

2.70

%

Dividend yield

 

0.00

%

The inputs utilized by management to value the warrants are highly subjective. The assumptions used in calculating the fair value of the warrants represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the fair value of the warrants may be materially different in the future.

Warrants Issued with June 2022 Offering

On June 27, 2022, in connection with the sale and issuance common stock as part of the June Offering, the Company issued 10,000,000 Pre-Funded Warrants at an exercise price of $0.0001 per share, and 30,000,000 accompanying Common Warrants at an exercise price of $1.00 per share. Each share of common stock and accompanying Common Warrant was sold at a public offering price of $1.00, less underwriting discounts and commissions, and each Pre-Funded Warrant and accompanying Common Warrant was sold at a public offering price of $0.9999, less underwriting discounts and commissions, as described in the prospectus supplement, dated June 22, 2022, filed with the Securities and Exchange Commission on June 24, 2022.

The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled.

On June 28, 2022, a warrantholder exercised 1,750,000 Pre-Funded Warrants on a cash basis and received 1,750,000 shares of common stock. The Company received $175 in cash proceeds for the exercise of these Pre-Funded Warrants.

As of September 30, 2022, the Company had 8,250,000 Pre-Funded Warrants outstanding with a weighted average exercise price of $0.0001 per share and an average contractual life of 5 years. As of September 30, 2022, the Company had 30,000,000 Common Warrants outstanding with a weighted average exercise price of $1.00 per share and an average contractual life of 5 years.

The Common Warrants were accounted for as liabilities under ASC 815-40, as these warrants provide for a settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. These warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the

statement of operations. The Pre-Funded Warrants were recorded at fair value as a liability as the Company could be required to settle the Pre-Funded Warrants in cash in the event of an acquisition of the Company under certain circumstances.

The fair value of the Common and Pre-Funded Warrants were estimated using the Black-Scholes option pricing model with the following assumptions:

Expected term (in years)

    

3.7

 

Volatility

 

91.53

%

Risk-free interest rate

 

4.11

%

Dividend yield

0.00

%

A summary of the Company’s outstanding common stock warrants as of September 30, 2022 is as follows:

Warrants

Outstanding as of December 31, 2021

125,618

Warrants granted and issued

 

40,000,000

Warrants exercised

 

(1,750,000)

Warrants exchanged

 

Outstanding as of September 30, 2022

38,375,618

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES
9 Months Ended
Sep. 30, 2022
LEASES  
LEASES

10. LEASES

The following table summarizes the Company’s lease related costs for the nine months ended September 30, 2022 and 2021:

Operating
(in thousands)

Lease Cost

Statement of Operations Location

2022

2021

Operating Lease Cost

General and administrative

$

126

$

126

Total Lease Cost

$

126

$

126

Average lease terms and discount rates for the Company’s operating leases were as follows:

Nine Months Ended

September 30, 

September 30, 

Other Information

    

2022

2021

Weighted-average remaining lease term

Operating leases

2.1 years

3.0 years

Weighted-average discount rate

Operating leases

5.69%

5.69%

The following table summarizes the maturities of lease liabilities as of September 30, 2022:

    

Operating

Year

(in thousands)

2022

$

128

2023

515

2024

426

Thereafter

Total lease payments

1,069

Less: interest

63

Total lease liabilities

$

1,006

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
INCOME TAXES
9 Months Ended
Sep. 30, 2022
INCOME TAXES  
INCOME TAXES

11. INCOME TAXES

On March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to provide certain relief as a result of the Covid-19 pandemic. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of social security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property and the creation of certain refundable employee retention credits. The CARES Act did not have a material impact on our financial statements for the three and nine months ended September 30, 2022. The Company continues to monitor any effects that may result from the CARES Act.

During the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
BENEFIT PLANS
9 Months Ended
Sep. 30, 2022
BENEFIT PLANS  
BENEFIT PLANS

12. BENEFIT PLANS

The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code in 2018. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company’s board of directors. The Company made approximately $0.4 million and $0.2 million in matching contributions to the plan during the nine months ended September 30, 2022 and 2021, respectively.

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER COMMON SHARE
9 Months Ended
Sep. 30, 2022
NET LOSS PER COMMON SHARE  
NET LOSS PER COMMON SHARE

13. NET LOSS PER COMMON SHARE

Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.

Diluted net loss per common share is computed by giving the effect of all potential shares of common stock, including stock options, preferred shares, warrants and instruments convertible into common stock, to the extent dilutive. Basic and diluted net loss per common share was the same for the three and nine months ended September 30, 2022 and 2021, as the inclusion of all potential common shares outstanding would have been anti-dilutive.

The following tables set forth the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2022 and 2021:

Three Months Ended

 

September 30, 

(in thousands, except for share data)

    

2022

    

2021

Numerator:

 

Net loss

$

(19,101)

$

(28,418)

Denominator:

 

Weighted-average common stock outstanding

 

48,000,183

26,177,079

Net loss per share attributable to common stockholders - basic and diluted

$

(0.40)

$

(1.09)

Nine Months Ended

 

September 30, 

    

2022

    

2021

Numerator:

 

  

 

  

Net loss

$

(68,079)

$

(78,425)

Denominator:

 

Weighted-average common stock outstanding

 

33,785,386

25,472,590

Net loss per share attributable to common stockholders - basic and diluted

$

(2.02)

$

(3.08)

The Company’s potentially dilutive securities, which include restricted stock units, stock options, and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding for the nine months ended September 30, 2022 and 2021, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:

As of

September 30, 

    

2022

    

2021

Options to purchase common stock

 

4,925,678

4,542,353

Restricted stock units

533,114

222,693

Warrants to purchase common stock

 

38,375,618

125,618

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTIES
9 Months Ended
Sep. 30, 2022
RELATED PARTIES  
RELATED PARTIES

14. RELATED PARTIES

In December 2018, the Company entered into an agreement (the “LaunchLabs Agreement”) with ARE-LaunchLabs NYC LLC (“Alexandria LaunchLabs”), a subsidiary of Alexandria Real Estate Equities, Inc. for use of specified premises within the Alexandria LaunchLabs space on a month-to-month basis. A member of the Company’s board of directors is the founder and executive chairman of Alexandria Real Estate Equities, Inc. During the three and nine months ended September 30, 2022, the Company made payments to Alexandria LaunchLabs of approximately $23,000, and $70,000, respectively, and during the three and nine months ended September 30, 2021, the Company made the same payments of approximately $23,000 and $70,000 respectively, under the LaunchLabs Agreement, which was recognized in research and development expenses. As of September 30, 2022, there were no amounts due to Alexandria LaunchLabs under the LaunchLabs Agreement.

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS
9 Months Ended
Sep. 30, 2022
SUBSEQUENT EVENTS  
SUBSEQUENT EVENTS

15. SUBSEQUENT EVENTS

On October 26, 2022, at a Special Meeting of Stockholders (the “Special Meeting”), the stockholders of Applied Therapeutics, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Company’s Amended

and Restated Certificate of Incorporation to increase the number of shares of the Company’s common stock authorized for issuance from 100,000,000 shares to 200,000,000 shares (the “Authorized Shares Increase Proposal”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware on October 26, 2022.

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Sep. 30, 2022
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Operations and Business

Operations and Business

Applied Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. In particular, the Company is currently targeting treatments for rare metabolic diseases such as Galactosemia, Sorbitol Dehydrogenase (“SORD”) deficiency, and diabetic complications including diabetic cardiomyopathy. The Company was incorporated in Delaware on January 20, 2016 and is headquartered in New York, New York.

On January 28, 2020, the Company completed its secondary public offering (the “Secondary Public Offering”), pursuant to which it issued and sold 2,741,489 shares of common stock at a public offering price of $45.50 per share, with an additional 411,223 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering, after deducting underwriting discounts and commissions and offering costs, were $134.1 million.

On June 4, 2020, the Company filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”) under which the Company may, from time to time, sell securities in one or more offerings having an aggregate offering price of up to $300.0 million. The Shelf Registration Statement was declared effective as of June 15, 2020.

On June 12, 2020, the Company entered into an equity distribution agreement (the “Goldman Equity Distribution Agreement”) with Goldman Sachs & Co. LLC (“Goldman”), as a sales agent to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100 million. Goldman may act as an agent on the Company’s behalf or purchase shares of the Company’s common stock as a principal. The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.

In February 2021, the Company completed an underwritten public offering of 3,450,000 shares of common stock (the “February Offering”), including the exercise in full of the underwriters’ option to purchase 450,000 additional shares of common stock, which option closed on February 19, 2021. The shares were offered at a price to the public of $23.00 per share, resulting in aggregate net proceeds of approximately $74.4 million, after deducting underwriting discounts and commissions and offering expenses.

On January 26, 2022, the Company entered into an equity distribution agreement (the “Cowen Equity Distribution Agreement) with Cowen and Company, LLC (“Cowen”), as a sales agent, to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has not sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.

On June 27, 2022, the Company completed an underwritten public offering (the “June Offering”) of 20,000,000 shares of common stock, par value $0.0001 per share, 10,000,000 pre-funded warrants to purchase shares of common stock (the “Pre-Funded Warrants”), and accompanying warrants to purchase up to 30,000,000 shares of common stock (the “Common Warrants”). The shares and accompanying Common Warrants were offered at a price to the public of $1.00 per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price

to the public of $0.9999, resulting in aggregate net proceeds of approximately $27.8 million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire five years from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed 9.99% of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than 9.99% of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than 19.99% of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.

The accompanying unaudited condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2021 included in the Annual Report, filed with the SEC on March 10, 2022 (the “Annual Report”).

The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments which are necessary for a fair presentation of the Company’s financial position as of September 30, 2022, results of operations for the three and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.

Liquidity and Going Concern

Liquidity and Going Concern

The Company has incurred, and expects to continue to incur, significant operating losses for the foreseeable future as it continues to develop its drug candidates. To date, the Company has not generated any revenue, and it does not expect to generate revenue unless and until it successfully completes development and obtains regulatory approval for one of its product candidates.

Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. We are actively pursuing several potential financing options. While we continue to explore opportunities to raise additional equity capital in the public markets, this has proven to be challenging in the biotech sector recently. Other options for structured finance which we continue to explore include a PIPE, debt, convertible debt, and synthetic royalty financing. Synthetic royalty financing, in particular, has become a favorable option for many companies for funding ongoing clinical development in late-stage and pre-approval programs. We have engaged an investment bank and we are specifically exploring this option in the near term. Additionally, we are in active dialogue with several potential partners regarding business development opportunities related to one or more of our programs.

There can be no assurances that our discussions with any of the current counterparties will be successful, and the Company expects to continue to pursue additional opportunities.

As reflected in the accompanying financial statements, the Company has a net loss of $68.1 million for the nine months ended September 30, 2022 and has an accumulated deficit of $334.4 million as of September 30, 2022. The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. While we believe that our cash and cash equivalents and short-term investments of $47.4 million at September 30, 2022 will be sufficient to fund our operations through June 30, 2023, given our planned expenditures for the next several years, we have concluded and our independent registered public accounting firm has agreed with our conclusion that there is still a substantial doubt regarding our ability to continue as a going concern within one year after the date this Quarterly Report on Form 10-Q is issued.

Risk and Uncertainties

Risks and Uncertainties

The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Significant Accounting Policies

Significant Accounting Policies

The significant accounting policies and estimates used in preparation of the condensed financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2022.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended
Sep. 30, 2022
Fair value  
Schedule of financial assets or liabilities measured at fair value on a recurring basis

As of September 30, 2022

(in thousands)

Level 1

Level 2

Level 3

Total

Cash

$

7,880

$

$

$

7,880

Money market funds

32,508

32,508

Total cash and cash equivalents

$

40,388

$

$

$

40,388

U.S. government agency debt securities

6,990

6,990

Total marketable securities

$

$

6,990

$

$

6,990

Total financial assets measured at fair value on a recurring basis

$

40,388

$

6,990

$

$

47,378

Warrant liabilities - Common Warrants

24,739

24,739

Total financial liabilities measured at fair value on a recurring basis

$

$

$

24,739

$

24,739

Schedule of aggregate fair values of the Company's warrant liability

The following table provides a roll forward of the aggregate fair values of the Company’s warrant liability, for which fair value is determined using Level 3 inputs (in thousands):

    

Warrant Liability

Common Warrant

Pre-Funded Warrant

Balance as of January 1, 2022

$

$

Initial fair value of Warrant Liability

 

13,734

 

8,101

Warrants exercised

(1,417)

Change in fair value

 

3,331

 

990

Balance as of September 30, 2022

$

17,065

$

7,674

Common And Pre-Funded Warrants  
Fair value  
Schedule of fair value of warrants using the Black Scholes option pricing model

Expected term (in years)

    

3.7

 

Volatility

 

91.53

%

Risk-free interest rate

 

4.11

%

Dividend yield

0.00

%

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS (Tables)
9 Months Ended
Sep. 30, 2022
INVESTMENTS  
Schedule of marketable securities by security type

As of September 30, 2022

As of December 31, 2021

Gross

Gross

 

Gross

Gross

 

    

Unrealized

    

Unrealized

    

Estimated

    

    

Unrealized

    

Unrealized

    

Estimated

(in thousands)

Cost

Gains

Losses

Fair Value

Cost

Gains

Losses

Fair Value

US government agency debt security

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

Total

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

Schedule of contractual maturities

As of September 30, 2022

As of December 31, 2021

Gross

Gross

 

Gross

Gross

 

Unrealized

Unrealized

    

Estimated

Unrealized

Unrealized

    

Estimated

(in thousands)

Cost

    

Gains

    

Losses

    

Fair Value

    

Cost

    

Gains

    

Losses

    

Fair Value

Due in one year or less

$

6,967

$

23

$

$

6,990

$

27,042

$

1

$

(108)

$

26,935

Due in one through two years

Total

$

6,967

$

23

  

$

$

6,990

$

27,042

$

1

  

$

(108)

$

26,935

Unrealized Gain (Loss) on Investments

As of September 30, 2022

Securities in an unrealized loss position less than 12 months

Securities in an unrealized loss position greater than 12 months

Total

Unrealized

    

Estimated

    

Unrealized

    

Estimated

    

Unrealized

    

Estimated

(in thousands)

Losses

Fair Value

Losses

Fair Value

Losses

Fair Value

US government agency debt security

$

$

$

$

$

$

Total

$

$

$

$

$

$

As of December 31, 2021

Securities in an unrealized loss position less than 12 months

Securities in an unrealized loss position greater than 12 months

Total

Unrealized

    

Estimated

    

Unrealized

    

Estimated

    

Unrealized

    

Estimated

(in thousands)

Losses

Fair Value

Losses

Fair Value

Losses

Fair Value

US government agency debt security

$

(108)

$

17,696

$

$

$

(108)

$

17,696

Total

$

(108)

$

17,696

$

$

$

(108)

$

17,696

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
9 Months Ended
Sep. 30, 2022
PREPAID EXPENSES AND OTHER CURRENT ASSETS  
Summary of prepaid expenses and other current assets

    

September 30, 

    

December 31,

(in thousands)

2022

2021

Prepaid research and development expenses

$

4,996

$

4,483

Insurance premium asset

1,914

1,616

Prepaid rent expenses

 

86

 

117

Prepaid insurance expenses

 

89

 

105

Prepaid commercial and patient advocacy

167

254

Research and development tax credit receivable

 

252

 

502

Interest receivable

24

23

Other prepaid expenses and current assets

604

471

Total prepaid expenses & other current assets

$

8,132

$

7,571

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
9 Months Ended
Sep. 30, 2022
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES  
Summary of accrued expenses and other current liabilities

    

September 30, 

    

December 31,

(in thousands)

2022

2021

Accrued pre-clinical and clinical expenses

$

8,836

$

9,912

Short-term insurance financing note

1,554

789

Accrued professional fees

 

837

 

419

Accrued compensation and benefits

 

1,484

 

2,779

Accrued commercial expenses

849

1,394

Accrued patent expenses

 

314

 

279

Other

 

458

 

987

Total accrued expenses & other current liabilities

$

14,332

$

16,559

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION (Tables)
9 Months Ended
Sep. 30, 2022
Stock-based compensation  
Schedule of stock-based compensation expenses

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

(in thousands)

    

2022

    

2021

    

2022

    

2021

Research and development

$

1,178

$

642

$

2,822

$

1,974

General and administrative

 

1,678

 

2,003

 

4,342

 

6,354

Total stock-based compensation expense

$

2,856

$

2,645

$

7,164

$

8,328

Schedule of options outstanding

    

    

    

Weighted-Average

    

 

 

Weighted-

 

Remaining

 

Aggregate

Options

 

Average

 

Contractual

 

Intrinsic

(in thousands, except for share data)

Outstanding

Exercise Price

 

Term (in years)

Value

Outstanding at December 31, 2021

 

4,704,888

$

13.29

7.7

$

10,305

Options granted

 

767,913

2.80

Options exercised

 

(47,602)

1.04

21

Forfeited

 

(357,833)

20.93

Expired

 

(141,688)

31.65

Outstanding at September 30, 2022

 

4,925,678

$

1.99

7.2

$

Exercisable at September 30, 2022

 

3,711,517

$

2.30

6.7

$

Nonvested at September 30, 2022

 

1,214,161

$

1.05

8.5

$

Schedule of restricted stock units outstanding

 

 

Weighted-Average

 

 

Grant Date

 

Aggregate

(in thousands, except for share data)

Shares

 

Fair Value

Intrinsic Value

Outstanding at December 31, 2021

 

469,485

$

18.05

$

4,202

Awarded

 

305,600

3.78

Released

 

(45,840)

25.57

Forfeited

 

(196,131)

18.36

Outstanding at September 30, 2022

 

533,114

$

9.10

$

496

Nonvested at September 30, 2022

 

528,712

$

9.06

$

492

Weighted Average Remaining Recognition Period (in years)

3.1

Stock options - Service conditions only  
Stock-based compensation  
Schedule of valuation assumptions

Nine Months Ended

 

September 30, 

    

2022

 

2021

Expected term (in years)

5.7

5.6

Volatility

 

75.83

%

70.99

%

Risk-free interest rate

 

2.13

%

0.91

%

Dividend yield

%

%

XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS (Tables)
9 Months Ended
Sep. 30, 2022
Warrants  
Schedule of warrants outstanding

Warrants

Outstanding as of December 31, 2021

125,618

Warrants granted and issued

 

40,000,000

Warrants exercised

 

(1,750,000)

Warrants exchanged

 

Outstanding as of September 30, 2022

38,375,618

Warrants Issued with Series A Preferred Stock | 2017 Warrants  
Warrants  
Schedule of fair value of warrants using the Black Scholes option pricing model

Contractual term (in years)

    

10.0

 

Volatility

 

74.48

%

Risk-free interest rate

 

3.20

%

Dividend yield

 

0.00

%

Warrants Issued with Series B Preferred Stock | 2018 Warrants  
Warrants  
Schedule of fair value of warrants using the Black Scholes option pricing model

Contractual term (in years)

    

10.0

 

Volatility

 

73.22

%

Risk-free interest rate

 

2.70

%

Dividend yield

 

0.00

%

Warrants Issued with Series B Preferred Stock | 2019 Warrants  
Warrants  
Schedule of fair value of warrants using the Black Scholes option pricing model

Contractual term (in years)

    

10.0

 

Volatility

 

73.22

%

Risk-free interest rate

 

2.70

%

Dividend yield

 

0.00

%

Common And Pre-Funded Warrants  
Warrants  
Schedule of fair value of warrants using the Black Scholes option pricing model

Expected term (in years)

    

3.7

 

Volatility

 

91.53

%

Risk-free interest rate

 

4.11

%

Dividend yield

0.00

%

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES (Tables)
9 Months Ended
Sep. 30, 2022
LEASES  
Summary of lease related costs

Operating
(in thousands)

Lease Cost

Statement of Operations Location

2022

2021

Operating Lease Cost

General and administrative

$

126

$

126

Total Lease Cost

$

126

$

126

Summary of lease terms and discount rates

Nine Months Ended

September 30, 

September 30, 

Other Information

    

2022

2021

Weighted-average remaining lease term

Operating leases

2.1 years

3.0 years

Weighted-average discount rate

Operating leases

5.69%

5.69%

Summary of maturities of lease liabilities

    

Operating

Year

(in thousands)

2022

$

128

2023

515

2024

426

Thereafter

Total lease payments

1,069

Less: interest

63

Total lease liabilities

$

1,006

XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER COMMON SHARE (Tables)
9 Months Ended
Sep. 30, 2022
NET LOSS PER COMMON SHARE  
Schedule of computation of basic and diluted net loss per common share

Three Months Ended

 

September 30, 

(in thousands, except for share data)

    

2022

    

2021

Numerator:

 

Net loss

$

(19,101)

$

(28,418)

Denominator:

 

Weighted-average common stock outstanding

 

48,000,183

26,177,079

Net loss per share attributable to common stockholders - basic and diluted

$

(0.40)

$

(1.09)

Nine Months Ended

 

September 30, 

    

2022

    

2021

Numerator:

 

  

 

  

Net loss

$

(68,079)

$

(78,425)

Denominator:

 

Weighted-average common stock outstanding

 

33,785,386

25,472,590

Net loss per share attributable to common stockholders - basic and diluted

$

(2.02)

$

(3.08)

Schedule of potential dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders

As of

September 30, 

    

2022

    

2021

Options to purchase common stock

 

4,925,678

4,542,353

Restricted stock units

533,114

222,693

Warrants to purchase common stock

 

38,375,618

125,618

XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock issued (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 9 Months Ended
Jun. 27, 2022
Jan. 26, 2022
Jun. 12, 2020
Jun. 04, 2020
Jan. 28, 2020
Feb. 28, 2021
Jun. 30, 2020
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Sale of stock                    
Common Stock, par value (in dollars per share)               $ 0.0001   $ 0.0001
Proceeds from stock issuance, net of cash issuance costs                 $ 74,420  
Common And Pre-Funded Warrants                    
Sale of stock                    
Warrants term 5 years                  
Secondary Public Offering, 2020                    
Sale of stock                    
Issue price (in dollars per share)         $ 45.50          
Proceeds from stock issuance, net of cash issuance costs         $ 134,100          
Secondary Public Offering, Excluding Underwriters' Option                    
Sale of stock                    
Issuance of common stock (in shares)         2,741,489          
Secondary Public Offering, Underwriters' Option                    
Sale of stock                    
Issuance of common stock (in shares)         411,223          
Shelf Registration Statement                    
Sale of stock                    
Maximum value of shares authorized to be sold in stock offering       $ 300,000            
Goldman Equity Distribution Agreement                    
Sale of stock                    
Maximum value of shares authorized to be sold in stock offering     $ 100,000       $ 100,000      
Maximum amount to be paid to sales agent (as a percent)             3.00%      
February Offering, 2021                    
Sale of stock                    
Issuance of common stock (in shares)           3,450,000        
Issue price (in dollars per share)           $ 23.00        
Proceeds from stock issuance, net of cash issuance costs           $ 74,400        
February Offering Underwriters' Option                    
Sale of stock                    
Issuance of common stock (in shares)           450,000        
Cowen Equity Distribution Agreement                    
Sale of stock                    
Issuance of common stock (in shares)               0    
Maximum value of shares authorized to be sold in stock offering   $ 100,000                
Maximum amount to be paid to sales agent (as a percent)   3.00%                
June Offering                    
Sale of stock                    
Issuance of common stock (in shares) 20,000,000                  
Common Stock, par value (in dollars per share) $ 0.0001                  
Issue price per share and accompanying warrant (in dollars per share) 1.00                  
Issue price per pre-funded warrant and accompanying warrant (in dollars per share) $ 0.9999                  
Proceeds from issuance of shares and pre-funded warrants, net $ 27,800                  
June Offering | Common And Pre-Funded Warrants                    
Sale of stock                    
Warrants term 5 years                  
Threshold percentage of aggregate beneficial ownership of holder for exercising warrants 9.99%                  
Threshold percentage of aggregate beneficial ownership of holder (together with affiliates) for exercising warrants 19.99%                  
June Offering | Pre-Funded Warrants                    
Sale of stock                    
Warrants to purchase common stock (in shares) 10,000,000                  
Warrants term               5 years    
June Offering | Common Warrants                    
Sale of stock                    
Warrants to purchase common stock (in shares) 30,000,000                  
Warrants term               5 years    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES      
Net loss $ (68,079) $ (78,425)  
Accumulated deficit (334,394)   $ (266,315)
Cash and cash equivalents and investments $ 47,400    
Substantial Doubt about Going Concern, within One Year true    
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
LICENSE AGREEMENT - Columbia (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 72 Months Ended
Jul. 15, 2022
Oct. 03, 2019
Mar. 31, 2019
Jan. 31, 2019
Oct. 31, 2016
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Agreements                      
Research and development           $ 13,116 $ 17,597 $ 43,542 $ 46,846    
General and administrative           6,240 10,833 20,436 31,658    
Operating expenses           19,356 28,430 63,978 78,504    
Accrued expenses and other current liabilities           14,332   14,332   $ 14,332 $ 16,559
Accounts payable           6,973   6,973   6,973 9,461
Columbia University                      
Agreements                      
Research and development           0 0 0 0    
General and administrative           100 $ 46 200 $ 200    
Operating expenses                   2,600  
Accrued expenses and other current liabilities           100   100   100 12
Accounts payable           $ 0   $ 0   $ 0 $ 100
2016 license agreement | Columbia University                      
Agreements                      
Percentage of outstanding common stock issued         5.00%            
Fair value of stock issued         $ 500            
Written notice period for termination of agreement         90 days            
Written notice period for termination of agreement, uncured material breach         30 days            
Extended written notice period for termination of agreement, attempt to cure material breach         90 days            
2016 license agreement | Columbia University | Minimum                      
Agreements                      
Percentage of sublicensing revenue, if sublicenses rights granted         10.00%            
2016 license agreement | Columbia University | Maximum                      
Agreements                      
Payment on achievement of specified development and regulatory milestones         $ 1,300            
Payment on achievement of specified level of aggregate annual net sales         $ 1,000            
Percentage of sublicensing revenue, if sublicenses rights granted         20.00%            
2019 license agreement | Columbia University                      
Agreements                      
Period within which termination of agreement will become effective 90 days                    
2019 license agreement | Columbia University | Maximum                      
Agreements                      
Payment on achievement of specified development and regulatory milestones       $ 1,300              
Payment on achievement of specified level of aggregate annual net sales       $ 1,000              
2019 research agreement | Columbia University                      
Agreements                      
Agreement term     12 months                
P13k Research agreement | Columbia University                      
Agreements                      
Agreement term   18 months                  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
LICENSE AGREEMENT - Miami University (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 23 Months Ended
Dec. 14, 2020
Oct. 28, 2020
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2021
Agreements                
Research and development     $ 13,116 $ 17,597 $ 43,542 $ 46,846    
General and administrative     6,240 10,833 20,436 31,658    
Operating expenses     19,356 28,430 63,978 78,504    
Accrued expenses and other current liabilities     14,332   14,332   $ 14,332 $ 16,559
2020 license agreement | University of Miami                
Agreements                
Amount of first payment to be made for license issue fee   $ 1,100            
Amount of second payment to be made for license issue fee, due on first anniversary of the date of license   500            
Payment to be made on achievement of specified patenting and development milestones   2,200            
Payment to be made on achievement of late stage regulatory milestones   $ 4,100            
Agreement term   10 years            
Written notice period for termination of agreement   60 days            
Written notice period of material breach leading to termination   60 days            
Research and development     25 200 75 200    
General and administrative     0 0 2 0    
Operating expenses             2,400  
Accrued expenses and other current liabilities     200   200   200 300
2020 license agreement | University of Miami | Minimum                
Agreements                
Royalties payment (as a percent)   0.88%            
Non-royalty sublicensing revenue payment (as a percent)   15.00%            
2020 license agreement | University of Miami | Maximum                
Agreements                
Royalties payment (as a percent)   5.00%            
Non-royalty sublicensing revenue payment (as a percent)   25.00%            
2020 research agreement and amendment | University of Miami                
Agreements                
Consideration $ 300              
Research and development     0 $ 100 100 $ 200    
Accrued expenses and other current liabilities     $ 100   $ 100   $ 100 $ 200
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS - FV hierarchy (Details) - Fair Value, Recurring
$ in Thousands
Sep. 30, 2022
USD ($)
Financial assets or liabilities measured at fair value on a recurring basis  
Cash and cash equivalents $ 40,388
Marketable securities 6,990
Total financial assets measured at fair value on a recurring basis 47,378
Warrant liabilities - Common Warrants 24,739
Total financial liabilities measured at fair value on a recurring basis 24,739
Level 1  
Financial assets or liabilities measured at fair value on a recurring basis  
Cash and cash equivalents 40,388
Total financial assets measured at fair value on a recurring basis 40,388
Level 2  
Financial assets or liabilities measured at fair value on a recurring basis  
Marketable securities 6,990
Total financial assets measured at fair value on a recurring basis 6,990
Level 3  
Financial assets or liabilities measured at fair value on a recurring basis  
Warrant liabilities - Common Warrants 24,739
Total financial liabilities measured at fair value on a recurring basis 24,739
Cash  
Financial assets or liabilities measured at fair value on a recurring basis  
Cash and cash equivalents 7,880
Cash | Level 1  
Financial assets or liabilities measured at fair value on a recurring basis  
Cash and cash equivalents 7,880
Money market funds  
Financial assets or liabilities measured at fair value on a recurring basis  
Cash and cash equivalents 32,508
Money market funds | Level 1  
Financial assets or liabilities measured at fair value on a recurring basis  
Cash and cash equivalents 32,508
U.S. government agency debt securities  
Financial assets or liabilities measured at fair value on a recurring basis  
Marketable securities 6,990
U.S. government agency debt securities | Level 2  
Financial assets or liabilities measured at fair value on a recurring basis  
Marketable securities $ 6,990
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS - Transfers (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
FAIR VALUE MEASUREMENTS  
Assets, transfer from level 1 to level 2 $ 0
Assets, transfer from level 2 to level 1 $ 0
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS - Warrants (Details) - June Offering
Jun. 27, 2022
shares
Common Warrants  
Warrants  
Warrants to purchase common stock (in shares) 30,000,000
Pre-Funded Warrants  
Warrants  
Warrants to purchase common stock (in shares) 10,000,000
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS - Warrants Valuation (Details) - Common And Pre-Funded Warrants
Jun. 27, 2022
Sep. 30, 2022
Y
Fair value    
Warrants term 5 years  
Expected term (in years)    
Fair value    
Measurement input   3.7
Volatility    
Fair value    
Measurement input   0.9153
Risk-free interest rate    
Fair value    
Measurement input   0.0411
Dividend yield    
Fair value    
Measurement input   0.0000
Probability of change in control    
Fair value    
Measurement input   10
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
FAIR VALUE MEASUREMENTS - Fair Values of Company's Warrant Liability (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2022
USD ($)
Common Warrants  
Fair Value  
Initial fair value of Warrant Liability - Common Warrants $ 13,734
Change in fair value 3,331
Ending Balance 17,065
Pre-Funded Warrants  
Fair Value  
Initial fair value of Warrant Liability - Common Warrants 8,101
Warrants exercised (1,417)
Change in fair value 990
Ending Balance $ 7,674
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS - By type (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Marketable securities by type    
Cost $ 6,967 $ 27,042
Gross Unrealized Gains 23 1
Gross Unrealized Losses 0 (108)
Estimated Fair Value 6,990 26,935
U.S. government agency debt securities    
Marketable securities by type    
Cost 6,967 27,042
Gross Unrealized Gains 23 1
Gross Unrealized Losses   (108)
Estimated Fair Value $ 6,990 $ 26,935
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS - Additional Information (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
INVESTMENTS    
Gross unrealized loss $ 0 $ 108
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS - By contractual maturity (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
INVESTMENTS    
Due in one year or less - Cost $ 6,967 $ 27,042
Due in on year or less - Gross Unrealized Gains 23 1
Due in one year or less - Gross Unrealized Losses   (108)
Due in one year or less - Estimated Fair Value 6,990 26,935
Cost 6,967 27,042
Gross Unrealized Gains 23 1
Gross Unrealized Losses 0 (108)
Estimated Fair Value $ 6,990 $ 26,935
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS - Realized gains and losses (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Marketable securities realized gain (loss) recorded    
Gross realized loss from sale of marketable securities $ 3 $ 200
Gross realized gain from sale of marketable securities $ 0 $ 0
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
INVESTMENTS - Unrealized losses and fair values of available-for-sale securities (Details)
$ in Thousands
Dec. 31, 2021
USD ($)
Securities in an unrealized loss position less than 12 months  
Unrealized Losses Less Than 12 months $ (108)
Estimated Fair Value Less Than 12 Months 17,696
Total Unrealized Losses (108)
Total Estimated Fair Value 17,696
U.S. government agency debt securities  
Securities in an unrealized loss position less than 12 months  
Unrealized Losses Less Than 12 months (108)
Estimated Fair Value Less Than 12 Months 17,696
Total Unrealized Losses (108)
Total Estimated Fair Value $ 17,696
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
PREPAID EXPENSES AND OTHER CURRENT ASSETS    
Prepaid research and development expenses $ 4,996 $ 4,483
Insurance premium asset 1,914 1,616
Prepaid rent expenses 86 117
Prepaid insurance expenses 89 105
Prepaid commercial and patient advocacy 167 254
Research and development tax credit receivable 252 502
Interest receivable 24 23
Other prepaid expenses and current assets 604 471
Total prepaid expenses & other current assets $ 8,132 $ 7,571
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES    
Accrued pre-clinical and clinical expenses $ 8,836 $ 9,912
Short-term insurance financing note 1,554 789
Accrued professional fees 837 419
Accrued compensation and benefits 1,484 2,779
Accrued commercial expenses 849 1,394
Accrued patent expenses 314 279
Other 458 987
Total accrued expenses & other current liabilities $ 14,332 $ 16,559
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION - Plans (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended
Aug. 02, 2022
Aug. 01, 2022
May 31, 2019
Sep. 30, 2022
Sep. 30, 2021
Options          
Stock-based compensation          
Weighted Average Remaining Recognition Period (in years)       2 years 3 months 18 days 2 years 6 months
2019 Plan          
Stock-based compensation          
Shares reserved (in shares)     4,530,000    
New shares reserved (in shares)     1,618,841    
Reserved shares available from 2016 Plan (in shares)     2,911,159    
Increase in number of shares reserved and available for issuance (as a percent)     5.00%    
Option exercise price upon option repricing (in dollars per share) $ 1.05        
Options vested upon option repricing (in Shares) 1,797,517        
Options non-vested upon option repricing (in Shares) 1,380,917        
Incremental stock based compensation expense $ 1.4        
Weighted Average Remaining Recognition Period (in years) 2 years 4 months 24 days        
Number of shares available for future issuance       1,331,659  
2019 Plan | Maximum          
Stock-based compensation          
Option exercise price upon option repricing (in dollars per share)   $ 49.60      
2019 Plan | Minimum          
Stock-based compensation          
Option exercise price upon option repricing (in dollars per share)   $ 1.22      
2019 Plan | Options          
Stock-based compensation          
Maximum number of shares authorized for issuance     13,000,000    
Expiration period     10 years    
Vesting period     4 years    
2019 Plan | Vested stock option          
Stock-based compensation          
Incremental stock based compensation expense $ 0.9        
2019 Plan | Non-vested stock option          
Stock-based compensation          
Incremental stock based compensation expense $ 0.5        
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION - Stock-based compensation expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Stock-based compensation        
Total stock-based compensation expense $ 2,856 $ 2,645 $ 7,164 $ 8,328
Research and development        
Stock-based compensation        
Total stock-based compensation expense 1,178 642 2,822 1,974
General and administrative        
Stock-based compensation        
Total stock-based compensation expense $ 1,678 $ 2,003 $ 4,342 $ 6,354
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION - Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Stock-based compensation        
Options granted (in shares)     767,913  
Stock-based compensation expense $ 2,856 $ 2,645 $ 7,164 $ 8,328
Unrecognized stock-based compensation balance for unvested options 9,900 20,200 $ 9,900 $ 20,200
Weighted-average fair value of options granted (in dollars per share)     $ 1.79 $ 10.01
Options        
Stock-based compensation        
Stock-based compensation expense $ 2,500 $ 2,200 $ 6,200 $ 7,000
Weighted Average Remaining Recognition Period (in years)     2 years 3 months 18 days 2 years 6 months
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION - Options activity (Details)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Options Outstanding    
Outstanding at beginning of period (in shares) | shares 4,704,888  
Options granted (in shares) | shares 767,913  
Options exercised (in shares) | shares (47,602)  
Forfeited (in shares) | shares (357,833)  
Expired (in shares) | shares (141,688)  
Outstanding at end of period (in shares) | shares 4,925,678 4,704,888
Exercisable at end of period (in shares) | shares 3,711,517  
Nonvested at end of period (in shares) | shares 1,214,161  
Weighted-Average Exercise Price    
Outstanding at beginning of period (in dollars per share) | $ / shares $ 13.29  
Options granted (in dollars per share) | $ / shares 2.80  
Options exercised (in dollars per share) | $ / shares 1.04  
Options forfeited (in dollars per share) | $ / shares 20.93  
Options expired (in dollars per share) | $ / shares 31.65  
Outstanding at end of period (in dollars per share) | $ / shares 1.99 $ 13.29
Exercisable at end of period (in dollars per share) | $ / shares 2.30  
Nonvested at end of period (in dollars per share) | $ / shares $ 1.05  
Weighted-Average Remaining Contractual Term-in years    
Outstanding 7 years 2 months 12 days 7 years 8 months 12 days
Exercisable 6 years 8 months 12 days  
Nonvested 8 years 6 months  
Aggregate Intrinsic Value    
Options exercised (in dollars) | $ $ 21  
Outstanding (in dollars) | $   $ 10,305
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION - Valuation assumptions (Details) - Stock options - Service conditions only
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Valuation Assumptions    
Expected term (in years) 5 years 8 months 12 days 5 years 7 months 6 days
Volatility (as a percent) 75.83% 70.99%
Risk-free interest rate (as a percent) 2.13% 0.91%
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION - RSUs (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Stock-based compensation          
Stock-based compensation expense $ 2,856 $ 2,645 $ 7,164 $ 8,328  
Restricted Stock Units (RSUs)          
Stock-based compensation          
Stock-based compensation expense 400 500 900 1,300  
Unamortized stock-based compensation costs for unvested awards $ 3,900 $ 5,100 $ 3,900 $ 5,100  
Summary of restricted stock units outstanding          
Outstanding at beginning of period ( in shares)     469,485    
Awarded (in shares)     305,600    
Released (in shares)     (45,840)    
Forfeited (in shares)     (196,131)    
Outstanding at end of period ( in shares) 533,114   533,114    
Nonvested at end of period (in shares) 528,712   528,712    
Weighted-Average Grant Date Fair Value          
Outstanding at beginning of period (in dollars per share)     $ 18.05    
Awarded (in dollars per share)     3.78    
Released (in dollars per share)     25.57    
Forfeited (in dollars per share)     18.36    
Outstanding at end of period (in dollars per share) $ 9.10   9.10    
Nonvested at end of period (in dollars per share) $ 9.06   $ 9.06    
Aggregate Intrinsic Value          
Outstanding at end of period (in dollars) $ 496   $ 496   $ 4,202
Nonvested at end of period (in dollars) $ 492   $ 492    
Weighted Average Remaining Recognition Period (in years)     3 years 1 month 6 days 2 years 10 months 24 days  
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCK BASED COMPENSATION - 2019 Employee Stock Purchase Plan (Details) - 2019 ESPP - shares
1 Months Ended 41 Months Ended
May 31, 2019
Sep. 30, 2022
Stock-based compensation    
Shares authorized (in shares) 180,000  
Shares issued under ESPP   0
Maximum    
Stock-based compensation    
Increase in number of shares reserved and available for issuance (as a percent) 1.00%  
Increase in number of shares reserved and available for issuance (in shares) 360,000  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Authorized stock (Details) - $ / shares
Sep. 30, 2022
Dec. 31, 2021
STOCKHOLDERS' EQUITY    
Common Stock, authorized (in shares) 100,000,000 100,000,000
Common Stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred Stock, authorized (in shares) 10,000,000 10,000,000
Preferred Stock, par value (in dollars per share) $ 0.0001 $ 0.0001
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - Common Stock and Equity Distribution Agreement (Details) - USD ($)
$ in Millions
1 Months Ended 9 Months Ended
Jan. 26, 2022
Jun. 12, 2020
Jun. 30, 2020
Sep. 30, 2022
Goldman Equity Distribution Agreement        
STOCKHOLDERS' EQUITY        
Maximum value of shares authorized to be sold in stock offering.   $ 100.0 $ 100.0  
Maximum amount to be paid to sales agent (as a percent)     3.00%  
Cowen Equity Distribution Agreement        
STOCKHOLDERS' EQUITY        
Maximum value of shares authorized to be sold in stock offering. $ 100.0      
Maximum amount to be paid to sales agent (as a percent) 3.00%      
Issuance of common stock (in shares)       0
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
STOCKHOLDERS' EQUITY - June 2022 Offering (Details) - USD ($)
$ / shares in Units, $ in Millions
9 Months Ended
Jun. 27, 2022
Sep. 30, 2022
Dec. 31, 2021
Equity      
Common Stock, par value (in dollars per share)   $ 0.0001 $ 0.0001
Common And Pre-Funded Warrants      
Equity      
Warrants term 5 years    
June Offering      
Equity      
Issuance of common stock (in shares) 20,000,000    
Common Stock, par value (in dollars per share) $ 0.0001    
Proceeds from issuance of shares and pre-funded warrants, net $ 27.8    
Issue price per share and accompanying warrant (in dollars per share) $ 1.00    
Issue price per pre-funded warrant and accompanying warrant (in dollars per share) $ 0.9999    
June Offering | Common And Pre-Funded Warrants      
Equity      
Warrants term 5 years    
Threshold percentage of aggregate beneficial ownership of holder for exercising warrants 9.99%    
Threshold percentage of aggregate beneficial ownership of holder (together with affiliates) for exercising warrants 19.99%    
June Offering | Pre-Funded Warrants      
Equity      
Warrants to purchase common stock (in shares) 10,000,000    
Warrants term   5 years  
June Offering | Common Warrants      
Equity      
Warrants to purchase common stock (in shares) 30,000,000    
Warrants term   5 years  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS - Issued with Series A Preferred Stock (Details)
$ / shares in Units, $ in Thousands
9 Months Ended
Feb. 05, 2021
USD ($)
shares
Jan. 26, 2017
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2022
Y
Warrants        
Proceeds from exercise of warrants | $     $ 69  
2017 Warrants | Warrants Issued with Series A Preferred Stock        
Warrants        
Warrants to purchase common stock (in shares) | shares   309,389    
Warrants to purchase common stock (in dollars) | $   $ 200    
Exercise price (in dollars per share) | $ / shares   $ 2.49    
Warrants exercised (in shares) | shares 27,855      
Stock issued in exercise of warrants (in shares) | shares 27,855      
Proceeds from exercise of warrants | $ $ 69      
2017 Warrants | Warrants Issued with Series A Preferred Stock | Contractual term (in years)        
Warrants        
Measurement input | Y       10.0
2017 Warrants | Warrants Issued with Series A Preferred Stock | Volatility        
Warrants        
Measurement input       0.7448
2017 Warrants | Warrants Issued with Series A Preferred Stock | Risk-free interest rate        
Warrants        
Measurement input       0.0320
2017 Warrants | Warrants Issued with Series A Preferred Stock | Dividend yield        
Warrants        
Measurement input       0.0000
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS - Issued with the 2018 Notes (Details) - Warrants Issued with the 2018 Notes - USD ($)
$ / shares in Units, $ in Millions
Nov. 05, 2018
Jan. 18, 2018
Warrants    
Initial fair value recorded as debt discount (in dollars)   $ 0.1
Warrants to purchase common stock (in shares) 76,847  
Warrants to purchase common stock (in dollars) $ 0.3  
Exercise price (in dollars per share) $ 6.59  
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS - Issued with Series B Preferred Stock (Details) - Warrants Issued with Series B Preferred Stock
$ / shares in Units, $ in Millions
1 Months Ended 2 Months Ended
Feb. 28, 2019
USD ($)
$ / shares
shares
Dec. 31, 2018
USD ($)
$ / shares
shares
Sep. 30, 2022
Y
2018 Warrants      
Warrants      
Warrants to purchase common stock (in shares) | shares   72,261  
Warrants to purchase common stock (in dollars) | $   $ 0.2  
Exercise price (in dollars per share) | $ / shares   $ 8.24  
Expiration term   10 years  
2018 Warrants | Contractual term (in years)      
Warrants      
Measurement input | Y     10.0
2018 Warrants | Volatility      
Warrants      
Measurement input     0.7322
2018 Warrants | Risk-free interest rate      
Warrants      
Measurement input     0.0270
2018 Warrants | Dividend yield      
Warrants      
Measurement input     0.0000
2019 Warrants      
Warrants      
Warrants to purchase common stock (in shares) | shares 23,867    
Warrants to purchase common stock (in dollars) | $ $ 0.1    
Exercise price (in dollars per share) | $ / shares $ 8.24    
Expiration term 10 years    
2019 Warrants | Contractual term (in years)      
Warrants      
Measurement input | Y     10.0
2019 Warrants | Volatility      
Warrants      
Measurement input     0.7322
2019 Warrants | Risk-free interest rate      
Warrants      
Measurement input     0.0270
2019 Warrants | Dividend yield      
Warrants      
Measurement input     0.0000
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS - Issued with June 2022 Offering (Details)
9 Months Ended
Jun. 28, 2022
USD ($)
shares
Jun. 27, 2022
$ / shares
shares
Sep. 30, 2022
Y
$ / shares
shares
Sep. 30, 2021
USD ($)
Dec. 31, 2021
shares
Warrants          
Proceeds from exercise of warrants | $       $ 69,000  
Common And Pre-Funded Warrants          
Warrants          
Warrants term   5 years      
Warrants exercised (in shares)     1,750,000    
Warrants outstanding (in shares)     38,375,618   125,618
Common And Pre-Funded Warrants | Contractual term (in years)          
Warrants          
Measurement input | Y     3.7    
Common And Pre-Funded Warrants | Volatility          
Warrants          
Measurement input     0.9153    
Common And Pre-Funded Warrants | Risk-free interest rate          
Warrants          
Measurement input     0.0411    
Common And Pre-Funded Warrants | Dividend yield          
Warrants          
Measurement input     0.0000    
June Offering          
Warrants          
Issue price per share and accompanying warrant (in dollars per share) | $ / shares   $ 1.00      
Issue price per pre-funded warrant and accompanying warrant (in dollars per share) | $ / shares   $ 0.9999      
June Offering | Common And Pre-Funded Warrants          
Warrants          
Warrants term   5 years      
Threshold percentage of aggregate beneficial ownership of holder for exercising warrants   9.99%      
Threshold percentage of aggregate beneficial ownership of holder (together with affiliates) for exercising warrants   19.99%      
June Offering | Pre-Funded Warrants          
Warrants          
Warrants to purchase common stock (in shares)   10,000,000      
Exercise price (in dollars per share) | $ / shares   $ 0.0001 $ 0.0001    
Warrants term     5 years    
Warrants exercised (in shares) 1,750,000        
Exercise of prefunded warrants for common stock (in shares) 1,750,000        
Proceeds from exercise of warrants | $ $ 175        
Warrants outstanding (in shares)     8,250,000    
June Offering | Common Warrants          
Warrants          
Warrants to purchase common stock (in shares)   30,000,000      
Exercise price (in dollars per share) | $ / shares   $ 1.00 $ 1.00    
Warrants term     5 years    
Warrants outstanding (in shares)     30,000,000    
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
WARRANTS - Warrant Activity (Details) - Common And Pre-Funded Warrants
9 Months Ended
Sep. 30, 2022
shares
Warrants  
Outstanding as of beginning of period 125,618
Warrants granted and issued 40,000,000
Warrants exercised (1,750,000)
Outstanding as of end of period 38,375,618
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES - Lease Cost (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Leases    
Operating Lease Cost $ 126 $ 126
General and administrative    
Leases    
Operating Lease Cost $ 126 $ 126
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES - Lease terms and discount rates (Details)
Sep. 30, 2022
Sep. 30, 2021
LEASES    
Weighted-average remaining lease term - operating leases 2 years 1 month 6 days 3 years
Weighted-average discount rate - operating leases 5.69% 5.69%
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
LEASES - Maturities of Lease Liabilities (Details)
$ in Thousands
Sep. 30, 2022
USD ($)
LEASES  
2022 $ 128
2023 515
2024 426
Total lease payments 1,069
Less: interest 63
Total lease liabilities $ 1,006
Operating Lease, Liability, Statement of Financial Position Current portion of operating lease liabilities, Noncurrent portion of operating lease liabilities
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
BENEFIT PLANS (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
BENEFIT PLANS    
Employer matching contributions to the plan $ 0.4 $ 0.2
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER COMMON SHARE - EPS (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Numerator:        
Net loss attributable to common stockholders-basic $ (19,101) $ (28,418) $ (68,079) $ (78,425)
Net loss attributable to common stockholders-diluted $ (19,101) $ (28,418) $ (68,079) $ (78,425)
Denominator:        
Weighted-average common stock outstanding-basic (in shares) 48,000,183 26,177,079 33,785,386 25,472,590
Weighted-average common stock outstanding-diluted (in shares) 48,000,183 26,177,079 33,785,386 25,472,590
Net loss per share attributable to common stockholders-basic (in dollars per share) $ (0.40) $ (1.09) $ (2.02) $ (3.08)
Net loss per share attributable to common stockholders-diluted (in dollars per share) $ (0.40) $ (1.09) $ (2.02) $ (3.08)
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
NET LOSS PER COMMON SHARE - Anti-dilutive securities (Details) - shares
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Options to purchase common stock    
Antidilutive securities excluded from computation of loss per share    
Potential dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders 4,925,678 4,542,353
Restricted stock units    
Antidilutive securities excluded from computation of loss per share    
Potential dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders 533,114 222,693
Warrants to purchase common stock    
Antidilutive securities excluded from computation of loss per share    
Potential dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders 38,375,618 125,618
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.22.2.2
RELATED PARTIES (Details) - LaunchLabs Agreement - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Related Party Transactions        
Payments to related party $ 23 $ 23 $ 70 $ 70
Due to related parties $ 0   $ 0  
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.22.2.2
SUBSEQUENT EVENTS (Details) - shares
Oct. 26, 2022
Sep. 30, 2022
Dec. 31, 2021
Subsequent event      
Common Stock, authorized (in shares)   100,000,000 100,000,000
Subsequent Event.      
Subsequent event      
Common Stock, authorized (in shares) 200,000,000    
XML 83 aplt-20220930x10q_htm.xml IDEA: XBRL DOCUMENT 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2019Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2019Member us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2019Member us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2019Member us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2018Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2018Member us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2018Member us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2018Member us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember aplt:MeasurementInputChangeOfControlProbabilityMember 2022-09-30 0001697532 aplt:EquityDistributionAgreementJanuary2022Member 2022-01-01 2022-09-30 0001697532 aplt:SecondaryPublicOfferingFebruary2021OverAllotmentOptionMember 2021-02-01 2021-02-28 0001697532 aplt:SecondaryPublicOfferingExcludingOverAllotmentOptionMember 2020-01-28 2020-01-28 0001697532 aplt:SecondaryPublicOffering2020OverAllotmentOptionMember 2020-01-28 2020-01-28 0001697532 aplt:EmployeeStockPurchasePlan2019Member 2019-05-01 2022-09-30 0001697532 us-gaap:RetainedEarningsMember 2022-09-30 0001697532 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001697532 us-gaap:RetainedEarningsMember 2022-06-30 0001697532 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001697532 2022-06-30 0001697532 us-gaap:RetainedEarningsMember 2022-03-31 0001697532 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001697532 2022-03-31 0001697532 us-gaap:RetainedEarningsMember 2021-12-31 0001697532 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001697532 us-gaap:RetainedEarningsMember 2021-09-30 0001697532 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001697532 us-gaap:RetainedEarningsMember 2021-06-30 0001697532 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001697532 2021-06-30 0001697532 us-gaap:RetainedEarningsMember 2021-03-31 0001697532 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001697532 2021-03-31 0001697532 us-gaap:RetainedEarningsMember 2020-12-31 0001697532 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001697532 us-gaap:CommonStockMember 2022-06-30 0001697532 us-gaap:CommonStockMember 2022-03-31 0001697532 us-gaap:CommonStockMember 2021-12-31 0001697532 us-gaap:CommonStockMember 2021-06-30 0001697532 us-gaap:CommonStockMember 2021-03-31 0001697532 us-gaap:CommonStockMember 2020-12-31 0001697532 aplt:SecondaryPublicOfferingFebruary2021Member 2021-02-28 0001697532 aplt:SecondaryPublicOfferingJanuary2020Member 2020-01-28 0001697532 2021-01-01 2021-12-31 0001697532 aplt:EquityIncentivePlan2019Member 2022-09-30 0001697532 us-gaap:EmployeeStockOptionMember aplt:EquityIncentivePlan2019Member 2019-05-31 0001697532 aplt:EmployeeStockPurchasePlan2019Member 2019-05-31 0001697532 aplt:StockOptionsVestingBasedOnServiceMember 2021-01-01 2021-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0001697532 us-gaap:EmployeeStockOptionMember aplt:EquityIncentivePlan2019Member 2019-05-01 2019-05-31 0001697532 aplt:StockOptionsVestingBasedOnServiceMember 2022-01-01 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:ResearchAgreement2020Member 2022-07-01 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:ResearchAgreement2020Member 2022-01-01 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:ResearchAgreement2020Member 2021-07-01 2021-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:ResearchAgreement2020Member 2021-01-01 2021-09-30 0001697532 aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember 2022-07-01 2022-09-30 0001697532 aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember 2022-01-01 2022-09-30 0001697532 aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember 2021-07-01 2021-09-30 0001697532 aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember 2021-01-01 2021-09-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001697532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2020-10-28 2022-09-30 0001697532 aplt:ColumbiaUniversityMember 2016-10-01 2022-09-30 0001697532 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001697532 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001697532 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001697532 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001697532 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001697532 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001697532 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2022-07-01 2022-09-30 0001697532 aplt:ColumbiaUniversityMember 2022-07-01 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2022-01-01 2022-09-30 0001697532 aplt:ColumbiaUniversityMember 2022-01-01 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2021-07-01 2021-09-30 0001697532 aplt:ColumbiaUniversityMember 2021-07-01 2021-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2021-01-01 2021-09-30 0001697532 aplt:ColumbiaUniversityMember 2021-01-01 2021-09-30 0001697532 aplt:PreFundedWarrantsMember 2022-09-30 0001697532 aplt:CommonWarrantsMember 2022-09-30 0001697532 aplt:PreFundedWarrantsMember 2022-01-01 2022-09-30 0001697532 aplt:CommonWarrantsMember 2022-01-01 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member 2022-01-01 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2019Member 2022-01-01 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2018Member 2022-01-01 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember 2022-01-01 2022-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001697532 aplt:VestedStockOptionAwardsMember aplt:EquityIncentivePlan2019Member 2022-08-02 2022-08-02 0001697532 aplt:NonVestedStockOptionAwardsMember aplt:EquityIncentivePlan2019Member 2022-08-02 2022-08-02 0001697532 aplt:LaunchlabsAgreementWithAlexandriaLaunchlabsMember 2022-09-30 0001697532 aplt:WarrantsIssuedWith2018NotesMember 2018-01-18 0001697532 us-gaap:SubsequentEventMember 2022-10-26 0001697532 us-gaap:CommonStockMember 2022-09-30 0001697532 us-gaap:CommonStockMember 2021-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember 2021-12-31 0001697532 aplt:PreFundedWarrantsMember aplt:June2022OfferingMember 2022-09-30 0001697532 aplt:CommonWarrantsMember aplt:June2022OfferingMember 2022-09-30 0001697532 aplt:PreFundedWarrantsMember aplt:June2022OfferingMember 2022-06-27 0001697532 aplt:CommonWarrantsMember aplt:June2022OfferingMember 2022-06-27 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2019Member 2019-02-28 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2018Member 2018-12-31 0001697532 aplt:WarrantsIssuedWith2018NotesMember 2018-11-05 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member 2017-01-26 0001697532 2021-09-30 0001697532 2020-12-31 0001697532 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:CashMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:CashMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0001697532 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001697532 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001697532 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001697532 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001697532 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2022-09-30 0001697532 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001697532 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001697532 us-gaap:EmployeeStockOptionMember 2022-07-01 2022-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-09-30 0001697532 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001697532 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001697532 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001697532 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001697532 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001697532 us-gaap:EmployeeStockOptionMember 2021-07-01 2021-09-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001697532 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001697532 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001697532 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2019Member 2019-02-01 2019-02-28 0001697532 aplt:WarrantsIssuedWith2018NotesMember 2018-11-05 2018-11-05 0001697532 aplt:WarrantsIssuedWithSeriesBPreferredStockMember aplt:Warrant2018Member 2018-11-01 2018-12-31 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member 2017-01-26 2017-01-26 0001697532 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001697532 2022-07-01 2022-09-30 0001697532 2022-11-08 0001697532 aplt:PreFundedAndCommonWarrantsMember 2022-01-01 2022-09-30 0001697532 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember 2022-06-27 2022-06-27 0001697532 aplt:PreFundedWarrantsMember aplt:June2022OfferingMember 2022-01-01 2022-09-30 0001697532 aplt:CommonWarrantsMember aplt:June2022OfferingMember 2022-01-01 2022-09-30 0001697532 aplt:PreFundedAndCommonWarrantsMember aplt:June2022OfferingMember 2022-06-27 2022-06-27 0001697532 aplt:EquityIncentivePlan2019Member 2022-08-02 2022-08-02 0001697532 srt:MinimumMember aplt:EquityIncentivePlan2019Member 2022-08-01 2022-08-01 0001697532 srt:MaximumMember aplt:EquityIncentivePlan2019Member 2022-08-01 2022-08-01 0001697532 aplt:EquityDistributionAgreementMember 2020-06-12 2020-06-12 0001697532 aplt:ShelfOfferingMember 2020-06-04 2020-06-04 0001697532 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001697532 2021-07-01 2021-09-30 0001697532 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001697532 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001697532 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001697532 aplt:WarrantsIssuedWithSeriesPreferredStockMember aplt:Warrant2017Member 2021-02-05 2021-02-05 0001697532 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001697532 aplt:PreFundedWarrantsMember aplt:June2022OfferingMember 2022-06-28 2022-06-28 0001697532 2022-04-01 2022-06-30 0001697532 2021-01-01 2021-03-31 0001697532 aplt:EquityDistributionAgreementJanuary2022Member 2022-01-26 2022-01-26 0001697532 aplt:EquityDistributionAgreementMember 2020-06-01 2020-06-30 0001697532 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001697532 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001697532 us-gaap:RestrictedStockUnitsRSUMember 2022-09-30 0001697532 aplt:EquityIncentivePlan2019Member 2019-05-01 2019-05-31 0001697532 srt:MaximumMember aplt:EmployeeStockPurchasePlan2019Member 2019-05-01 2019-05-31 0001697532 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001697532 aplt:June2022OfferingMember 2022-06-27 2022-06-27 0001697532 aplt:SecondaryPublicOfferingFebruary2021Member 2021-02-01 2021-02-28 0001697532 aplt:SecondaryPublicOfferingJanuary2020Member 2020-01-28 2020-01-28 0001697532 aplt:UniversityOfMiamiMember srt:MinimumMember aplt:LicenseAgreement2020Member 2020-10-28 2020-10-28 0001697532 aplt:UniversityOfMiamiMember srt:MaximumMember aplt:LicenseAgreement2020Member 2020-10-28 2020-10-28 0001697532 aplt:ColumbiaUniversityMember aplt:ResearchServiceAgreementP13kMember 2019-10-03 2019-10-03 0001697532 aplt:ColumbiaUniversityMember aplt:ResearchAgreement2019Member 2019-03-01 2019-03-31 0001697532 aplt:ColumbiaUniversityMember aplt:LicenseAgreement2019Member 2022-07-15 2022-07-15 0001697532 aplt:ColumbiaUniversityMember srt:MinimumMember aplt:LicenseAgreement2016Member 2016-10-01 2016-10-31 0001697532 aplt:ColumbiaUniversityMember aplt:LicenseAgreement2016Member 2016-10-01 2016-10-31 0001697532 aplt:ColumbiaUniversityMember srt:MaximumMember aplt:LicenseAgreement2019Member 2019-01-01 2019-01-31 0001697532 aplt:ColumbiaUniversityMember srt:MaximumMember aplt:LicenseAgreement2016Member 2016-10-01 2016-10-31 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2020-10-28 2020-10-28 0001697532 aplt:UniversityOfMiamiMember aplt:ResearchAgreement2020Member 2020-12-14 2020-12-14 0001697532 aplt:June2022OfferingMember 2022-06-27 0001697532 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001697532 aplt:EquityIncentivePlan2019Member 2019-05-31 0001697532 2022-01-01 2022-09-30 0001697532 2021-01-01 2021-09-30 0001697532 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001697532 2021-04-01 2021-06-30 0001697532 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001697532 2022-01-01 2022-03-31 0001697532 aplt:UniversityOfMiamiMember aplt:ResearchAgreement2020Member 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2022-09-30 0001697532 aplt:ColumbiaUniversityMember 2022-09-30 0001697532 aplt:UniversityOfMiamiMember aplt:ResearchAgreement2020Member 2021-12-31 0001697532 aplt:UniversityOfMiamiMember aplt:LicenseAgreement2020Member 2021-12-31 0001697532 aplt:ColumbiaUniversityMember 2021-12-31 0001697532 2022-09-30 0001697532 2021-12-31 iso4217:USD shares iso4217:USD shares pure aplt:Y 48000183 26177079 33785386 25472590 0001697532 --12-31 2022 Q3 false 0 0 33785386 25472590 48000183 26177079 48058956 26215514 -19101000 -28418000 -68079000 -78425000 -0.40 -1.09 -2.02 -3.08 0 http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2022#OperatingLeaseLiabilityNoncurrent -19101000 -28418000 -0.40 -1.09 -68079000 -78425000 -2.02 -3.08 10-Q true 2022-09-30 false 001-38898 Applied Therapeutics, Inc. DE 81-3405262 545 Fifth Avenue Suite 1400 New York NY 10017 212 220-9226 Common Stock APLT NASDAQ Yes Yes Non-accelerated Filer true true true false 48058956 40388000 53888000 6990000 26935000 8132000 7571000 55510000 88394000 970000 1298000 199000 200000 56679000 89892000 470000 442000 6973000 9461000 14332000 16559000 24739000 46514000 26462000 536000 891000 536000 891000 47050000 27353000 0.0001 0.0001 100000000 100000000 48058956 26215514 5000 3000 0.0001 0.0001 10000000 10000000 0 0 343995000 328958000 23000 -107000 -334394000 -266315000 9629000 62539000 56679000 89892000 13116000 17597000 43542000 46846000 6240000 10833000 20436000 31658000 19356000 28430000 63978000 78504000 -19356000 -28430000 -63978000 -78504000 227000 76000 414000 321000 -36000 4321000 -8000 -64000 -194000 -242000 255000 12000 -4101000 79000 -19101000 -28418000 -68079000 -78425000 -19101000 -28418000 -68079000 -78425000 -0.40 -1.09 -2.02 -3.08 48000183 26177079 33785386 25472590 -19101000 -28418000 -68079000 -78425000 17000 -69000 130000 -142000 17000 -69000 130000 -142000 -19084000 -28487000 -67949000 -78567000 0.0001 22493661 2000 242780000 -160731000 -112000 81939000 203000 3450000 1000 74386000 74387000 37400 67000 67000 465 1000 1000 1988 27855 69000 69000 2981000 2981000 -24179000 -24179000 -42000 -42000 26010439 3000 320282000 -184910000 -154000 135221000 35000 35000 465 1000 1000 82668 341000 341000 920 1000 1000 37884 2702000 2702000 -25828000 -25828000 -31000 -31000 26130536 3000 323360000 -210738000 -185000 112440000 920 1000 1000 70368 103000 103000 115 1000 1000 12690 2645000 2645000 -28418000 -28418000 -69000 -69000 26214399 3000 326108000 -239156000 -254000 86701000 0.0001 26215514 3000 328958000 -266315000 -107000 62539000 21417 21417 2077000 2077000 441000 441000 -23121000 -23121000 27000 27000 26215514 3000 331476000 -289436000 -80000 41963000 96000 20000000 2000 5966000 5968000 1750000 1417000 1417000 1750000 21417 16593 2231000 2231000 -25857000 -25857000 86000 86000 46253524 5000 341090000 -315293000 6000 25808000 1750000 47602 49000 49000 7830 2856000 2856000 -19101000 -19101000 17000 17000 48058956 5000 343995000 -334394000 23000 9629000 -68079000 -78425000 7164000 8328000 441000 2806000 3163000 328000 308000 1000 1000 -327000 -299000 4321000 3105000 4434000 262000 1107000 -2488000 8530000 -3000000 149000 -62200000 -63786000 36911000 109119000 5539000 56986000 104206000 20075000 626000 27811000 165000 74420000 3105000 4434000 2340000 3534000 49000 512000 69000 28625000 75901000 -13500000 12741000 53888000 57466000 40388000 70207000 21835000 1417000 130000 -142000 8000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operations and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Applied Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. In particular, the Company is currently targeting treatments for rare metabolic diseases such as Galactosemia, Sorbitol Dehydrogenase (“SORD”) deficiency, and diabetic complications including diabetic cardiomyopathy. The Company was incorporated in Delaware on January 20, 2016 and is headquartered in New York, New York.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2020, the Company completed its secondary public offering (the “Secondary Public Offering”), pursuant to which it issued and sold 2,741,489 shares of common stock at a public offering price of $45.50 per share, with an additional 411,223 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering, after deducting underwriting discounts and commissions and offering costs, were $134.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 4, 2020, the Company filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”) under which the Company may, from time to time, sell securities in one or more offerings having an aggregate offering price of up to $300.0<span style="white-space:pre-wrap;"> million. The Shelf Registration Statement was declared effective as of June 15, 2020. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 12, 2020, the Company entered into an equity distribution agreement (the “Goldman Equity Distribution Agreement”) with Goldman Sachs &amp; Co. LLC (“Goldman”), as a sales agent to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100<span style="white-space:pre-wrap;"> million. Goldman may act as an agent on the Company’s behalf or purchase shares of the Company’s common stock as a principal. </span><span style="background:#ffffff;">The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.</span><span style="white-space:pre-wrap;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In February 2021, the Company completed an underwritten public offering of 3,450,000 shares of common stock (the “February Offering”), including the exercise in full of the underwriters’ option to purchase 450,000 additional shares of common stock, which option closed on February 19, 2021. The shares were offered at a price to the public of $23.00 per share, resulting in aggregate net proceeds of approximately $74.4 million, after deducting underwriting discounts and commissions and offering expenses<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On January 26, 2022, the Company entered into an equity distribution agreement (the “Cowen Equity Distribution Agreement) with Cowen and Company, LLC (“Cowen”), as a sales agent, to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to </span><span style="background:#ffffff;">$100.0</span><span style="background:#ffffff;"> million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to </span><span style="background:#ffffff;">3%</span><span style="background:#ffffff;"> of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;">t sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On June 27, 2022, the Company</span><i style="font-style:italic;background:#ffffff;"> </i><span style="background:#ffffff;">completed an underwritten public offering (the “June Offering”) of </span><span style="background:#ffffff;">20,000,000</span><span style="background:#ffffff;"> shares of common stock, par value </span><span style="background:#ffffff;">$0.0001</span><span style="background:#ffffff;"> per share, </span><span style="background:#ffffff;">10,000,000</span><span style="background:#ffffff;"> pre-funded warrants to purchase shares of common stock (the “Pre-Funded Warrants”), and accompanying warrants to purchase up to </span><span style="background:#ffffff;">30,000,000</span><span style="background:#ffffff;"> shares of common stock (the “Common Warrants”). The shares and accompanying Common Warrants were offered at a price to the public of </span><span style="background:#ffffff;">$1.00</span><span style="background:#ffffff;"> per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">to the public of </span><span style="background:#ffffff;">$0.9999</span><span style="background:#ffffff;">, resulting in aggregate net proceeds of approximately </span><span style="background:#ffffff;">$27.8</span><span style="background:#ffffff;"> million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire </span><span style="background:#ffffff;">five years</span><span style="background:#ffffff;"> from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than </span><span style="background:#ffffff;">19.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2021 included in the Annual Report, filed with the SEC on March 10, 2022 (the “Annual Report”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments which are necessary for a fair presentation of the Company’s financial position as of September 30, 2022, results of operations for the three and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred, and expects to continue to incur, significant operating losses for the foreseeable future as it continues to develop its drug candidates. To date, the Company has not generated any revenue, and it does not expect to generate revenue unless and until it successfully completes development and obtains regulatory approval for one of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. We are actively pursuing several potential financing options. While we continue to explore opportunities to raise additional equity capital in the public markets, this has proven to be challenging in the biotech sector recently. Other options for structured finance which we continue to explore include a PIPE, debt, convertible debt, and synthetic royalty financing. Synthetic royalty financing, in particular, has become a favorable option for many companies for funding ongoing clinical development in late-stage and pre-approval programs. We have engaged an investment bank and we are specifically exploring this option in the near term. Additionally, we are in active dialogue with several potential partners regarding business development opportunities related to one or more of our programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There can be no assurances that our discussions with any of the current counterparties will be successful, and the Company expects to continue to pursue additional opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As reflected in the accompanying financial statements, the Company has a net loss of $68.1 million for the nine months ended September 30, 2022 and has an accumulated deficit of $334.4 million as of September 30, 2022. The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. While we believe that our cash and cash equivalents and short-term investments of $47.4 million at September 30, 2022 will be sufficient to fund our operations through June 30, 2023, given our planned expenditures for the next several years, we have concluded and our independent registered public accounting firm has agreed with our conclusion that there is still a substantial doubt regarding our ability to continue as a going concern within one year after the date this Quarterly Report on Form 10-Q is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The significant accounting policies and estimates used in preparation of the condensed financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operations and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Applied Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. In particular, the Company is currently targeting treatments for rare metabolic diseases such as Galactosemia, Sorbitol Dehydrogenase (“SORD”) deficiency, and diabetic complications including diabetic cardiomyopathy. The Company was incorporated in Delaware on January 20, 2016 and is headquartered in New York, New York.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 28, 2020, the Company completed its secondary public offering (the “Secondary Public Offering”), pursuant to which it issued and sold 2,741,489 shares of common stock at a public offering price of $45.50 per share, with an additional 411,223 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares. The aggregate net proceeds received by the Company from the offering, after deducting underwriting discounts and commissions and offering costs, were $134.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 4, 2020, the Company filed a shelf registration statement on Form S-3 (the “Shelf Registration Statement”) under which the Company may, from time to time, sell securities in one or more offerings having an aggregate offering price of up to $300.0<span style="white-space:pre-wrap;"> million. The Shelf Registration Statement was declared effective as of June 15, 2020. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 12, 2020, the Company entered into an equity distribution agreement (the “Goldman Equity Distribution Agreement”) with Goldman Sachs &amp; Co. LLC (“Goldman”), as a sales agent to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100<span style="white-space:pre-wrap;"> million. Goldman may act as an agent on the Company’s behalf or purchase shares of the Company’s common stock as a principal. </span><span style="background:#ffffff;">The Goldman Equity Distribution Agreement was terminated as of January 24, 2022.</span><span style="white-space:pre-wrap;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In February 2021, the Company completed an underwritten public offering of 3,450,000 shares of common stock (the “February Offering”), including the exercise in full of the underwriters’ option to purchase 450,000 additional shares of common stock, which option closed on February 19, 2021. The shares were offered at a price to the public of $23.00 per share, resulting in aggregate net proceeds of approximately $74.4 million, after deducting underwriting discounts and commissions and offering expenses<span style="font-size:12pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On January 26, 2022, the Company entered into an equity distribution agreement (the “Cowen Equity Distribution Agreement) with Cowen and Company, LLC (“Cowen”), as a sales agent, to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to </span><span style="background:#ffffff;">$100.0</span><span style="background:#ffffff;"> million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to </span><span style="background:#ffffff;">3%</span><span style="background:#ffffff;"> of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has </span><span style="background:#ffffff;">no</span><span style="background:#ffffff;">t sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On June 27, 2022, the Company</span><i style="font-style:italic;background:#ffffff;"> </i><span style="background:#ffffff;">completed an underwritten public offering (the “June Offering”) of </span><span style="background:#ffffff;">20,000,000</span><span style="background:#ffffff;"> shares of common stock, par value </span><span style="background:#ffffff;">$0.0001</span><span style="background:#ffffff;"> per share, </span><span style="background:#ffffff;">10,000,000</span><span style="background:#ffffff;"> pre-funded warrants to purchase shares of common stock (the “Pre-Funded Warrants”), and accompanying warrants to purchase up to </span><span style="background:#ffffff;">30,000,000</span><span style="background:#ffffff;"> shares of common stock (the “Common Warrants”). The shares and accompanying Common Warrants were offered at a price to the public of </span><span style="background:#ffffff;">$1.00</span><span style="background:#ffffff;"> per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">to the public of </span><span style="background:#ffffff;">$0.9999</span><span style="background:#ffffff;">, resulting in aggregate net proceeds of approximately </span><span style="background:#ffffff;">$27.8</span><span style="background:#ffffff;"> million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire </span><span style="background:#ffffff;">five years</span><span style="background:#ffffff;"> from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than </span><span style="background:#ffffff;">19.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 31, 2021 included in the Annual Report, filed with the SEC on March 10, 2022 (the “Annual Report”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The unaudited condensed financial statements have been prepared on the same basis as the audited financial statements. In the opinion of management, the accompanying unaudited condensed financial statements contain all adjustments which are necessary for a fair presentation of the Company’s financial position as of September 30, 2022, results of operations for the three and nine months ended September 30, 2022 and 2021 and cash flows for the nine months ended September 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2022.</p> 2741489 45.50 411223 134100000 300000000.0 100000000 3450000 450000 23.00 74400000 100000000.0 0.03 0 20000000 0.0001 10000000 30000000 1.00 0.9999 27800000 P5Y 0.0999 0.0999 0.1999 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred, and expects to continue to incur, significant operating losses for the foreseeable future as it continues to develop its drug candidates. To date, the Company has not generated any revenue, and it does not expect to generate revenue unless and until it successfully completes development and obtains regulatory approval for one of its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under ASC Topic 205-40, Presentation of Financial Statements - Going Concern, management is required at each reporting period to evaluate whether there are conditions and events, considered in the aggregate, that raise substantial doubt about an entity's ability to continue as a going concern within one year after the date that the financial statements are issued. We are actively pursuing several potential financing options. While we continue to explore opportunities to raise additional equity capital in the public markets, this has proven to be challenging in the biotech sector recently. Other options for structured finance which we continue to explore include a PIPE, debt, convertible debt, and synthetic royalty financing. Synthetic royalty financing, in particular, has become a favorable option for many companies for funding ongoing clinical development in late-stage and pre-approval programs. We have engaged an investment bank and we are specifically exploring this option in the near term. Additionally, we are in active dialogue with several potential partners regarding business development opportunities related to one or more of our programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There can be no assurances that our discussions with any of the current counterparties will be successful, and the Company expects to continue to pursue additional opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As reflected in the accompanying financial statements, the Company has a net loss of $68.1 million for the nine months ended September 30, 2022 and has an accumulated deficit of $334.4 million as of September 30, 2022. The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. While we believe that our cash and cash equivalents and short-term investments of $47.4 million at September 30, 2022 will be sufficient to fund our operations through June 30, 2023, given our planned expenditures for the next several years, we have concluded and our independent registered public accounting firm has agreed with our conclusion that there is still a substantial doubt regarding our ability to continue as a going concern within one year after the date this Quarterly Report on Form 10-Q is issued.</p> -68100000 -334400000 47400000 true <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and reliance on third-party manufacturers.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The significant accounting policies and estimates used in preparation of the condensed financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report. There have been no material changes to the Company’s significant accounting policies during the nine months ended September 30, 2022. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Any recent pronouncements issued by the FASB or other authoritative standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. LICENSE AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Columbia University</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In October 2016, the Company entered into a license agreement (the “2016 Columbia Agreement”) with the Trustees of Columbia University (“Columbia University”) to obtain an exclusive royalty-bearing sublicensable license in respect to certain patents. As part of the consideration for entering into the 2016 Columbia Agreement, the Company issued to Columbia University shares equal to 5% of its outstanding common stock on a fully diluted basis at the time of issue. The common stock had a fair value of $0.5 million at the time of issuance. The Company will be required to make further payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual net sales, in each case in connection with products covered by the 2016 Columbia Agreement. The Company will also be required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">on the Company’s, its affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent upon the approval of the licensed products, in the mid-six figures beginning on the 10th anniversary of the effective date of the 2016 Columbia Agreement. The Company has not granted any sublicenses under the 2016 Columbia Agreement. However, if the Company sublicenses the rights granted under the 2016 Columbia Agreement to one or more third parties, it will be required to pay Columbia University a portion of the net sublicensing revenue received from such third parties, at percentages between 10% and 20%, depending on the stage of development at the time such revenue is received from such third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2016 Columbia Agreement will terminate upon the expiration of all the Company’s royalty payment obligations in all countries. The Company may terminate the 2016 Columbia Agreement for convenience upon 90 days’ written notice to Columbia University. At its election, Columbia University may terminate the 2016 Columbia Agreement, or convert the licenses granted to the Company into non-exclusive, non-sublicensable licenses, in the case of (a) the Company’s uncured material breach upon 30 days’ written notice (which shall be extended to 90 days if the Company is diligently attempting to cure such material breach), (b) the Company’s failure to achieve the specified development and funding milestone events, or (c) the Company’s insolvency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2019, the Company entered into a second license agreement with Columbia University (the “2019 Columbia Agreement”). Pursuant to the 2019 Columbia Agreement, Columbia University granted the Company a royalty-bearing, sublicensable license that is exclusive with respect to certain patents, and non-exclusive with respect to certain know-how, in each case to develop, manufacture and commercialize PI3k inhibitor products. The license grant is worldwide. Under the 2019 Columbia Agreement, the Company is obligated to use commercially reasonable efforts to research, discover, develop and market licensed products for commercial sale in the licensed territory, and to comply with certain obligations to meet specified development and funding milestones within defined time periods. Columbia University retains the right to conduct, and grant third parties the right to conduct, non-clinical academic research using the licensed technology; provided that such research is not funded by a commercial entity or for-profit entity or results in rights granted to a commercial or for-profit entity. As consideration for entering into the 2019 Columbia Agreement, the Company made a nominal upfront payment to Columbia University. The Company will be required to make further payments to Columbia University of up to an aggregate of $1.3 million for the achievement of specified development and regulatory milestones, and up to an aggregate of $1.0 million for the achievement of a specified level of aggregate annual net sales, in each case in connection with products covered by the 2019 Columbia Agreement. The Company will also be required to pay tiered royalties to Columbia University in the low- to mid-single digit percentages on the Company’s, its affiliates’ and its sublicensees’ net sales of licensed products, subject to specified offsets and reductions. In addition, the Company is required to make specified annual minimum royalty payments to Columbia University, which is contingent upon the approval of the licensed products, in the mid-six figures beginning on the tenth anniversary of the effective date of the 2019 Columbia Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In March 2019, and in connection with the 2016 Columbia Agreement, the Company entered into a research services agreement (the “2019 Columbia Research Agreement”) with Columbia University with the purpose of analyzing structural and functional changes in brain tissue in an animal model of Galactosemia, and the effects of certain compounds whose intellectual property rights were licensed to the Company as part of the 2016 Columbia Agreement on any such structural and functional changes. The 2019 Columbia Research Agreement had a term of </span>12 months<span style="white-space:pre-wrap;"> from its effective date and expired in accordance with its terms. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 3, 2019, and in connection with the 2019 Columbia Agreement, the Company entered into a research services agreement (the “PI3k Columbia Research Agreement” and collectively with the 2016 Columbia Agreement, 2019 Columbia Agreement and 2019 Columbia Research Agreement, the “Columbia Agreements”) with Columbia University with the purpose of analyzing PI3k inhibitors for the treatment of lymphoid malignancies. The PI3k Columbia Research Agreement had a term of 18 months from its effective date and expired in accordance with its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2022, the Company recorded $0 and $0 in research and development expenses, respectively; and $0.1 million and $0.2 million in general and administrative expense, respectively, related to the Columbia Agreements. During the three and nine months ended September 30, 2021, the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Company recorded $0 and $0, respectively, in research and development expense and $46,000 and $0.2 million, respectively, in general and administrative expense related to the Columbia Agreements. In aggregate, the Company has incurred $2.6 million in expense from the execution of the Columbia Agreements through September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As of September 30, 2022, the Company had $0.1 million due to Columbia University included in accrued expenses and $0 included in accounts payable. As of December 31, 2021, the Company had $12,000 due to Columbia University included in accrued expenses and $0.1 million included in accounts payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Due to regulatory changes impacting development of the PI3K inhibitor class of compounds, the company has determined that it will discontinue its early stage preclinical PI3K program. On July 15, 2022, the Company notified Columbia University that it is terminating the 2019 Columbia Agreement, effective in </span>90 days according to the terms of the 2019 Columbia Agreement, or at an earlier date agreed by the parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company and Columbia entered into an agreement terminating the 2019 Columbia Agreement (the “2022 Columbia Termination Agreement”) as of July 25, 2022. Under the terms of the 2022 Columbia Termination Agreement, the Company assigned certain regulatory documents regarding the preclinical PI3k inhibitor AT-104 to Columbia and granted Columbia a non-exclusive royalty free license (with rights to sublicense any future Columbia licensee) under certain know-how, technical information and data relating to AT-104 that was developed by the Company during the term of the 2019 Columbia Agreement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">University of Miami</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">2020 Miami License Agreement</i><span style="display:inline-block;width:16.53pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 28, 2020, the Company entered into a license agreement with the University of Miami (the “2020 Miami License Agreement”) relating to certain technology that is co-owned by the University of Miami (UM), the University of Rochester (UR) and University College London (UCL). UM was granted an exclusive agency from UR and UCL to license each of their rights in the technology. Pursuant to the 2020 Miami License Agreement, UM, on behalf of itself and UR and UCL, granted the Company a royalty-bearing, sublicensable license that is exclusive with respect to certain patent applications and patents that may grant from the applications, and non-exclusive with respect to certain know-how, in each case to research, develop, make, have made, use, sell and import products for use in treating and/or detecting certain inherited neuropathies, in particular those caused by mutation in the sorbitol dehydrogenase (SORD) gene. The license grant is worldwide. Under the 2020 Miami License Agreement, the Company is obligated to use commercially reasonable efforts to develop, manufacture, market and sell licensed products in the licensed territory, and to comply with certain obligations to meet specified development milestones within defined time periods. UM retains for itself, UR, and UCL the right to use the licensed patent rights and licensed technology for their internal non-commercial educational, research and clinical patient care purposes, including in sponsored research and collaboration with commercial entities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the terms of the 2020 Miami License Agreement, the Company was obligated to pay UM an up-front non-refundable license fee of $1.1 million, and a second non-refundable license fee of $0.5 million due on the first anniversary of the date of the license. The Company will be required to make further payments to UM of up to an aggregate $2.2 million for the achievement of specified patenting and development milestones, and up to an aggregate of $4.1 million for achievement of late stage regulatory milestones. The Company will also be required to pay royalties ranging from 0.88% - 5% on the Company’s, the Company’s affiliates’ and the Company’s sublicensees’ net sales of licensed products. If the Company sublicenses the rights granted under the 2020 Miami License Agreement to one or more third parties, the Company will be required to pay to UM a portion of the non-royalty sublicensing revenue received from such third parties ranging from 15% – 25%. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The 2020 Miami License Agreement terminates upon the later of the expiration of all issued patents and filed patent applications or 10 years after the first commercial sale of the last product or process for which a royalty is due, unless earlier terminated. In addition, the 2020 Miami License Agreement may be terminated by the Company at any time upon 60 days prior written notice to UM, and may be terminated by either the Company or UM upon material breach of an obligation if action to cure the breach is not initiated within 60 days of receipt of written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">During the three and nine months ended September 30, 2022 the company recorded $25,000 and $75,000, respectively, in research and development expense related to the Miami License Agreement.  During the three and nine months ended September 30, 2021 the Company recorded $0.2 million in research and development expense related to the 2020 Miami License Agreement. During the three and nine months ended September 30, 2022, the Company recorded $0 and $2,000, respectively, in general and administrative expense related to the 2020 Miami License Agreement. There were no general and administrative expense recorded during the three and nine months ended September 30, 2021. In aggregate, the Company has incurred $2.4 million in expense from execution of the 2020 Miami License Agreement through September 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">The Company had $0.2 million and $0.3 million due to UM included in accrued expenses as of September 30, 2022 and December 31, 2021, respectively, relating to the 2020 Miami License Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">2020 Miami Option Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 28, 2020, the Company entered into an option agreement with the University of Miami (the “2020 Miami Option Agreement”) concerning certain research activities and technology relating to SORD neuropathy that may be pursued and developed by UM. Under the 2020 Miami Option Agreement, if UM conducts such research activities, then UM is obligated to grant the Company certain option rights to access and use the research results and to obtain licenses to any associated patent rights upon the Company making specified payments to UM within specified time limits. If the Company elects to obtain option rights the Company will be required to make payments to UM in the low-six figures to the low-seven figures, depending upon the rights the Company elects to obtain, and the Company will be obligated to make certain milestone payments in the high-six figures to mid-seven figures if UM conducts and completes certain research activities within specified time periods and the Company elects to receive rights to use the results of that research.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">2020 Miami Sponsored Research Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On December 14, 2020, the Company entered into a research agreement with the University of Miami (the “2020 Miami Research Agreement”), under which the University of Miami will conduct a research study relating to SORD neuropathy and deliver a final report on the study to the Company. The term of the research agreement is from December 14, 2020 through December 30, 2021, and was extended through August 31, 2022, whereby the research study was completed. The total consideration for the 2020 Miami Research Agreement was </span>$0.3 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2022, the Company recorded $0 and $0.1 million, respectively, in research and development expense in relation to the 2020 Miami Research Agreement. During the three and nine months ended September 30, 2021, the Company recorded $0.1 million and $0.2 million, respectively, in research and development expense in relation to the 2020 Miami Research Agreement. The Company had $0.1 million and $0.2 million as of September 30, 2022 and December 31, 2021, respectively, in accrued expense in relation to the 2020 Miami Research Agreement.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Bayh-Dole Act</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Some of the intellectual property rights the Company has licensed, including certain rights licensed in the agreements described above, may have been generated through the use of U.S. government funding. As a result, the U.S. government may have certain rights to intellectual property embodied in the Company’s current or future product candidates under the Bayh-Dole Act of 1980, or Bayh-Dole Act, including the grant to the government of a non-exclusive, worldwide, freedom to operate license under any patents, and the requirement, absent a waiver, to manufacture products substantially in the United States.  To the extent any of the Company’s current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"> <span style="visibility:hidden;">​</span></p> 0.05 500000 1300000 1000000.0 0.10 0.20 P90D P30D P90D 1300000 1000000.0 P12M P18M 0 0 100000 200000 0 0 46000 200000 2600000 100000 0 12000 100000 P90D 1100000 500000 2200000 4100000 0.0088 0.05 0.15 0.25 P10Y P60D P60D 25000 75000 200000 200000 0 2000 0 0 2400000 200000 300000 300000 0 100000 100000 200000 100000 200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. FAIR VALUE MEASUREMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables summarize, as of September 30, 2022, the Company’s financial assets and liabilities that are measured at fair value on a recurring basis, according to the fair value hierarchy described in the significant accounting policies in the Company’s audited financial statements as of and for the year ended December 31, 2021, and the notes thereto, which are included in the Annual Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,880</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,508</p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,388</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. government agency debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total financial assets measured at fair value on a recurring basis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 47,378</p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liabilities - Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total financial liabilities measured at fair value on a recurring basis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Investments in U.S. government agency debt securities</span> have been classified as Level 2 as they are valued using quoted prices in less active markets or other directly or indirectly observable inputs. <span style="background:#ffffff;">Fair values of U.S. government agency debt securities</span> were derived from a consensus or weighted average price based on input of market prices from multiple sources at each reporting period. During the period ended September 30, 2022, there were no transfers of financial assets between Level 1 and Level <span style="-sec-ix-hidden:Hidden_1hjM666e5EarZSn2_vuelw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On June 27, 2022 the Company issued Common Warrants exercisable for 30,000,000 shares of common stock and Pre-Funded Warrants exercisable for 10,000,000 shares of common stock in connection with the June Offering (see note 1 and note 8 for more information on the June Offering). The Common Warrants were accounted for as liabilities under ASC 815-40, <i style="font-style:italic;">Derivatives and Hedging, Contracts in Entity’s Own Equity</i> (“ASC 815-40”), as these warrants provide for a settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. The Pre-Funded Warrants were recorded at fair value as a liability as the Company could be required to settle the Pre-Funded Warrants in cash under certain circumstances. These warrant liabilities were measured at fair value at inception and are then subsequently measured on a recurring basis, with changes in fair value recognized in other income (expense) within the Company’s statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses a Black-Scholes option pricing model to estimate the fair value of the Common and Pre-Funded Warrants, which utilizes certain unobservable inputs and is therefore considered a Level 3 fair value measurement. Certain inputs used in this Black-Scholes pricing model may fluctuate in future periods based upon factors that are outside of the Company’s control, including a potential change in control outside of the Company’s control. A significant change in one or more of these inputs used in the calculation of the fair value may cause a significant change to the fair value of the Company’s warrant liabilities, which could also result in material non-cash gains or losses being reported in the Company’s consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Common and Pre-Funded Warrants were initially valued and remeasured using a Black-Scholes option pricing model with a range of assumptions as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilized a probability-weighted approach that considered the probability of a change in control at the Company in the Black-Scholes option pricing model, whereby a 10% probability of change in control was used for each of the five years in the term of the agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a roll forward of the aggregate fair values of the Company’s warrant liability, for which fair value is determined using Level 3 inputs (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant Liability</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Funded Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Initial fair value of Warrant Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,734</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,101</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,417)</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 990</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,674</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The inputs utilized by management to value the warrant liability for Common and Pre-Funded Warrants are highly subjective. The assumptions used in calculating the fair value of the warrant liability for Common and Pre-Funded Warrants represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the fair value of the warrant liability for Common and Pre-Funded Warrants may be materially different in the future.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,880</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,880</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 32,508</p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,388</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">U.S. government agency debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total financial assets measured at fair value on a recurring basis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,388</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 47,378</p></td></tr><tr><td style="vertical-align:top;width:49.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrant liabilities - Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td></tr><tr><td style="vertical-align:top;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total financial liabilities measured at fair value on a recurring basis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 24,739</p></td></tr></table> 7880000 7880000 32508000 32508000 40388000 40388000 6990000 6990000 6990000 6990000 40388000 6990000 47378000 24739000 24739000 24739000 24739000 0 30000000 10000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 3.7 0.9153 0.0411 0.0000 10 P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a roll forward of the aggregate fair values of the Company’s warrant liability, for which fair value is determined using Level 3 inputs (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrant Liability</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Warrant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Pre-Funded Warrant</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Initial fair value of Warrant Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13,734</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 8,101</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,417)</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 990</p></td></tr><tr><td style="vertical-align:bottom;width:71.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,674</p></td></tr></table> 13734000 8101000 1417000 3331000 990000 17065000 7674000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. INVESTMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable Securities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities, which the Company classifies as available-for-sale securities, primarily consist of U.S. government debt obligations. Marketable securities with remaining effective maturities of twelve months or less from the balance sheet date are classified as short-term; otherwise, they are classified as long-term on the balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables provide the Company’s marketable securities by security type (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">US government agency debt security</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,935</p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,935</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, the Company’s investment portfolio reported no<span style="white-space:pre-wrap;"> unrealized loss. Based on its evaluations, the Company determined that a credit loss allowance is not required since the decline was not related to underlying credit issues of the counterparties. The counterparties to these investments have high credit quality with investment grade ratings of at least AA+ or above, along with a history of no defaults. No single investment in the portfolio had an individually material unrealized loss and in the aggregate. In addition, the Company does not intend to sell these investments and it is not more likely than not that the Company will be required to sell these investments before recovery of their amortized cost bases. Accordingly, based on the foregoing evaluation, the Company did not record any credit losses during the nine months ended September 30, 2022. Unrealized gains are also reflected, net of tax, as other comprehensive income (loss) in the Statements of Comprehensive Loss.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contractual maturities of the Company’s marketable securities are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07206726%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due in one year or less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,935</p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due in one through two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,935</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At September 30, 2022, the Company had $23,000 of gross unrealized gains and $0 of gross unrealized losses primarily due to fluctuations in the fair value of certain U.S. government agency debt securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the three and nine months ended September 30, 2022, the Company recorded gross realized losses of $3,000 and $0.2 million, respectively, and no gross realized gains of from the sale of marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of September 30, 2022 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:63.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position greater than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">US government agency debt security</p></td><td style="vertical-align:bottom;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of December 31, 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:63.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position greater than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">US government agency debt security</p></td><td style="vertical-align:bottom;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">US government agency debt security</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,935</p></td></tr><tr><td style="vertical-align:bottom;width:27.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,935</p></td></tr></table> 6967000 23000 6990000 27042000 1000 108000 26935000 6967000 23000 6990000 27042000 1000 108000 26935000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.07206726%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:36.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due in one year or less</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,935</p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due in one through two years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:27.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,967</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 27,042</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,935</p></td></tr></table> 6967000 23000 6990000 27042000 1000 108000 26935000 6967000 23000 6990000 27042000 1000 108000 26935000 23000 0 3000 200000 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:63.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of September 30, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position greater than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">US government agency debt security</p></td><td style="vertical-align:bottom;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:63.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, 2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Securities in an unrealized loss position greater than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:20.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">US government agency debt security</p></td><td style="vertical-align:bottom;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td></tr><tr><td style="vertical-align:bottom;width:35.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total</p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,696</p></td></tr></table> 108000 17696000 108000 17696000 108000 17696000 108000 17696000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. PREPAID EXPENSES AND OTHER CURRENT ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.67%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,483</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance premium asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,616</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid rent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 105</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid commercial and patient advocacy </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development tax credit receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 502</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses and current assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 471</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses &amp; other current assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,571</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.67%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid research and development expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,483</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Insurance premium asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,616</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid rent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 117</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 105</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid commercial and patient advocacy </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development tax credit receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 502</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other prepaid expenses and current assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 471</p></td></tr><tr><td style="vertical-align:bottom;width:70.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses &amp; other current assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,571</p></td></tr></table> 4996000 4483000 1914000 1616000 86000 117000 89000 105000 167000 254000 252000 502000 24000 23000 604000 471000 8132000 7571000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued pre-clinical and clinical expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,912</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term insurance financing note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 1,554</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 789</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 837</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 419</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 1,484</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,779</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued commercial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 849</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,394</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued patent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 314</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 279</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 458</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 987</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses &amp; other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,559</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued pre-clinical and clinical expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,836</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,912</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term insurance financing note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 1,554</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 789</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 837</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 419</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued compensation and benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 1,484</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,779</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued commercial expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 849</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,394</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued patent expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 314</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 279</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="font-size:11pt;"> 458</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 987</p></td></tr><tr><td style="vertical-align:bottom;width:70.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total accrued expenses &amp; other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,559</p></td></tr></table> 8836000 9912000 1554000 789000 837000 419000 1484000 2779000 849000 1394000 314000 279000 458000 987000 14332000 16559000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. STOCK-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2019, the Company’s board of directors (the “Board”) adopted its 2019 Equity Incentive Plan (“2019 Plan”), which was subsequently approved by its stockholders and became effective on May 13, 2019. As a result, no additional awards under the Company’s 2016 Equity Incentive Plan, as amended (the “2016 Plan”) will be granted and all outstanding stock awards granted under the 2016 Plan that are repurchased, forfeited, expired, or are cancelled will become available for grant under the 2019 Plan in accordance with its terms. The 2016 Plan will continue to govern outstanding equity awards granted thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The 2019 Plan provides for the issuance of incentive stock options (“ISOs”) to employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, performance cash awards and other forms of stock awards to the Company’s employees, officers, and directors, as well as non- employees, consultants, and affiliates to the Company. Under the terms of the 2019 Plan, stock options may not be granted at an exercise price less than fair market value of the Company’s common stock on the date of the grant. The 2019 Plan is administered by the Compensation Committee of the Company’s Board.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Initially, subject to adjustments as provided in the 2019 Plan, the maximum number of the Company’s common stock that may be issued under the 2019 Plan was 4,530,000 shares, which is the sum of (i) 1,618,841 new shares, plus (ii) the number of shares (not to exceed 2,911,159 shares) that remained available for the issuance of awards under the 2016 Plan, at the time the 2019 Plan became effective, and (iii) any shares subject to outstanding stock options or other stock awards granted under the 2016 Plan that are forfeited, expired, or reacquired. The 2019 Plan provides that the number of shares reserved and available for issuance under the 2019 Plan will automatically increase each January 1, beginning on January 1, 2020, by 5% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Board. Subject to certain changes in capitalization of the Company, the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of ISOs shall be equal to 13,000,000 shares of common stock. Stock options awarded under the 2019 Plan expire 10 years after grant and typically vest over four years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On August 2, 2022, the Board took action in accordance with its authority under the terms of the 2019 Plan to reset the per-share exercise price of all stock options previously granted under the 2019 Plan to </span><span style="background:#ffffff;">$1.05</span><span style="background:#ffffff;"> per share (the "Options Repricing"), which is equal to the closing price of a share of the Company’s common stock on August 1, 2022. The Options Repricing was deemed to be a Type I modification event under ASC 718, </span><i style="font-style:italic;background:#ffffff;">Compensation-Stock Compensation</i><span style="background:#ffffff;">. No other terms of the repriced stock options were modified, and the repriced stock options will continue to vest according to their original vesting schedules and will retain their original expiration dates. As a result of the Options Repricing, </span><span style="background:#ffffff;">1,797,517</span><span style="background:#ffffff;"> vested and </span><span style="background:#ffffff;">1,380,917</span><span style="background:#ffffff;"> unvested stock options outstanding as of August 2, 2022, with original exercise prices ranging from </span><span style="background:#ffffff;">$1.22</span><span style="background:#ffffff;"> to </span><span style="background:#ffffff;">$49.60</span><span style="background:#ffffff;">, were repriced. The Options Repricing resulted in incremental </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">stock-based compensation expense of </span><span style="background:#ffffff;">$1.4</span><span style="background:#ffffff;"> million, of which </span><span style="background:#ffffff;">$0.9</span><span style="background:#ffffff;"> million related to vested stock option awards and was expensed on the repricing date, and </span><span style="background:#ffffff;">$0.5</span><span style="background:#ffffff;"> million of which related to unvested stock option awards and is being amortized on a ratable basis over the remaining weighted-average vesting period of those awards being approximately </span><span style="background:#ffffff;">2.4</span><span style="background:#ffffff;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of September 30, 2022, there were 1,331,659 shares of common stock available for issuance under the 2019 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock-Based Compensation Expense</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Total stock-based compensation expense recorded for employees, directors and non-employees (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,974</p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,354</p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,328</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Option Activity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the nine months ended September 30, 2022 the Company granted 767,913 options to shares of common stock. For the three and nine months ended September 30, 2022, amortization of stock compensation of options amounted to $2.5 million and $6.2 million, respectively, and for the three and nine months ended September 30, 2021, amortization of stock compensation of options amounted to $2.2 million and $7.0 million, respectively.<span style="font-family:'Segoe UI';font-size:9pt;"> </span>As of September 30, 2022 and 2021, the total unrecognized stock-based compensation balance for unvested options was $9.9 million and $20.2 million, respectively, which is expected to be recognized over 2.3 years and 2.5 years, respectively. The weighted-average fair value per share of options granted during the nine months ended September 30, 2022 and 2021 was $1.79 and $10.01, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the information about options outstanding at September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands, except for share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,704,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,305</p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 767,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (357,833)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (141,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,925,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,711,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nonvested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,214,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Valuation of Stock Options Granted to Employees that Contain Service Conditions Only</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option award granted with service-based vesting is estimated on the date of the grant using the Black-Scholes option valuation model based on the weighted average assumptions noted in the table below for those options granted in the nine months ended September 30, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 75.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 70.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Restricted Stock Unit Activity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the nine months ended September 30, 2022, the Company granted 305,600 RSUs to shares of common stock. For the three months ended September 30, 2022 and 2021, amortization of stock compensation of RSUs amounted to $0.4 million and $0.5 million, respectively. <span style="background:#ffffff;">For the nine months ended September 30, 2022 and 2021, amortization of stock compensation of RSU’s amounted to </span><span style="background:#ffffff;">$0.9</span><span style="background:#ffffff;"> million and </span><span style="background:#ffffff;">$1.3</span><span style="background:#ffffff;"> million, respectively. </span>As of September 30, 2022 and 2021, the unamortized compensation costs associated with non-vested restricted stock awards were $3.9 million and $5.1 million, respectively, with a weighted-average remaining amortization period of 3.1 and 2.9 years, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the information about restricted stock units outstanding at September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands, except for share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 469,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,202</p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Awarded</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 305,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,840)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (196,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 533,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 496</p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 528,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 492</p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted Average Remaining Recognition Period (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2019 Employee Stock Purchase Plan</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In May 2019, the Company’s Board and its stockholders approved the 2019 Employee Stock Purchase Plan (the “ESPP”), which became effective as of May 13, 2019. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 180,000 shares. The ESPP provides for an annual increase on the first day of each year beginning in 2020 and ending in 2029, in each case subject to the approval of the Board, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the calendar month before the date of the automatic increase and (ii) 360,000 shares; provided that prior to the date of any such increase, the Board may determine that such increase will be less than the amount set forth in clauses (i) and (ii). As of September 30, 2022, no shares of common stock had been issued under the ESPP. The first offering period has not yet been decided by the Board.</p> 4530000 1618841 2911159 0.05 13000000 P10Y P4Y 1.05 1797517 1380917 1.22 49.60 1400000 900000 500000 P2Y4M24D 1331659 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 642</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,974</p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,354</p></td></tr><tr><td style="vertical-align:bottom;width:57.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,645</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8,328</p></td></tr></table> 1178000 642000 2822000 1974000 1678000 2003000 4342000 6354000 2856000 2645000 7164000 8328000 767913 2500000 6200000 2200000 7000000.0 9900000 20200000 P2Y3M18D P2Y6M 1.79 10.01 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(in thousands, except for share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term (in years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,704,888</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,305</p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 767,913</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (47,602)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21</p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (357,833)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (141,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 31.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,925,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:49.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,711,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:top;width:49.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nonvested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,214,161</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 8.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr></table> 4704888 13.29 P7Y8M12D 10305000 767913 2.80 47602 1.04 21000 357833 20.93 141688 31.65 4925678 1.99 P7Y2M12D 3711517 2.30 P6Y8M12D 1214161 1.05 P8Y6M <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 5.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 75.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 70.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:65.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> P5Y8M12D P5Y7M6D 0.7583 0.7099 0.0213 0.0091 305600 400000 500000 900000 1300000 3900000 5100000 P3Y1M6D P2Y10M24D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted-Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands, except for share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 469,485</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,202</p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Awarded</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 305,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Released</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,840)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (196,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 18.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 533,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 496</p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Nonvested at September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 528,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 9.06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 492</p></td></tr><tr><td style="vertical-align:top;width:54.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:54.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted Average Remaining Recognition Period (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 469485 18.05 4202000 305600 3.78 45840 25.57 196131 18.36 533114 9.10 496000 528712 9.06 492000 P3Y1M6D 180000 0.01 360000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. STOCKHOLDERS’ EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As of September 30, 2022, and December 31, 2021, the authorized capital stock of the Company consists of </span><span style="font-weight:normal;">100,000,000</span><span style="font-weight:normal;"> shares of common stock, par value </span><span style="font-weight:normal;">$0.0001</span><span style="font-weight:normal;"> per share and </span><span style="font-weight:normal;">10,000,000</span><span style="font-weight:normal;"> shares of preferred stock, par value </span><span style="font-weight:normal;">$0.0001</span><span style="font-weight:normal;"> per share. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Goldman Equity Distribution Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In June 2020, the Company entered into the Goldman Equity Distribution Agreement to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0<span style="white-space:pre-wrap;"> million. The issuance and sale of shares of common stock by the Company pursuant to the Goldman Equity Distribution Agreement is deemed an “at-the-market” offering under the Securities Act of 1933, as amended, or the Securities Act. Goldman is entitled to compensation for its services equal to up to </span>3.0%<span style="white-space:pre-wrap;"> of the gross offering proceeds of all shares of the Company’s common stock sold through it as a sales agent pursuant to the Goldman Equity Distribution Agreement. The Goldman Equity Distribution Agreement was terminated as of January 24, 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Cowen Equity Distribution Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 26, 2022, the Company entered into the Cowen Equity Distribution Agreement to sell shares of the Company’s common stock, from time to time, having an aggregate offering price of up to $100.0 million. Pursuant to the Cowen Equity Distribution Agreement shares of our common stock may be offered and sold through the sales agent in sales deemed “at-the-market” offerings under the Securities Act of 1933, as amended, or the Securities Act. Under the Cowen Equity Distribution Agreement, the sales agent will be entitled to compensation of up to 3% of the gross offering proceeds of all shares of our common stock sold through it pursuant to the Cowen Equity Distribution Agreement. In connection with the sale of shares of our common stock on our behalf, the sales agent may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation paid to the sales agent may be deemed to be underwriting commissions or discounts. As of September 30, 2022, the Company has not sold any shares of common stock pursuant to the Cowen Equity Distribution Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">June 2022 Offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">On June 27, 2022, the Company completed the June Offering, an underwritten public offering of </span><span style="background:#ffffff;">20,000,000</span><span style="background:#ffffff;"> shares of common stock, par value </span><span style="background:#ffffff;">$0.0001</span><span style="background:#ffffff;"> per share, </span><span style="background:#ffffff;">10,000,000</span><span style="background:#ffffff;"> Pre-Funded Warrants, and accompanying Common Warrants to purchase up to </span><span style="background:#ffffff;">30,000,000</span><span style="background:#ffffff;"> shares of common stock. The shares and accompanying Common Warrants were offered at a price to the public of </span><span style="background:#ffffff;">$1.00</span><span style="background:#ffffff;"> per share and warrant, and the Pre-Funded Warrants and accompanying Common Warrants were offered at a price to the public of </span><span style="background:#ffffff;">$0.9999</span><span style="background:#ffffff;">, resulting in aggregate net proceeds of approximately </span><span style="background:#ffffff;">$27.8</span><span style="background:#ffffff;"> million, after deducting underwriting discounts and commissions and offering expenses. The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire </span><span style="background:#ffffff;">five years</span><span style="background:#ffffff;"> from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than </span><span style="background:#ffffff;">19.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled. The Company intends to use the net proceeds from the June Offering for general corporate </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">purposes, which may include research and development costs, including the conduct of clinical trials and process development and manufacturing of the Company’s product candidates, expansion of the Company’s research and development capabilities, working capital and capital expenditures.</span></p> 100000000 100000000 0.0001 0.0001 10000000 10000000 0.0001 0.0001 100000000.0 0.030 100000000.0 0.03 0 20000000 0.0001 10000000 30000000 1.00 0.9999 27800000 P5Y 0.0999 0.0999 0.1999 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants Issued with Series A Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On January 26, 2017, in connection with the sale and issuance of the Series A Preferred Stock, the Company issued equity-classified warrants to purchase </span><span style="font-weight:normal;">309,389</span><span style="font-weight:normal;"> shares of common stock (the “2017 Warrants”), valued at </span><span style="font-weight:normal;">$0.2</span><span style="font-weight:normal;"> million, and included in the issuance costs of the Series A Preferred Stock. The warrants vested immediately and have an exercise price of </span><span style="font-weight:normal;">$2.49</span><span style="font-weight:normal;"> per share and expire on March 13, 2027.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of warrants issued was estimated using the Black-Scholes option pricing model with the following assumptions for the 2017 Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.6%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:85.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 74.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 5, 2021, a warrantholder exercised 27,855 warrants on a cash basis and received 27,855 shares of common stock. The Company received $69,000 in cash proceeds for the exercise of these warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants Issued with the 2018 Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 18, 2018, the Company entered into a placement agent agreement through which it became obligated to issue common stock warrants in connection with the issuance of convertible promissory notes, issued on February 5, 2018 (the “2018 Notes”). The obligation to issue the 2018 Notes Warrants was recorded as a liability at its fair value, (see Note 3), which was initially $0.1 million, and was included in the issuance costs of the 2018 Notes. On November 5, 2018, in connection with the extinguishment of the 2018 Notes into shares of Series B Preferred Stock, the Company issued the 2018 Notes Warrants, which were equity-classified warrants upon issuance, to purchase 76,847 shares of common stock, valued at $0.3 million. The 2018 Notes Warrants vested immediately upon issuance and have an exercise price of $6.59 per share and expire on November 4, 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants Issued with Series B Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November and December 2018, in connection with the sale and issuance of the Series B Preferred Stock, the Company was obligated to issue equity-classified warrants to purchase 72,261 shares of common stock (collectively the “2018 Warrants”), valued in the aggregate at $0.2 million, which was included in the issuance costs for the Series B Preferred Stock. The warrants vest immediately upon issuance, have an exercise price of $8.24 per share and expire 10 years from the date of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The fair value of the 2018 Warrants was estimated using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 73.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In February 2019, in connection with the sale and issuance of the Series B Preferred Stock, the Company was obligated to issue warrants to purchase 23,867 shares of common stock (collectively the “2019 Warrants”), valued in the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">aggregate at $0.1 million, which was included in the issuance costs for the Series B Preferred Stock. The warrants vested immediately upon issuance, have an exercise price of $8.24 per share and expire 10 years from the date of issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The fair value of the 2019 Warrants was estimated using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 73.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The inputs utilized by management to value the warrants are highly subjective. The assumptions used in calculating the fair value of the warrants represent the Company’s best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and the Company uses different assumptions, the fair value of the warrants may be materially different in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants Issued with June 2022 Offering</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On June 27, 2022, in connection with the sale and issuance common stock as part of the June Offering, the Company issued </span><span style="background:#ffffff;">10,000,000</span><span style="background:#ffffff;"> Pre-Funded Warrants at an exercise price of </span><span style="background:#ffffff;">$0.0001</span><span style="background:#ffffff;"> per share, and </span><span style="background:#ffffff;">30,000,000</span><span style="background:#ffffff;"> accompanying Common Warrants at an exercise price of </span><span style="background:#ffffff;">$1.00</span><span style="background:#ffffff;"> per share. Each share of common stock and accompanying Common Warrant was sold at a public offering price of </span><span style="background:#ffffff;">$1.00</span><span style="background:#ffffff;">, less underwriting discounts and commissions, and each Pre-Funded Warrant and accompanying Common Warrant was sold at a public offering price of </span><span style="background:#ffffff;">$0.9999</span><span style="background:#ffffff;">, less underwriting discounts and commissions, as described in the prospectus supplement, dated June 22, 2022, filed with the Securities and Exchange Commission on June 24, 2022. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Pre-Funded Warrants and the Common Warrants are immediately exercisable and will expire </span><span style="background:#ffffff;">five years</span><span style="background:#ffffff;"> from the date of issuance. Holders may not exercise any Pre-Funded Warrants or Common Warrants that would cause the aggregate number of shares of common stock beneficially owned by the holder to exceed </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock immediately after exercise. Holders of the Pre-Funded Warrants and/or Common Warrants (together with affiliates) who immediately prior to June 27, 2022 beneficially owned more than </span><span style="background:#ffffff;">9.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock may not exercise any portion of their Pre-Funded Warrants or Common Warrants if the holder (together with affiliates) would beneficially own more than </span><span style="background:#ffffff;">19.99%</span><span style="background:#ffffff;"> of the Company’s outstanding common stock after exercise. The Pre-Funded Warrants and Common Warrants are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions for no consideration of assets to the Company’s stockholders. In the event of certain corporate transactions, the holders of the Pre-Funded Warrants and/or Common Warrants will be entitled to receive, upon exercise, the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants and/or Common Warrants immediately prior to such transaction. The Pre-Funded Warrants and Common Warrants do not entitle the holders thereof to any voting rights or any of the other rights or privileges to which the Company’s stockholders are entitled.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 28, 2022, a warrantholder exercised 1,750,000 Pre-Funded Warrants on a cash basis and received 1,750,000 shares of common stock. The Company received $175 in cash proceeds for the exercise of these Pre-Funded Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">As of September 30, 2022, the Company had </span><span style="background:#ffffff;">8,250,000</span><span style="background:#ffffff;"> Pre-Funded Warrants outstanding with a weighted average exercise price of </span><span style="background:#ffffff;">$0.0001</span><span style="background:#ffffff;"> per share and an average contractual life of </span><span style="background:#ffffff;">5 years</span><span style="background:#ffffff;">. As of September 30, 2022, the Company had </span><span style="background:#ffffff;">30,000,000</span><span style="background:#ffffff;"> Common Warrants outstanding with a weighted average exercise price of </span><span style="background:#ffffff;">$1.00</span><span style="background:#ffffff;"> per share and an average contractual life of </span><span style="background:#ffffff;">5 years</span><span style="background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Common Warrants were accounted for as liabilities under ASC 815-40, as these warrants provide for a settlement provision that does not meet the requirements of the indexation guidance under ASC 815-40. These warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented within the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">statement of operations. The Pre-Funded Warrants were recorded at fair value as a liability as the Company could be required to settle the Pre-Funded Warrants in cash in the event of an acquisition of the Company under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the Common and Pre-Funded Warrants were estimated using the Black-Scholes option pricing model with the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A summary of the Company’s outstanding common stock warrants as of September 30, 2022 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,618</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted and issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,000,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,750,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exchanged</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,375,618</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> 309389 200000 2.49 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.6%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:85.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 74.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 10.0 0.7448 0.0320 0.0000 27855 27855 69000 100000 76847 300000 6.59 72261 200000 8.24 P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contractual term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 73.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> 10.0 0.7322 0.0270 0.0000 23867 100000 8.24 P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:85.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 73.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:85.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 10.0 0.7322 0.0270 0.0000 10000000 0.0001 30000000 1.00 1.00 0.9999 P5Y 0.0999 0.0999 0.1999 1750000 1750000 175 8250000 0.0001 P5Y 30000000 1.00 P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 91.53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 0.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 3.7 0.9153 0.0411 0.0000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 125,618</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants granted and issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 40,000,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,750,000)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants exchanged</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;border-bottom:1.5pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 38,375,618</p></td></tr></table> 125618 40000000 1750000 38375618 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. LEASES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company’s lease related costs for the nine months ended September 30, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b><b style="font-weight:bold;"><br/></b><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Operations Location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Lease Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Lease Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Average lease terms and discount rates for the Company’s operating leases were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.37%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">2.1 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.0 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.69%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.69%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the maturities of lease liabilities as of September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 128</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 515</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 426</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,069</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_NgePggg_NUWCm5t-oLFWGg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,006</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;width:24.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b><b style="font-weight:bold;"><br/></b><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Operations Location</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating Lease Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Lease Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:37.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 126</p></td></tr></table> 126000 126000 126000 126000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:81.37%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other Information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">2.1 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">3.0 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.69%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">5.69%</p></td></tr></table> P2Y1M6D P3Y 0.0569 0.0569 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 128</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 515</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 426</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,069</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 63</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:84.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_NgePggg_NUWCm5t-oLFWGg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Total lease liabilities</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,006</p></td></tr></table> 128000 515000 426000 1069000 63000 1006000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. INCOME TAXES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to provide certain relief as a result of the Covid-19 pandemic. The CARES Act provides numerous tax provisions and other stimulus measures, including temporary changes regarding the prior and future utilization of net operating losses, temporary changes to the prior and future limitations on interest deductions, temporary suspension of certain payment requirements for the employer portion of social security taxes, technical corrections from prior tax legislation for tax depreciation of certain qualified improvement property and the creation of certain refundable employee retention credits. The CARES Act did not have a material impact on our financial statements for the three and nine months ended September 30, 2022. The Company continues to monitor any effects that may result from the CARES Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the nine months ended September 30, 2022 and the year ended December 31, 2021, the Company recorded a full valuation allowance on federal and state deferred tax assets since management does not forecast the Company to be in a profitable position in the near future.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. BENEFIT PLANS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code in 2018. This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Matching contributions to the plan may be made at the discretion of the Company’s board of directors. The Company made approximately </span><span style="font-weight:normal;">$</span><span style="font-weight:normal;">0.4</span><span style="font-weight:normal;"> million</span><span style="font-weight:normal;"> and </span><span style="font-weight:normal;">$</span><span style="font-weight:normal;">0.2</span><span style="font-weight:normal;"> million</span><span style="font-weight:normal;"> in matching contributions to the plan during the nine months ended September 30, 2022 and 2021, respectively.</span> </p> 400000 200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. NET LOSS PER COMMON SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per common share is computed by dividing the net loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per common share is computed by giving the effect of all potential shares of common stock, including stock options, preferred shares, warrants and instruments convertible into common stock, to the extent dilutive. Basic and diluted net loss per common share was the same for the three and nine months ended September 30, 2022 and 2021, as the inclusion of all potential common shares outstanding would have been anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables set forth the computation of basic and diluted net loss per common share for the three and nine months ended September 30, 2022 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands, except for share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dXDb7iH3TUG_UJ_glN_G7g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_U1IH7NCUzkiFdpDR8w2qQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,418)</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted-average common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 48,000,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,177,079</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Net loss per share attributable to common stockholders - basic and diluted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_XcNJWvyDl0mVONe2HYpnuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gP6Yd9YoSEuxiM9gmmPlUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.09)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_O8BUeTr6wkW6rLcwbKDUtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,079)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PrbujhU0x0K4Fc08bhSUrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78,425)</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted-average common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,785,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25,472,590</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Net loss per share attributable to common stockholders - basic and diluted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Kh1y2nrPSECsg13-qhcGUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_n9t0qcpC1065U2Bdg7ZStg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.08)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s potentially dilutive securities, which include restricted stock units, stock options, and warrants, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding for the nine months ended September 30, 2022 and 2021, from the computation of diluted net loss per share attributable to common stockholders because including them would have had an anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"> </b><b style="font-weight:bold;">of</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,925,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,542,353</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 533,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 222,693</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,375,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 125,618</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands, except for share data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_dXDb7iH3TUG_UJ_glN_G7g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (19,101)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_U1IH7NCUzkiFdpDR8w2qQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,418)</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted-average common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 48,000,183</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 26,177,079</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Net loss per share attributable to common stockholders - basic and diluted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_XcNJWvyDl0mVONe2HYpnuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.40)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gP6Yd9YoSEuxiM9gmmPlUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.09)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_O8BUeTr6wkW6rLcwbKDUtQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (68,079)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_PrbujhU0x0K4Fc08bhSUrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (78,425)</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Weighted-average common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 33,785,386</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 25,472,590</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">Net loss per share attributable to common stockholders - basic and diluted</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Kh1y2nrPSECsg13-qhcGUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_n9t0qcpC1065U2Bdg7ZStg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3.08)</p></td></tr></table> -19101000 -28418000 48000183 26177079 -0.40 -1.09 -68079000 -78425000 33785386 25472590 -2.02 -3.08 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"> </b><b style="font-weight:bold;">of</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:27.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,925,678</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,542,353</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 533,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 222,693</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,375,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 125,618</p></td></tr></table> 4925678 4542353 533114 222693 38375618 125618 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. RELATED PARTIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the Company entered into an agreement (the “LaunchLabs Agreement”) with ARE-LaunchLabs NYC LLC (“Alexandria LaunchLabs”), a subsidiary of Alexandria Real Estate Equities, Inc. for use of specified premises within the Alexandria LaunchLabs space on a month-to-month basis. A member of the Company’s board of directors is the founder and executive chairman of Alexandria Real Estate Equities, Inc. During the three and nine months ended September 30, 2022, the Company made payments to Alexandria LaunchLabs of approximately $23,000, and $70,000, respectively, and during the three and nine months ended September 30, 2021, the Company made the same payments of approximately $23,000 and $70,000 respectively, under the LaunchLabs Agreement, which was recognized in research and development expenses. As of September 30, 2022, there were no amounts due to Alexandria LaunchLabs under the LaunchLabs Agreement.</p> 23000 70000 23000 70000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">15. SUBSEQUENT EVENTS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On October 26, 2022, at a Special Meeting of Stockholders (the “Special Meeting”), the stockholders of Applied Therapeutics, Inc. (the “Company”) approved an amendment (the “Amendment”) to the Company’s Amended </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and Restated Certificate of Incorporation to increase the number of shares of the Company’s common stock authorized for issuance from 100,000,000 shares to 200,000,000 shares (the “Authorized Shares Increase Proposal”). The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware on October 26, 2022.</p> 100000000 200000000 EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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

/XXG:#ISX?I_6*Z0*/["?JV_#R=H_'C?#Z]7Z(OL]'=[,ML.9.]%Q,0 MF&3\$EVAQ\4$7;R_1.\1*= RI5N.BS4?Z$)BJ>1ZW"#E&:TC5NN(5>6S_XLC?>76^9W^_.I_><-+',-0 MDW\\#NP9M.C#.],S;ON*_T_)WEAAMU;8I[)'HSAF6U@CF?HJEITDQAF2DXS: M!KS(_81#[ZS7N;TJM]I-GJ,@L+V!_KQ?7C-@^=[,98QXP,6\+P).$WD0+KXPF[2\P-#GBZ,6'@]_.8QM_CRCA)M*1" M[4&-0T#I@)D?T+E M-M4TU$'?7NRB/U!+ P04 " #Q.FE5M#&AO4 ' @00 &0 'AL+W=O M(D:+AD#4G;U?[XM8$"3HB;:,[V0PLD[V/C R_VP>[E<\)_IBO& M,O(2A7%ZU5EEV?JBVTUG*Q;YZ7FR9K'X9)'PR,_$+E]VTS5G_CP/BL*N91C] M;N0'<6=\F1][X./+9).%0

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 224 318 1 false 62 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Balance Sheets Sheet http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Condensed Statements of Operations Sheet http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations Condensed Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Condensed Statements of Comprehensive Income (Loss) Sheet http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss Condensed Statements of Comprehensive Income (Loss) Statements 5 false false R6.htm 00400 - Statement - Condensed Statements of Stockholders' Equity Sheet http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity Statements 6 false false R7.htm 00405 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical) Sheet http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical Condensed Statements of Stockholders' Equity (Parenthetical) Statements 7 false false R8.htm 00500 - Statement - Condensed Statements of Cash Flows Sheet http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 8 false false R9.htm 00505 - Statement - Condensed Statements of Cash Flows (Parenthetical) Sheet http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlowsParenthetical Condensed Statements of Cash Flows (Parenthetical) Statements 9 false false R10.htm 10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 10201 - Disclosure - LICENSE AGREEMENT Sheet http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreement LICENSE AGREEMENT Notes 11 false false R12.htm 10301 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurements FAIR VALUE MEASUREMENTS Notes 12 false false R13.htm 10401 - Disclosure - INVESTMENTS Sheet http://www.appliedtherapeutics.com/role/DisclosureInvestments INVESTMENTS Notes 13 false false R14.htm 10501 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 14 false false R15.htm 10601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 15 false false R16.htm 10701 - Disclosure - STOCK BASED COMPENSATION Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation STOCK BASED COMPENSATION Notes 16 false false R17.htm 10801 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquity STOCKHOLDERS' EQUITY Notes 17 false false R18.htm 10901 - Disclosure - WARRANTS Sheet http://www.appliedtherapeutics.com/role/DisclosureWarrants WARRANTS Notes 18 false false R19.htm 11001 - Disclosure - LEASES Sheet http://www.appliedtherapeutics.com/role/DisclosureLeases LEASES Notes 19 false false R20.htm 11101 - Disclosure - INCOME TAXES Sheet http://www.appliedtherapeutics.com/role/DisclosureIncomeTaxes INCOME TAXES Notes 20 false false R21.htm 11201 - Disclosure - BENEFIT PLANS Sheet http://www.appliedtherapeutics.com/role/DisclosureBenefitPlans BENEFIT PLANS Notes 21 false false R22.htm 11301 - Disclosure - NET LOSS PER COMMON SHARE Sheet http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShare NET LOSS PER COMMON SHARE Notes 22 false false R23.htm 11401 - Disclosure - RELATED PARTIES Sheet http://www.appliedtherapeutics.com/role/DisclosureRelatedParties RELATED PARTIES Notes 23 false false R24.htm 11501 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.appliedtherapeutics.com/role/DisclosureSubsequentEvents SUBSEQUENT EVENTS Notes 24 false false R25.htm 20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 30303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurements 26 false false R27.htm 30403 - Disclosure - INVESTMENTS (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosureInvestmentsTables INVESTMENTS (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosureInvestments 27 false false R28.htm 30503 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 28 false false R29.htm 30603 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities 29 false false R30.htm 30703 - Disclosure - STOCK BASED COMPENSATION (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables STOCK BASED COMPENSATION (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation 30 false false R31.htm 30903 - Disclosure - WARRANTS (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables WARRANTS (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosureWarrants 31 false false R32.htm 31003 - Disclosure - LEASES (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosureLeasesTables LEASES (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosureLeases 32 false false R33.htm 31303 - Disclosure - NET LOSS PER COMMON SHARE (Tables) Sheet http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareTables NET LOSS PER COMMON SHARE (Tables) Tables http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShare 33 false false R34.htm 40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock issued (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock issued (Details) Details 34 false false R35.htm 40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesLiquidityAndGoingConcernDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details) Details 35 false false R36.htm 40201 - Disclosure - LICENSE AGREEMENT - Columbia (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails LICENSE AGREEMENT - Columbia (Details) Details 36 false false R37.htm 40202 - Disclosure - LICENSE AGREEMENT - Miami University (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails LICENSE AGREEMENT - Miami University (Details) Details 37 false false R38.htm 40301 - Disclosure - FAIR VALUE MEASUREMENTS - FV hierarchy (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails FAIR VALUE MEASUREMENTS - FV hierarchy (Details) Details 38 false false R39.htm 40302 - Disclosure - FAIR VALUE MEASUREMENTS - Transfers (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTransfersDetails FAIR VALUE MEASUREMENTS - Transfers (Details) Details 39 false false R40.htm 40303 - Disclosure - FAIR VALUE MEASUREMENTS - Warrants (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails FAIR VALUE MEASUREMENTS - Warrants (Details) Details 40 false false R41.htm 40304 - Disclosure - FAIR VALUE MEASUREMENTS - Warrants Valuation (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails FAIR VALUE MEASUREMENTS - Warrants Valuation (Details) Details 41 false false R42.htm 40305 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Values of Company's Warrant Liability (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails FAIR VALUE MEASUREMENTS - Fair Values of Company's Warrant Liability (Details) Details 42 false false R43.htm 40401 - Disclosure - INVESTMENTS - By type (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails INVESTMENTS - By type (Details) Details 43 false false R44.htm 40402 - Disclosure - INVESTMENTS - Additional Information (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureInvestmentsAdditionalInformationDetails INVESTMENTS - Additional Information (Details) Details 44 false false R45.htm 40403 - Disclosure - INVESTMENTS - By contractual maturity (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails INVESTMENTS - By contractual maturity (Details) Details 45 false false R46.htm 40404 - Disclosure - INVESTMENTS - Realized gains and losses (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureInvestmentsRealizedGainsAndLossesDetails INVESTMENTS - Realized gains and losses (Details) Details 46 false false R47.htm 40405 - Disclosure - INVESTMENTS - Unrealized losses and fair values of available-for-sale securities (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails INVESTMENTS - Unrealized losses and fair values of available-for-sale securities (Details) Details 47 false false R48.htm 40501 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) Details http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 48 false false R49.htm 40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables 49 false false R50.htm 40701 - Disclosure - STOCK BASED COMPENSATION - Plans (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails STOCK BASED COMPENSATION - Plans (Details) Details 50 false false R51.htm 40702 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expense (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails STOCK BASED COMPENSATION - Stock-based compensation expense (Details) Details 51 false false R52.htm 40703 - Disclosure - STOCK BASED COMPENSATION - Options (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails STOCK BASED COMPENSATION - Options (Details) Details 52 false false R53.htm 40704 - Disclosure - STOCK BASED COMPENSATION - Options activity (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails STOCK BASED COMPENSATION - Options activity (Details) Details 53 false false R54.htm 40705 - Disclosure - STOCK BASED COMPENSATION - Valuation assumptions (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails STOCK BASED COMPENSATION - Valuation assumptions (Details) Details 54 false false R55.htm 40706 - Disclosure - STOCK BASED COMPENSATION - RSUs (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails STOCK BASED COMPENSATION - RSUs (Details) Details 55 false false R56.htm 40707 - Disclosure - STOCK BASED COMPENSATION - 2019 Employee Stock Purchase Plan (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails STOCK BASED COMPENSATION - 2019 Employee Stock Purchase Plan (Details) Details 56 false false R57.htm 40801 - Disclosure - STOCKHOLDERS' EQUITY - Authorized stock (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityAuthorizedStockDetails STOCKHOLDERS' EQUITY - Authorized stock (Details) Details 57 false false R58.htm 40802 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock and Equity Distribution Agreement (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails STOCKHOLDERS' EQUITY - Common Stock and Equity Distribution Agreement (Details) Details 58 false false R59.htm 40803 - Disclosure - STOCKHOLDERS' EQUITY - June 2022 Offering (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails STOCKHOLDERS' EQUITY - June 2022 Offering (Details) Details 59 false false R60.htm 40901 - Disclosure - WARRANTS - Issued with Series A Preferred Stock (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails WARRANTS - Issued with Series A Preferred Stock (Details) Details 60 false false R61.htm 40902 - Disclosure - WARRANTS - Issued with the 2018 Notes (Details) Notes http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails WARRANTS - Issued with the 2018 Notes (Details) Details 61 false false R62.htm 40903 - Disclosure - WARRANTS - Issued with Series B Preferred Stock (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails WARRANTS - Issued with Series B Preferred Stock (Details) Details 62 false false R63.htm 40904 - Disclosure - WARRANTS - Issued with June 2022 Offering (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails WARRANTS - Issued with June 2022 Offering (Details) Details 63 false false R64.htm 40905 - Disclosure - WARRANTS - Warrant Activity (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails WARRANTS - Warrant Activity (Details) Details 64 false false R65.htm 41001 - Disclosure - LEASES - Lease Cost (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails LEASES - Lease Cost (Details) Details 65 false false R66.htm 41002 - Disclosure - LEASES - Lease terms and discount rates (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails LEASES - Lease terms and discount rates (Details) Details 66 false false R67.htm 41003 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails LEASES - Maturities of Lease Liabilities (Details) Details 67 false false R68.htm 41201 - Disclosure - BENEFIT PLANS (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureBenefitPlansDetails BENEFIT PLANS (Details) Details http://www.appliedtherapeutics.com/role/DisclosureBenefitPlans 68 false false R69.htm 41301 - Disclosure - NET LOSS PER COMMON SHARE - EPS (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails NET LOSS PER COMMON SHARE - EPS (Details) Details http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareTables 69 false false R70.htm 41302 - Disclosure - NET LOSS PER COMMON SHARE - Anti-dilutive securities (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails NET LOSS PER COMMON SHARE - Anti-dilutive securities (Details) Details 70 false false R71.htm 41401 - Disclosure - RELATED PARTIES (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails RELATED PARTIES (Details) Details http://www.appliedtherapeutics.com/role/DisclosureRelatedParties 71 false false R72.htm 41501 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails SUBSEQUENT EVENTS (Details) Details http://www.appliedtherapeutics.com/role/DisclosureSubsequentEvents 72 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 29 fact(s) appearing in ix:hidden were eligible for transformation: aplt:FairValueAssetsLevel2ToLevel1TransfersAmount1, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareBasic, us-gaap:EarningsPerShareDiluted, us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic, us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted, us-gaap:PreferredStockSharesOutstanding, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding, us-gaap:WeightedAverageNumberOfSharesOutstandingBasic - aplt-20220930x10q.htm 9 aplt-20220930x10q.htm aplt-20220930.xsd aplt-20220930_cal.xml aplt-20220930_def.xml aplt-20220930_lab.xml aplt-20220930_pre.xml aplt-20220930xex31d1.htm aplt-20220930xex31d2.htm aplt-20220930xex32d1.htm aplt-20220930xex32d2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "aplt-20220930x10q.htm": { "axisCustom": 0, "axisStandard": 18, "contextCount": 224, "dts": { "calculationLink": { "local": [ "aplt-20220930_cal.xml" ] }, "definitionLink": { "local": [ "aplt-20220930_def.xml" ] }, "inline": { "local": [ "aplt-20220930x10q.htm" ] }, "labelLink": { "local": [ "aplt-20220930_lab.xml" ] }, "presentationLink": { "local": [ "aplt-20220930_pre.xml" ] }, "schema": { "local": [ "aplt-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 492, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 31, "http://www.appliedtherapeutics.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 37 }, "keyCustom": 87, "keyStandard": 231, "memberCustom": 33, "memberStandard": 23, "nsprefix": "aplt", "nsuri": "http://www.appliedtherapeutics.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - LICENSE AGREEMENT", "role": "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreement", "shortName": "LICENSE AGREEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurements", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - INVESTMENTS", "role": "http://www.appliedtherapeutics.com/role/DisclosureInvestments", "shortName": "INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:PrepaidAndOtherAssetsCurrentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "role": "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:PrepaidAndOtherAssetsCurrentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "role": "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - STOCK BASED COMPENSATION", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation", "shortName": "STOCK BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:StockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10901 - Disclosure - WARRANTS", "role": "http://www.appliedtherapeutics.com/role/DisclosureWarrants", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:StockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11001 - Disclosure - LEASES", "role": "http://www.appliedtherapeutics.com/role/DisclosureLeases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - Condensed Balance Sheets", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets", "shortName": "Condensed Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11101 - Disclosure - INCOME TAXES", "role": "http://www.appliedtherapeutics.com/role/DisclosureIncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11201 - Disclosure - BENEFIT PLANS", "role": "http://www.appliedtherapeutics.com/role/DisclosureBenefitPlans", "shortName": "BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11301 - Disclosure - NET LOSS PER COMMON SHARE", "role": "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShare", "shortName": "NET LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11401 - Disclosure - RELATED PARTIES", "role": "http://www.appliedtherapeutics.com/role/DisclosureRelatedParties", "shortName": "RELATED PARTIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "11501 - Disclosure - SUBSEQUENT EVENTS", "role": "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30403 - Disclosure - INVESTMENTS (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "aplt:PrepaidAndOtherAssetsCurrentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "aplt:PrepaidAndOtherAssetsCurrentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_HbHlNcIDh0SlPb4pzCR_lQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - Condensed Balance Sheets (Parenthetical)", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical", "shortName": "Condensed Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30703 - Disclosure - STOCK BASED COMPENSATION (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables", "shortName": "STOCK BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30903 - Disclosure - WARRANTS (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables", "shortName": "WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31003 - Disclosure - LEASES (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosureLeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "31303 - Disclosure - NET LOSS PER COMMON SHARE (Tables)", "role": "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareTables", "shortName": "NET LOSS PER COMMON SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_HbHlNcIDh0SlPb4pzCR_lQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock issued (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Stock issued (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_1_28_2020_us-gaap_SubsidiarySaleOfStockAxis_aplt_SecondaryPublicOfferingJanuary2020Member_s9fhUk1e10iTAbwBXEZnFg", "decimals": "INF", "lang": null, "name": "us-gaap:SharesIssuedPricePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_HbHlNcIDh0SlPb4pzCR_lQ", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesLiquidityAndGoingConcernDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Liquidity and Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-5", "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - LICENSE AGREEMENT - Columbia (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "shortName": "LICENSE AGREEMENT - Columbia (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_srt_CounterpartyNameAxis_aplt_ColumbiaUniversityMember__9OJJI_c3ECPaGPVOF31RA", "decimals": "-3", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40202 - Disclosure - LICENSE AGREEMENT - Miami University (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "shortName": "LICENSE AGREEMENT - Miami University (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_10_28_2020_To_10_28_2020_srt_CounterpartyNameAxis_aplt_UniversityOfMiamiMember_us-gaap_TypeOfArrangementAxis_aplt_LicenseAgreement2020Member_RLqDNHcmq0C1aUOnoSAHdA", "decimals": "-5", "lang": null, "name": "aplt:NonCollaborativeArrangementLicenseIssueFeePaymentOne", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_L5kzxxbnnUmA3r7T-LfrWw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENTS - FV hierarchy (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails", "shortName": "FAIR VALUE MEASUREMENTS - FV hierarchy (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_L5kzxxbnnUmA3r7T-LfrWw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "aplt:FairValueAssetsLevel1ToLevel2TransfersAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENTS - Transfers (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTransfersDetails", "shortName": "FAIR VALUE MEASUREMENTS - Transfers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "aplt:FairValueAssetsLevel1ToLevel2TransfersAmount1", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - Condensed Statements of Operations", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations", "shortName": "Condensed Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "lang": null, "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_6_27_2022_us-gaap_ClassOfWarrantOrRightAxis_aplt_CommonWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_aplt_June2022OfferingMember_giOLIBaewEKIKkDW9AqRPg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - FAIR VALUE MEASUREMENTS - Warrants (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_6_27_2022_To_6_27_2022_us-gaap_ClassOfWarrantOrRightAxis_aplt_PreFundedAndCommonWarrantsMember_FcwM8_MafUCwf2YltgJYlQ", "decimals": null, "first": true, "lang": "en-US", "name": "aplt:WarrantAndRightsOutstandingTerm", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - FAIR VALUE MEASUREMENTS - Warrants Valuation (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "shortName": "FAIR VALUE MEASUREMENTS - Warrants Valuation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aplt_PreFundedAndCommonWarrantsMember_us-gaap_MeasurementInputTypeAxis_aplt_MeasurementInputChangeOfControlProbabilityMember_10Z4lIDPeEGkOAWrIPKcAg", "decimals": "0", "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_XXBxzCQFaU2Nq3fL8WZ6HA", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_aplt_CommonWarrantsMember_GGxYIz_0D06arinNmiTSCg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40305 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Values of Company's Warrant Liability (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails", "shortName": "FAIR VALUE MEASUREMENTS - Fair Values of Company's Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_FairValueByLiabilityClassAxis_aplt_CommonWarrantsMember_GGxYIz_0D06arinNmiTSCg", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - INVESTMENTS - By type (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails", "shortName": "INVESTMENTS - By type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_O4Kig2oCzEmy9n5tnRjHFQ", "decimals": "-3", "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40402 - Disclosure - INVESTMENTS - Additional Information (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsAdditionalInformationDetails", "shortName": "INVESTMENTS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40403 - Disclosure - INVESTMENTS - By contractual maturity (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails", "shortName": "INVESTMENTS - By contractual maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40404 - Disclosure - INVESTMENTS - Realized gains and losses (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsRealizedGainsAndLossesDetails", "shortName": "INVESTMENTS - Realized gains and losses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_EfN3WPtgukqjZ6NFTV310A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40405 - Disclosure - INVESTMENTS - Unrealized losses and fair values of available-for-sale securities (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails", "shortName": "INVESTMENTS - Unrealized losses and fair values of available-for-sale securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_EfN3WPtgukqjZ6NFTV310A", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "aplt:PrepaidAndOtherAssetsCurrentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "aplt:PrepaidResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "aplt:PrepaidAndOtherAssetsCurrentDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "aplt:PrepaidResearchAndDevelopmentExpenses", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "aplt:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "aplt:AccruedPreClinicalAndClinicalExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "aplt:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "aplt:AccruedPreClinicalAndClinicalExpensesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - Condensed Statements of Comprehensive Income (Loss)", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss", "shortName": "Condensed Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_gKiaCzaSpEeVMe6tjLHrKQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - STOCK BASED COMPENSATION - Plans (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails", "shortName": "STOCK BASED COMPENSATION - Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_5_31_2019_us-gaap_PlanNameAxis_aplt_EquityIncentivePlan2019Member_AdKdcU8D9E6WzDGRj1iw5A", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40702 - Disclosure - STOCK BASED COMPENSATION - Stock-based compensation expense (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "STOCK BASED COMPENSATION - Stock-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_X-fDdaFNS0aYfR3mn5x-eg", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40703 - Disclosure - STOCK BASED COMPENSATION - Options (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "shortName": "STOCK BASED COMPENSATION - Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "2", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_HbHlNcIDh0SlPb4pzCR_lQ", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_EfN3WPtgukqjZ6NFTV310A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40704 - Disclosure - STOCK BASED COMPENSATION - Options activity (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails", "shortName": "STOCK BASED COMPENSATION - Options activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_aplt_StockOptionsVestingBasedOnServiceMember_D8gZ69ebTUK6gzGnYpQk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40705 - Disclosure - STOCK BASED COMPENSATION - Valuation assumptions (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails", "shortName": "STOCK BASED COMPENSATION - Valuation assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_aplt_StockOptionsVestingBasedOnServiceMember_D8gZ69ebTUK6gzGnYpQk9w", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_GrNBkbEPhESRMA51jKILNw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40706 - Disclosure - STOCK BASED COMPENSATION - RSUs (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails", "shortName": "STOCK BASED COMPENSATION - RSUs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_8NYXsVPSa0WiaF0H8djMew", "decimals": "-5", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_5_31_2019_us-gaap_PlanNameAxis_aplt_EmployeeStockPurchasePlan2019Member_D0MLdWMVP02znAuKDhdlHw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40707 - Disclosure - STOCK BASED COMPENSATION - 2019 Employee Stock Purchase Plan (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "shortName": "STOCK BASED COMPENSATION - 2019 Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_5_31_2019_us-gaap_PlanNameAxis_aplt_EmployeeStockPurchasePlan2019Member_D0MLdWMVP02znAuKDhdlHw", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - STOCKHOLDERS' EQUITY - Authorized stock (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityAuthorizedStockDetails", "shortName": "STOCKHOLDERS' EQUITY - Authorized stock (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "p", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_6_12_2020_To_6_12_2020_us-gaap_SubsidiarySaleOfStockAxis_aplt_EquityDistributionAgreementMember_nq3FIYVDEECVTEnbB0YDcw", "decimals": "-6", "first": true, "lang": null, "name": "aplt:StockOfferingValueSharesAuthorizedToBeSold", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40802 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock and Equity Distribution Agreement (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails", "shortName": "STOCKHOLDERS' EQUITY - Common Stock and Equity Distribution Agreement (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_HbHlNcIDh0SlPb4pzCR_lQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40803 - Disclosure - STOCKHOLDERS' EQUITY - June 2022 Offering (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "shortName": "STOCKHOLDERS' EQUITY - June 2022 Offering (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_AK8_Q78i-0SQtyq7IZy_QQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - Condensed Statements of Stockholders' Equity", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity", "shortName": "Condensed Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7wnlQI0aPEWuRU_n9wiM1g", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021__IWHt2iYREalD85O5OUY8w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40901 - Disclosure - WARRANTS - Issued with Series A Preferred Stock (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "shortName": "WARRANTS - Issued with Series A Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "aplt:StockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_1_26_2017_us-gaap_ClassOfWarrantOrRightAxis_aplt_WarrantsIssuedWithSeriesPreferredStockMember_us-gaap_FinancialInstrumentAxis_aplt_Warrant2017Member_7ithRlaMPUGxrEntE5MUhQ", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "aplt:StockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_1_18_2018_us-gaap_ClassOfWarrantOrRightAxis_aplt_WarrantsIssuedWith2018NotesMember__Ps8rhBvRUmXn026PKEk8w", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40902 - Disclosure - WARRANTS - Issued with the 2018 Notes (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "shortName": "WARRANTS - Issued with the 2018 Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "aplt:StockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_1_18_2018_us-gaap_ClassOfWarrantOrRightAxis_aplt_WarrantsIssuedWith2018NotesMember__Ps8rhBvRUmXn026PKEk8w", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "aplt:StockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_12_31_2018_us-gaap_ClassOfWarrantOrRightAxis_aplt_WarrantsIssuedWithSeriesBPreferredStockMember_us-gaap_FinancialInstrumentAxis_aplt_Warrant2018Member_B0gG8fA1cUKztqxp2MlI6A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40903 - Disclosure - WARRANTS - Issued with Series B Preferred Stock (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "shortName": "WARRANTS - Issued with Series B Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "aplt:StockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_12_31_2018_us-gaap_ClassOfWarrantOrRightAxis_aplt_WarrantsIssuedWithSeriesBPreferredStockMember_us-gaap_FinancialInstrumentAxis_aplt_Warrant2018Member_B0gG8fA1cUKztqxp2MlI6A", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021__IWHt2iYREalD85O5OUY8w", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromWarrantExercises", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40904 - Disclosure - WARRANTS - Issued with June 2022 Offering (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "shortName": "WARRANTS - Issued with June 2022 Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_6_27_2022_us-gaap_ClassOfWarrantOrRightAxis_aplt_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_aplt_June2022OfferingMember_8WEptbqClk2e2Fya6aZ7NQ", "decimals": "4", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_HbHlNcIDh0SlPb4pzCR_lQ", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_ClassOfWarrantOrRightAxis_aplt_PreFundedAndCommonWarrantsMember_qNkz64cjw0SlC1A93LVyUg", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40905 - Disclosure - WARRANTS - Warrant Activity (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails", "shortName": "WARRANTS - Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_ClassOfWarrantOrRightAxis_aplt_PreFundedAndCommonWarrantsMember_AtxGuCeA00mL1hGgL5d0iA", "decimals": "INF", "lang": null, "name": "aplt:WarrantsGrantedAndIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41001 - Disclosure - LEASES - Lease Cost (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails", "shortName": "LEASES - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "aplt:LesseeOperatingLeaseAdditionalInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41002 - Disclosure - LEASES - Lease terms and discount rates (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails", "shortName": "LEASES - Lease terms and discount rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "aplt:LesseeOperatingLeaseAdditionalInformationTableTextBlock", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41003 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails", "shortName": "LEASES - Maturities of Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41201 - Disclosure - BENEFIT PLANS (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureBenefitPlansDetails", "shortName": "BENEFIT PLANS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanCostRecognized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R69": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "41301 - Disclosure - NET LOSS PER COMMON SHARE - EPS (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails", "shortName": "NET LOSS PER COMMON SHARE - EPS (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "Unit_Divide_USD_shares_HbHlNcIDh0SlPb4pzCR_lQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00405 - Statement - Condensed Statements of Stockholders' Equity (Parenthetical)", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical", "shortName": "Condensed Statements of Stockholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_4_1_2022_To_6_30_2022_VUr6N-PCdkSSvyw-O3PfoQ", "decimals": "-3", "lang": null, "name": "aplt:StockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_77JotCkd8kyBVuiBj_zDaw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41302 - Disclosure - NET LOSS PER COMMON SHARE - Anti-dilutive securities (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails", "shortName": "NET LOSS PER COMMON SHARE - Anti-dilutive securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_77JotCkd8kyBVuiBj_zDaw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_aplt_LaunchlabsAgreementWithAlexandriaLaunchlabsMember_xP5Z5Paww022h2fy7Ym0Fw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41401 - Disclosure - RELATED PARTIES (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails", "shortName": "RELATED PARTIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_RelatedPartyTransactionAxis_aplt_LaunchlabsAgreementWithAlexandriaLaunchlabsMember_xP5Z5Paww022h2fy7Ym0Fw", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_9_30_2022_78EpqQACa0uWfnfmEJkWoQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "41501 - Disclosure - SUBSEQUENT EVENTS (Details)", "role": "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "As_Of_10_26_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_IZa9w9Hs90mU4io2HFes3A", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares__3Ba4ef-DUOzqekrT-iqfA", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00500 - Statement - Condensed Statements of Cash Flows", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows", "shortName": "Condensed Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2022_To_9_30_2022_TU2Ftqe8ME619sMx5gVHow", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021__IWHt2iYREalD85O5OUY8w", "decimals": "-3", "first": true, "lang": null, "name": "aplt:CashStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00505 - Statement - Condensed Statements of Cash Flows (Parenthetical)", "role": "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlowsParenthetical", "shortName": "Condensed Statements of Cash Flows (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "aplt-20220930x10q.htm", "contextRef": "Duration_1_1_2021_To_9_30_2021__IWHt2iYREalD85O5OUY8w", "decimals": "-3", "first": true, "lang": null, "name": "aplt:CashStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_h1opX57pz0uEfOKvCoBNlg", "xsiNil": "false" } } }, "segmentCount": 62, "tag": { "aplt_AccruedCommercialExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for commercial expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Commercial Expenses, Current", "terseLabel": "Accrued commercial expenses" } } }, "localname": "AccruedCommercialExpensesCurrent", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aplt_AccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other, used to reflect current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Expenses and Other Current Liabilities.", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aplt_AccruedPatentExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for patent expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Patent Expenses, Current", "terseLabel": "Accrued patent expenses" } } }, "localname": "AccruedPatentExpensesCurrent", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aplt_AccruedPreClinicalAndClinicalExpensesCurrent": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for pre-clinical and clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Pre Clinical and Clinical Expenses, Current", "terseLabel": "Accrued pre-clinical and clinical expenses" } } }, "localname": "AccruedPreClinicalAndClinicalExpensesCurrent", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "aplt_AdjustmentsToAdditionalPaidInCapitalOptionsIssuedInLieuOfBonus": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance of options in lieu of bonus.", "label": "Adjustments to Additional Paid in Capital, Options Issued In Lieu Of Bonus", "terseLabel": "Issuance of options in-lieu of bonus" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOptionsIssuedInLieuOfBonus", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "aplt_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from adjustment to direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Adjustment", "terseLabel": "Secondary public offering issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsAdjustment", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "aplt_AmortizationOfInsurancePremium": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings for the periodic recognition of insurance premium.", "label": "Amortization of Insurance Premium", "terseLabel": "Amortization of insurance premium" } } }, "localname": "AmortizationOfInsurancePremium", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_AmortizationOfLeaseholdImprovements": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings for the periodic recognition of leasehold improvements.", "label": "Amortization of Leasehold Improvements", "terseLabel": "Amortization of leasehold improvements" } } }, "localname": "AmortizationOfLeaseholdImprovements", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_CashStockIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash stock issuance costs subtracted from gross proceeds.", "label": "Cash Stock Issuance Costs", "terseLabel": "Cash issuance costs, February Offering" } } }, "localname": "CashStockIssuanceCosts", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlowsParenthetical" ], "xbrltype": "monetaryItemType" }, "aplt_ColumbiaUniversityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Columbia University.", "label": "Columbia University" } } }, "localname": "ColumbiaUniversityMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "domainItemType" }, "aplt_CommonStockCapitalSharesReservedForFutureIssuanceNewShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate number of new share reserved for future issuance under the plan.", "label": "Common Stock, Capital Shares Reserved for Future Issuance, New Shares", "terseLabel": "New shares reserved (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuanceNewShares", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "aplt_CommonStockCapitalSharesReservedForFutureIssuancePreviousPlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Aggregate number of shares remaining available from previous plan reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance Previous Plan", "terseLabel": "Reserved shares available from 2016 Plan (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuancePreviousPlan", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "aplt_CommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to common warrants.", "label": "Common Warrants" } } }, "localname": "CommonWarrantsMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "domainItemType" }, "aplt_ConversionOfWarrantLiabilityToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of conversion of warrant liability to equity for warrant exercises.", "label": "Conversion Of Warrant Liability To Equity", "terseLabel": "Conversion of warrant liability to equity for warrant exercises" } } }, "localname": "ConversionOfWarrantLiabilityToEquity", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "weight": 1.0 }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Rolling Year Two", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax, Rolling within One Year", "terseLabel": "Due in on year or less - Gross Unrealized Gains" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxRollingWithinOneYear", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "aplt_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxRollingWithinOneYear": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "weight": 1.0 }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security, maturing in next rolling fiscal year following latest fiscal year, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Rolling within One Year", "negatedLabel": "Due in one year or less - Gross Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxRollingWithinOneYear", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "aplt_EmployeeStockPurchasePlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2019 employee stock purchase plan.", "label": "2019 ESPP" } } }, "localname": "EmployeeStockPurchasePlan2019Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "aplt_EquityDistributionAgreementJanuary2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen Equity Distribution Agreement, January 2022.", "label": "Cowen Equity Distribution Agreement" } } }, "localname": "EquityDistributionAgreementJanuary2022Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails" ], "xbrltype": "domainItemType" }, "aplt_EquityDistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Goldman Equity Distribution Agreement, June 2020.", "label": "Goldman Equity Distribution Agreement" } } }, "localname": "EquityDistributionAgreementMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails" ], "xbrltype": "domainItemType" }, "aplt_EquityIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2019 equity incentive plan.", "label": "2019 Plan" } } }, "localname": "EquityIncentivePlan2019Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "aplt_ExerciseOfPreFundedWarrantsForStockNotYetIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares not yet issued upon exercise of pre-funded warrants during the period.", "label": "Exercise Of Pre Funded Warrants For Stock Not Yet Issued, Shares", "negatedLabel": "Exercise of prefunded warrants for common stock not yet issued (in shares)" } } }, "localname": "ExerciseOfPreFundedWarrantsForStockNotYetIssuedShares", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_FairValueAssetsLevel1ToLevel2TransfersAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value, Assets, Level 1 to Level 2 Transfers, Amount 1", "terseLabel": "Assets, transfer from level 1 to level 2" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount1", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTransfersDetails" ], "xbrltype": "monetaryItemType" }, "aplt_FairValueAssetsLevel2ToLevel1TransfersAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value, Assets, Level 2 to Level 1 Transfers, Amount 1", "terseLabel": "Assets, transfer from level 2 to level 1" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount1", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTransfersDetails" ], "xbrltype": "monetaryItemType" }, "aplt_IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and other current liabilities.", "label": "Increase Decrease in Accrued Liabilities and Other Current Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_IncreaseDecreaseInFinancedInsurancePremium": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in financed insurance premium.", "label": "Increase (Decrease) In Financed Insurance Premium", "negatedLabel": "Financed insurance premium" } } }, "localname": "IncreaseDecreaseInFinancedInsurancePremium", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_InitialMeasurementOfWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of initial measurement of warrant liability.", "label": "Initial Measurement Of Warrant Liability", "terseLabel": "Initial measurement of warrant liability" } } }, "localname": "InitialMeasurementOfWarrantLiability", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_InsurancePremiumAssetCurrent": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to insurance premium asset within a future period of one year or the normal operating cycle, if longer.", "label": "Insurance Premium Asset, Current", "terseLabel": "Insurance premium asset" } } }, "localname": "InsurancePremiumAssetCurrent", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "aplt_IssuePricePerShareAndWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The issue price per common share and accompanying warrant.", "label": "Issue Price Per Share And Warrant", "terseLabel": "Issue price per share and accompanying warrant (in dollars per share)" } } }, "localname": "IssuePricePerShareAndWarrant", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "perShareItemType" }, "aplt_June2022OfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to June 2022 offering.", "label": "June Offering" } } }, "localname": "June2022OfferingMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "domainItemType" }, "aplt_LaunchlabsAgreementWithAlexandriaLaunchlabsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to LaunchLabs Agreement with ARE LaunchLabs NYC LLC (\"Alexandria LaunchLabs\"), a subsidiary of Alexandria Real Estate Equities, Inc.", "label": "LaunchLabs Agreement" } } }, "localname": "LaunchlabsAgreementWithAlexandriaLaunchlabsMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "aplt_LesseeOperatingLeaseAdditionalInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of additional information under operating leases. May include, but not limited to, lease terms and discount rates.", "label": "Lessee Operating Lease, Additional Information [Table Text Block]", "terseLabel": "Summary of lease terms and discount rates" } } }, "localname": "LesseeOperatingLeaseAdditionalInformationTableTextBlock", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "aplt_LicenseAgreement2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2016 license agreement.", "label": "2016 license agreement" } } }, "localname": "LicenseAgreement2016Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "domainItemType" }, "aplt_LicenseAgreement2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2019 license agreement.", "label": "2019 license agreement" } } }, "localname": "LicenseAgreement2019Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "domainItemType" }, "aplt_LicenseAgreement2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2020 license agreement.", "label": "2020 license agreement" } } }, "localname": "LicenseAgreement2020Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "domainItemType" }, "aplt_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for license agreements.", "label": "License Agreement [Text Block]", "terseLabel": "LICENSE AGREEMENT" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreement" ], "xbrltype": "textBlockItemType" }, "aplt_LiquidityAndGoingConcernPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liquidity and going concern of the reporting entity.", "label": "Liquidity and Going Concern, Policy [Policy Text Block]", "terseLabel": "Liquidity and Going Concern" } } }, "localname": "LiquidityAndGoingConcernPolicyPolicyTextBlock", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "aplt_MeasurementInputChangeOfControlProbabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input using probability of change in control for each year in the term of the agreements.", "label": "Probability of change in control" } } }, "localname": "MeasurementInputChangeOfControlProbabilityMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails" ], "xbrltype": "domainItemType" }, "aplt_NonCollaborativeArrangementConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred under the agreement during the period.", "label": "Non-Collaborative Arrangement, Consideration", "terseLabel": "Consideration" } } }, "localname": "NonCollaborativeArrangementConsideration", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "monetaryItemType" }, "aplt_NonCollaborativeArrangementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LICENSE AGREEMENT" } } }, "localname": "NonCollaborativeArrangementDisclosureAbstract", "nsuri": "http://www.appliedtherapeutics.com/20220930", "xbrltype": "stringItemType" }, "aplt_NonCollaborativeArrangementLicenseIssueFeePaymentOne": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of first payment to be made for license issue fee under non-collaborative arrangement.", "label": "Non-collaborative Arrangement, License Issue Fee, Payment One", "terseLabel": "Amount of first payment to be made for license issue fee" } } }, "localname": "NonCollaborativeArrangementLicenseIssueFeePaymentOne", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "monetaryItemType" }, "aplt_NonCollaborativeArrangementLicenseIssueFeePaymentTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of second payment to be made for license issue fee, due on first anniversary of the date of license, under non-collaborative arrangement.", "label": "Non-collaborative Arrangement, License Issue Fee, Payment Two", "terseLabel": "Amount of second payment to be made for license issue fee, due on first anniversary of the date of license" } } }, "localname": "NonCollaborativeArrangementLicenseIssueFeePaymentTwo", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "monetaryItemType" }, "aplt_NonCollaborativeArrangementPaymentOnAchievementOfLateStageRegulatoryMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the payment on achievement of late stage regulatory milestones under non-collaborative arrangement.", "label": "Non-collaborative Arrangement, Payment on Achievement of Late Stage Regulatory Milestones", "terseLabel": "Payment to be made on achievement of late stage regulatory milestones" } } }, "localname": "NonCollaborativeArrangementPaymentOnAchievementOfLateStageRegulatoryMilestones", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "monetaryItemType" }, "aplt_NonCollaborativeArrangementPaymentOnAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the payment on achievement of specified development and regulatory milestones under non-collaborative arrangement.", "label": "Non-collaborative Arrangement Payment on Achievement of Specified Development and Regulatory Milestones", "terseLabel": "Payment on achievement of specified development and regulatory milestones" } } }, "localname": "NonCollaborativeArrangementPaymentOnAchievementOfSpecifiedDevelopmentAndRegulatoryMilestones", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "monetaryItemType" }, "aplt_NonCollaborativeArrangementPaymentOnAchievementOfSpecifiedPatentingAndDevelopmentMilestones": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the payment to be made on achievement of specified patenting and development milestones under non-collaborative arrangement.", "label": "Non-collaborative Arrangement, Payment on Achievement of Specified Patenting and Development Milestones", "terseLabel": "Payment to be made on achievement of specified patenting and development milestones" } } }, "localname": "NonCollaborativeArrangementPaymentOnAchievementOfSpecifiedPatentingAndDevelopmentMilestones", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "monetaryItemType" }, "aplt_NonCollaborativeArrangementPercentageOfOutstandingCommonStockIssuedOnCertainTriggerEvents": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of outstanding common stock issued on certain trigger events under non-collaborative arrangement.", "label": "Non-collaborative Arrangement Percentage of Outstanding Common Stock Issued on Certain Trigger Events", "terseLabel": "Percentage of outstanding common stock issued" } } }, "localname": "NonCollaborativeArrangementPercentageOfOutstandingCommonStockIssuedOnCertainTriggerEvents", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "percentItemType" }, "aplt_NonCollaborativeCollaborativeArrangementCureOfMaterialBreachNotInitiatedTermination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the written notice period of material breach after which contract may be terminated if action to cure the breach is not initiated, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Non-Collaborative Collaborative Arrangement, Cure of Material Breach Not Initiated, Termination,", "terseLabel": "Written notice period of material breach leading to termination" } } }, "localname": "NonCollaborativeCollaborativeArrangementCureOfMaterialBreachNotInitiatedTermination", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "durationItemType" }, "aplt_NonCollaborativeCollaborativeArrangementExtendedWrittenNoticePeriodForTerminationOfAgreementBasedOnAttemptToCureMaterialBreach": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the extended written notice period for termination of agreement, attempt to cure material breach under non-collaborative arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Non-collaborative Collaborative Arrangement Extended Written Notice Period for Termination of Agreement Based on Attempt to Cure Material Breach", "terseLabel": "Extended written notice period for termination of agreement, attempt to cure material breach" } } }, "localname": "NonCollaborativeCollaborativeArrangementExtendedWrittenNoticePeriodForTerminationOfAgreementBasedOnAttemptToCureMaterialBreach", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "durationItemType" }, "aplt_NonCollaborativeCollaborativeArrangementPaymentOnAchievementOfSpecifiedLevelOfAggregateAnnualNetSales": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the payment on achievement of specified level of aggregate annual net sales under non-collaborative arrangement.", "label": "Non-collaborative collaborative Arrangement Payment on Achievement of Specified Level of Aggregate Annual Net Sales", "terseLabel": "Payment on achievement of specified level of aggregate annual net sales" } } }, "localname": "NonCollaborativeCollaborativeArrangementPaymentOnAchievementOfSpecifiedLevelOfAggregateAnnualNetSales", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "monetaryItemType" }, "aplt_NonCollaborativeCollaborativeArrangementPercentageOfSublicensingRevenueIfSublicensesRightsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of sublicensing revenue received from third parties to be paid by entity to party to agreement, if sublicenses rights are granted, under non-collaborative arrangement.", "label": "Non-collaborative Collaborative Arrangement Percentage of Sublicensing Revenue If sublicenses Rights Granted", "terseLabel": "Percentage of sublicensing revenue, if sublicenses rights granted" } } }, "localname": "NonCollaborativeCollaborativeArrangementPercentageOfSublicensingRevenueIfSublicensesRightsGranted", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "percentItemType" }, "aplt_NonCollaborativeCollaborativeArrangementPeriodWithinWhichTerminationOfAgreementWillBeEffective": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents period within which termination of agreement under non-collaborative arrangement will become effective due to written notice provided by entity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Non-collaborative Collaborative Arrangement, Period Within Which Termination of Agreement Will Be Effective", "terseLabel": "Period within which termination of agreement will become effective" } } }, "localname": "NonCollaborativeCollaborativeArrangementPeriodWithinWhichTerminationOfAgreementWillBeEffective", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "durationItemType" }, "aplt_NonCollaborativeCollaborativeArrangementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the agreement term under non-collaborative arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Non-collaborative Collaborative Arrangement Term", "terseLabel": "Agreement term" } } }, "localname": "NonCollaborativeCollaborativeArrangementTerm", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "durationItemType" }, "aplt_NonCollaborativeCollaborativeArrangementWrittenNoticePeriodForTerminationOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the written notice period for termination of agreement under non-collaborative arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Non-collaborative Collaborative Arrangement Written Notice Period for Termination of Agreement", "terseLabel": "Written notice period for termination of agreement" } } }, "localname": "NonCollaborativeCollaborativeArrangementWrittenNoticePeriodForTerminationOfAgreement", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "durationItemType" }, "aplt_NonCollaborativeCollaborativeArrangementWrittenNoticePeriodForTerminationOfAgreementBasedOnUncuredMaterialBreach": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the written notice period for termination of agreement with uncured material breach under collaborative arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Non-collaborative Collaborative Arrangement Written Notice Period for Termination of Agreement Based on Uncured Material Breach", "terseLabel": "Written notice period for termination of agreement, uncured material breach" } } }, "localname": "NonCollaborativeCollaborativeArrangementWrittenNoticePeriodForTerminationOfAgreementBasedOnUncuredMaterialBreach", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "durationItemType" }, "aplt_NonRoyaltySublicensingRevenuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The amount the entity will be required to pay of non-royalty sublicensing revenue received from third parties as a percent of non-royalty sublicensing revenue.", "label": "Non-royalty Sublicensing Revenue, Percentage", "terseLabel": "Non-royalty sublicensing revenue payment (as a percent)" } } }, "localname": "NonRoyaltySublicensingRevenuePercentage", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "percentItemType" }, "aplt_NonVestedStockOptionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to non vested stock option awards.", "label": "Non Vested Stock Option Awards [Member]", "terseLabel": "Non-vested stock option" } } }, "localname": "NonVestedStockOptionAwardsMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "aplt_OptionsIssuedInLieuOfBonus": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of options issued in lieu of bonus.", "label": "Options Issued In Lieu Of Bonus", "terseLabel": "Issuance of options in-lieu of bonus" } } }, "localname": "OptionsIssuedInLieuOfBonus", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_PreFundedAndCommonWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded and common warrants.", "label": "Common And Pre-Funded Warrants" } } }, "localname": "PreFundedAndCommonWarrantsMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "aplt_PreFundedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to pre-funded warrants.", "label": "Pre-Funded Warrants" } } }, "localname": "PreFundedWarrantsMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "domainItemType" }, "aplt_PrepaidAndOtherAssetsCurrentDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on prepaid and other current assets.", "label": "Prepaid, and Other Assets, Current Disclosure [Text Block]", "terseLabel": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "PrepaidAndOtherAssetsCurrentDisclosureTextBlock", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "aplt_PrepaidCommercialAndPatientAdvocacy": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 5.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for commercial and patient advocacy.", "label": "Prepaid Commercial and Patient Advocacy", "terseLabel": "Prepaid commercial and patient advocacy" } } }, "localname": "PrepaidCommercialAndPatientAdvocacy", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "aplt_PrepaidResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for research and development expenses that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research And Development Expenses", "terseLabel": "Prepaid research and development expenses" } } }, "localname": "PrepaidResearchAndDevelopmentExpenses", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "aplt_ProceedsFromFinancedInsurancePremium": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from financed insurance premium.", "label": "Proceeds From Financed Insurance Premium", "terseLabel": "Proceeds from financed insurance premium" } } }, "localname": "ProceedsFromFinancedInsurancePremium", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_ProceedsFromIssuanceOfCommonStockNet": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity, net.", "label": "Proceeds From Issuance Of Common Stock, Net", "terseLabel": "Proceeds from stock issuance, net of cash issuance costs", "verboseLabel": "Proceeds from February Offering, net of cash issuance costs of $165" } } }, "localname": "ProceedsFromIssuanceOfCommonStockNet", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_ProceedsFromIssuanceOfSharesAndPreFundedWarrants": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of shares and pre-funded warrants.", "label": "Proceeds From Issuance Of Shares And Pre Funded Warrants", "terseLabel": "Proceeds from June Offering issuance of shares and pre-funded warrants" } } }, "localname": "ProceedsFromIssuanceOfSharesAndPreFundedWarrants", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_ProceedsFromIssuanceOfSharesAndPreFundedWarrantsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of shares and pre-funded warrants net of underwriting discounts and commissions and offering expenses.", "label": "Proceeds From Issuance Of Shares And Pre Funded Warrants, Net", "terseLabel": "Proceeds from issuance of shares and pre-funded warrants, net" } } }, "localname": "ProceedsFromIssuanceOfSharesAndPreFundedWarrantsNet", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails" ], "xbrltype": "monetaryItemType" }, "aplt_ResearchAgreement2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to 2019 research services agreement.", "label": "2019 research agreement" } } }, "localname": "ResearchAgreement2019Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "domainItemType" }, "aplt_ResearchAgreement2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2020 research agreement and subsequent amendments.", "label": "2020 research agreement and amendment" } } }, "localname": "ResearchAgreement2020Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "domainItemType" }, "aplt_ResearchAndDevelopmentTaxCreditReceivable": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 6.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to research and development tax credit receivable expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Research and development tax credit receivable" } } }, "localname": "ResearchAndDevelopmentTaxCreditReceivable", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "aplt_ResearchServiceAgreementP13kMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to PI3k Research Services Agreement.", "label": "P13k Research agreement" } } }, "localname": "ResearchServiceAgreementP13kMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "domainItemType" }, "aplt_RestrictedStockUnitsNumberOfUnitsReleasedForCommonStockNotYetIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of restricted stock units released for common stock not yet issued.", "label": "Restricted Stock Units, Number of Units Released For Common Stock Not Yet Issued", "negatedLabel": "Restricted Stock Units released for common stock not yet issued (in shares)" } } }, "localname": "RestrictedStockUnitsNumberOfUnitsReleasedForCommonStockNotYetIssued", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_RoyaltiesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The royalties the entity will be required to pay as a percentage of on the Company's, the Company's affiliates' and the Company's sublicensees' net sales of licensed products.", "label": "Royalties, Percentage", "terseLabel": "Royalties payment (as a percent)" } } }, "localname": "RoyaltiesPercentage", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "percentItemType" }, "aplt_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities and other current liabilities.", "label": "Schedule of Accrued Liabilities And Other Liabilities, Current [Table Text Block]", "terseLabel": "Summary of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesCurrentTableTextBlock", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "aplt_SecondaryPublicOffering2020OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment under the secondary public offering completed in January 2020.", "label": "Secondary Public Offering, Underwriters' Option" } } }, "localname": "SecondaryPublicOffering2020OverAllotmentOptionMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "domainItemType" }, "aplt_SecondaryPublicOfferingExcludingOverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a secondary public offering, excluding right given to the underwriter to sell additional shares over the initial allotment.", "label": "Secondary Public Offering, Excluding Underwriters' Option" } } }, "localname": "SecondaryPublicOfferingExcludingOverAllotmentOptionMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "domainItemType" }, "aplt_SecondaryPublicOfferingFebruary2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a secondary public offering, including right given to the underwriter to sell additional shares over the initial allotment. Completed in February 2021.", "label": "February Offering, 2021" } } }, "localname": "SecondaryPublicOfferingFebruary2021Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "aplt_SecondaryPublicOfferingFebruary2021OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment under the secondary public offering completed in February 2021.", "label": "February Offering Underwriters' Option" } } }, "localname": "SecondaryPublicOfferingFebruary2021OverAllotmentOptionMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "domainItemType" }, "aplt_SecondaryPublicOfferingJanuary2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a secondary public offering, including right given to the underwriter to sell additional shares over the initial allotment. Completed in January 2020.", "label": "Secondary Public Offering, 2020" } } }, "localname": "SecondaryPublicOfferingJanuary2020Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "domainItemType" }, "aplt_SecurityDepositAndLeaseholdImprovementsNet": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. Also includes the carrying balance as of the balance sheet date of leasehold improvements net of depreciation or amortization.", "label": "Security Deposit and Leasehold Improvements, Net", "terseLabel": "Security deposits and leasehold improvements" } } }, "localname": "SecurityDepositAndLeaseholdImprovementsNet", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aplt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuanceNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents increase in number of shares reserved and available for issuance at beginning of each fiscal year under the plan.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Increase in Number of Shares Reserved and Available for issuance, Number", "terseLabel": "Increase in number of shares reserved and available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuanceNumber", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "aplt_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of increase in number of shares reserved and available for issuance at beginning of each fiscal year under the plan.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Reserved and Available for issuance Percentage", "terseLabel": "Increase in number of shares reserved and available for issuance (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesReservedAndAvailableForIssuancePercentage", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "percentItemType" }, "aplt_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date of non vested equity instruments other than options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Nonvested at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "perShareItemType" }, "aplt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "na", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "aplt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPriorPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised in prior period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Prior Period", "terseLabel": "Issuance of common stock for options exercised in prior periods under Equity Incentive Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPriorPeriod", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for nonvested portions of options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Remaining Contractual Term", "terseLabel": "Nonvested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "aplt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "na", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Terms [Abstract]", "terseLabel": "Weighted-Average Remaining Contractual Term-in years" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermsAbstract", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "aplt_ShelfOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to shelf offering.", "label": "Shelf Registration Statement" } } }, "localname": "ShelfOfferingMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "domainItemType" }, "aplt_StockIssuanceCommissionsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum commissions to be paid as a percent of gross offering proceeds.", "label": "Stock Issuance, Commissions, Percentage", "terseLabel": "Maximum amount to be paid to sales agent (as a percent)" } } }, "localname": "StockIssuanceCommissionsPercentage", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails" ], "xbrltype": "percentItemType" }, "aplt_StockIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of stock issuance cost during period.", "label": "Stock Issuance Costs", "terseLabel": "Stock issuance costs" } } }, "localname": "StockIssuanceCosts", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "monetaryItemType" }, "aplt_StockIssuanceCostsInAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issuance costs during the period included in accrued expenses.", "label": "Stock Issuance Costs In Accrued Expenses", "terseLabel": "Offering costs still in accrued expense" } } }, "localname": "StockIssuanceCostsInAccruedExpenses", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "aplt_StockIssuedDuringPeriodSharesCommonStockPreFundedWarrantsAndCommonStockWarrantsSoldForCash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new shares issued, pre-funded warrants issued and common stock warrants sold for cash.", "label": "Stock Issued During Period, Shares, Common Stock, Pre Funded Warrants And Common Stock Warrants Sold For Cash", "terseLabel": "Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of issuance costs (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockPreFundedWarrantsAndCommonStockWarrantsSoldForCash", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares for issue on exercise of pre-funded warrants during the current period.", "label": "Stock Issued During Period, Shares, Exercise Of Pre Funded Warrants", "terseLabel": "Exercise of prefunded warrants for common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in exercise of warrants.", "label": "Stock Issued During Period, Shares, Exercise Of Warrants", "terseLabel": "Exercise of warrants of common stock (in shares)", "verboseLabel": "Stock issued in exercise of warrants (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_StockIssuedDuringPeriodSharesPreFundedWarrantsExercisesInPriorPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock issued as a result of the exercise of pre-funded warrants exercised in prior period.", "label": "Stock Issued During Period, Shares, Pre-Funded Warrants, Exercises in Prior Period", "terseLabel": "Issuance of common stock for pre-funded warrants exercised in prior periods (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesPreFundedWarrantsExercisesInPriorPeriod", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndCommonStockWarrantsSoldForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of new shares issued, pre-funded warrants issued and common stock warrants sold for cash.", "label": "Stock Issued During Period, Value, Common Stock, Pre Funded Warrants And Common Stock Warrants Sold For Cash", "terseLabel": "Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockPreFundedWarrantsAndCommonStockWarrantsSoldForCash", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "aplt_StockIssuedDuringPeriodValueConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to consideration in an agreement.", "label": "Stock Issued During Period, Value, Consideration", "terseLabel": "Fair value of stock issued" } } }, "localname": "StockIssuedDuringPeriodValueConsideration", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails" ], "xbrltype": "monetaryItemType" }, "aplt_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of shares issued on exercise of pre-funded warrants.", "label": "Stock Issued During Period, Value, Exercise Of Pre Funded Warrants", "terseLabel": "Exercise of prefunded warrants for common stock" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "aplt_StockIssuedDuringPeriodValueExerciseOfWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Value, Exercise Of Warrants", "terseLabel": "Exercise of warrants of common stock" } } }, "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "aplt_StockIssuedDuringPeriodValueStockOptionsExercisedInPriorPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options exercised in prior period.", "label": "Stock Issued During Period, Value, Stock Options Exercised in Prior Period", "terseLabel": "Issuance of common stock for options exercised in prior periods under Equity Incentive Plan" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedInPriorPeriod", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "aplt_StockIssuedSharesRestrictedStockAwardReleasedInPriorPeriods": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares released in prior prior periods for issuance related to Restricted Stock Awards.", "label": "Stock Issued, Shares, Restricted Stock Award, Released in Prior Periods", "terseLabel": "Issuance of common stock for Restricted Stock released in prior periods under Equity Incentive Plan (in shares)" } } }, "localname": "StockIssuedSharesRestrictedStockAwardReleasedInPriorPeriods", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_StockOfferingValueSharesAuthorizedToBeSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum value of shares authorized to be sold in stock offering.", "label": "Stock Offering, Value, Shares Authorized to be Sold", "terseLabel": "Maximum value of shares authorized to be sold in stock offering" } } }, "localname": "StockOfferingValueSharesAuthorizedToBeSold", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails" ], "xbrltype": "monetaryItemType" }, "aplt_StockOptionExercisePriceOptionRepricing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share price upon reset of per-share exercise price of all stock options previously granted under the Plan.", "label": "Stock Option, Exercise Price, Option Repricing", "terseLabel": "Option exercise price upon option repricing (in dollars per share)" } } }, "localname": "StockOptionExercisePriceOptionRepricing", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "perShareItemType" }, "aplt_StockOptionNonVestedNumberOfSharesOptionRepricing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares non-vested upon option repricing of stock previously granted under the plan.", "label": "Stock Option Non Vested Number of Shares, Option Repricing", "terseLabel": "Options non-vested upon option repricing (in Shares)" } } }, "localname": "StockOptionNonVestedNumberOfSharesOptionRepricing", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "aplt_StockOptionVestedNumberOfSharesOptionRepricing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares vested upon option repricing of stock options previously granted under the plan.", "label": "Stock Option Vested, Number of Shares, Option Repricing", "terseLabel": "Options vested upon option repricing (in Shares)" } } }, "localname": "StockOptionVestedNumberOfSharesOptionRepricing", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "aplt_StockOptionsExercisedForCommonStockNotYetIssuedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of stock options exercised for common stock not yet issued.", "label": "Stock Options Exercised for Common Stock Not Yet Issued, Shares", "negatedLabel": "Exercise of options for common stock not yet issued (in shares)" } } }, "localname": "StockOptionsExercisedForCommonStockNotYetIssuedShares", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "aplt_StockOptionsExercisedForCommonStockNotYetIssuedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock options exercised for common stock not yet issued.", "label": "Stock Options Exercised for Common Stock Not Yet Issued, Value", "negatedLabel": "Exercise of options for common stock not yet issued" } } }, "localname": "StockOptionsExercisedForCommonStockNotYetIssuedValue", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "aplt_StockOptionsVestingBasedOnServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents a stock option award with vesting based on length of service.", "label": "Stock options - Service conditions only" } } }, "localname": "StockOptionsVestingBasedOnServiceMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "aplt_StockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Stockholders' Equity Note, Warrants or Rights [Text Block]", "terseLabel": "WARRANTS" } } }, "localname": "StockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrants" ], "xbrltype": "textBlockItemType" }, "aplt_ThresholdPercentageOfAggregateBeneficialOwnershipToExerciseWarrantsOne": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold one percentage of aggregate beneficial ownership of holder for exercising warrants.", "label": "Threshold Percentage Of Aggregate Beneficial Ownership To Exercise Warrants, One", "terseLabel": "Threshold percentage of aggregate beneficial ownership of holder for exercising warrants" } } }, "localname": "ThresholdPercentageOfAggregateBeneficialOwnershipToExerciseWarrantsOne", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "percentItemType" }, "aplt_ThresholdPercentageOfAggregateBeneficialOwnershipToExerciseWarrantsTwo": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold two percentage of aggregate beneficial ownership of holder (together with affiliates) for exercising warrants where holder (together with affiliates) exceeded threshold one prior to specified date.", "label": "Threshold Percentage Of Aggregate Beneficial Ownership To Exercise Warrants, Two", "terseLabel": "Threshold percentage of aggregate beneficial ownership of holder (together with affiliates) for exercising warrants" } } }, "localname": "ThresholdPercentageOfAggregateBeneficialOwnershipToExerciseWarrantsTwo", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "percentItemType" }, "aplt_UniversityOfMiamiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "University of Miami.", "label": "University of Miami" } } }, "localname": "UniversityOfMiamiMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "domainItemType" }, "aplt_VestedStockOptionAwardsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to vested stock option awards.", "label": "Vested Stock Option Awards [Member]", "terseLabel": "Vested stock option" } } }, "localname": "VestedStockOptionAwardsMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "aplt_Warrant2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security, issued in 2017, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount", "label": "2017 Warrants" } } }, "localname": "Warrant2017Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "domainItemType" }, "aplt_Warrant2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security, issued in 2018, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "2018 Warrants" } } }, "localname": "Warrant2018Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "domainItemType" }, "aplt_Warrant2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security, issued in 2019, that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "2019 Warrants" } } }, "localname": "Warrant2019Member", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "domainItemType" }, "aplt_WarrantAndRightsOutstandingTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrant and Rights Outstanding, Term", "terseLabel": "Warrants term" } } }, "localname": "WarrantAndRightsOutstandingTerm", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "durationItemType" }, "aplt_WarrantIssuedPricePerPreFundedWarrantAndAccompanyingWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The issue price per pre-funded warrant and accompanying warrant.", "label": "Warrant Issued, Price Per Pre-Funded Warrant and Accompanying Warrant", "terseLabel": "Issue price per pre-funded warrant and accompanying warrant (in dollars per share)" } } }, "localname": "WarrantIssuedPricePerPreFundedWarrantAndAccompanyingWarrant", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails" ], "xbrltype": "perShareItemType" }, "aplt_WarrantLiabilityCurrent": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of warrant liability, classified as current.", "label": "Warrant Liability, Current", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityCurrent", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "aplt_WarrantLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of warrant liabilities.", "label": "Warrant Liability, Fair Value Disclosure", "terseLabel": "Warrant liabilities - Common Warrants" } } }, "localname": "WarrantLiabilityFairValueDisclosure", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "aplt_WarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised during the period.", "label": "Warrants Exercised", "negatedLabel": "Warrants exercised", "terseLabel": "Warrants exercised (in shares)" } } }, "localname": "WarrantsExercised", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "aplt_WarrantsGrantedAndIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants granted and issued during the period.", "label": "Warrants Granted and Issued", "terseLabel": "Warrants granted and issued" } } }, "localname": "WarrantsGrantedAndIssued", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "aplt_WarrantsIssuedWith2018NotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrants issued with the 2018 notes", "label": "Warrants Issued with the 2018 Notes" } } }, "localname": "WarrantsIssuedWith2018NotesMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails" ], "xbrltype": "domainItemType" }, "aplt_WarrantsIssuedWithSeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to warrants issued with series B preferred stock.", "label": "Warrants Issued with Series B Preferred Stock" } } }, "localname": "WarrantsIssuedWithSeriesBPreferredStockMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "domainItemType" }, "aplt_WarrantsIssuedWithSeriesPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to warrants issued with Series A Preferred Stock.", "label": "Warrants Issued with Series A Preferred Stock" } } }, "localname": "WarrantsIssuedWithSeriesPreferredStockMember", "nsuri": "http://www.appliedtherapeutics.com/20220930", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r460" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r461" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r459" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r34", "r36", "r82", "r83", "r194", "r207" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r175", "r176", "r177", "r178", "r193", "r206", "r250", "r251", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r445", "r446", "r454", "r455" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r175", "r176", "r177", "r178", "r193", "r206", "r250", "r251", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r445", "r446", "r454", "r455" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r173", "r175", "r176", "r177", "r178", "r193", "r206", "r230", "r250", "r251", "r287", "r288", "r289", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r445", "r446", "r454", "r455" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r173", "r175", "r176", "r177", "r178", "r193", "r206", "r230", "r250", "r251", "r287", "r288", "r289", "r393", "r394", "r395", "r396", "r397", "r398", "r417", "r445", "r446", "r454", "r455" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r35", "r36", "r82", "r83", "r194", "r207" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r28", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation and benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInsuranceCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Insurance, Current", "terseLabel": "Short-term insurance financing note" } } }, "localname": "AccruedInsuranceCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "totalLabel": "Total accrued expenses & other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r40", "r41", "r42", "r437", "r451", "r452" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive gain/(loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r39", "r42", "r49", "r50", "r51", "r85", "r86", "r87", "r325", "r372", "r447", "r448" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r85", "r86", "r87", "r299", "r300", "r301", "r333" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r254", "r303", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r192", "r220", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Issuance of common stock warrants in connection with the issuance of Series B convertible preferred stock", "verboseLabel": "Warrants to purchase common stock (in dollars)" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r292" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Total stock-based compensation expense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potential dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive securities excluded from computation of loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r13", "r78", "r129", "r131", "r135", "r154", "r179", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r320", "r326", "r348", "r381", "r383", "r421", "r436" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r27", "r78", "r154", "r179", "r180", "r181", "r183", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r320", "r326", "r348", "r381", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r336" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total financial assets measured at fair value on a recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r142" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized Gains", "totalLabel": "Gross Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r143" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized Losses", "negatedTotalLabel": "Gross Unrealized Losses", "verboseLabel": "Gross unrealized loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r140", "r161" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]", "terseLabel": "Securities in an unrealized loss position less than 12 months" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Amortized Cost", "totalLabel": "Due in one year or less - Cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0 }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetailsCalc2": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling fiscal year following latest fiscal year. For interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.", "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Rolling within One Year, Fair Value", "terseLabel": "Due in one year or less - Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r138", "r141", "r161", "r425" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Estimated Fair Value", "totalLabel": "Estimated Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByContractualMaturityDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Realized Gain (Loss) [Abstract]", "terseLabel": "Marketable securities realized gain (loss) recorded" } } }, "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsRealizedGainsAndLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r283", "r284", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "verboseLabel": "Operations and Business" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r12", "r73" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash and cash equivalents and investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesLiquidityAndGoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r68", "r73", "r74" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r68", "r349" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "STOCKHOLDERS' EQUITY", "verboseLabel": "Equity" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r228", "r256" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants to purchase common stock (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Outstanding as of end of period", "periodStartLabel": "Outstanding as of beginning of period", "terseLabel": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r228", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsWarrantActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]", "terseLabel": "Agreements" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r85", "r86", "r333" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityAuthorizedStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityAuthorizedStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r18", "r220" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 100,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 48,058,956 shares issued and outstanding as of September 30, 2022 and 26,215,514 shares issued and outstanding as of December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BENEFIT PLANS" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r45", "r47", "r48", "r55", "r429", "r443" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss), net of tax" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r122", "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Risk and Uncertainties" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r195", "r358", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "terseLabel": "Initial fair value recorded as debt discount (in dollars)" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWith2018NotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "auth_ref": [ "r148", "r165", "r168" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months", "terseLabel": "Estimated Fair Value Less Than 12 Months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r148", "r165" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "negatedLabel": "Unrealized Losses Less Than 12 months" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "terseLabel": "Gross realized gain from sale of marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsRealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "auth_ref": [ "r149" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Loss", "terseLabel": "Gross realized loss from sale of marketable securities" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsRealizedGainsAndLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r150" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "auth_ref": [ "r146", "r162", "r168" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "totalLabel": "Total Estimated Fair Value" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r147", "r163" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Total Unrealized Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Summary of prepaid expenses and other current assets" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Employer matching contributions to the plan" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r257", "r258", "r293", "r294", "r296", "r305" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCK BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r80", "r182", "r184", "r185", "r189", "r190", "r191", "r376", "r426", "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r56", "r90", "r91", "r92", "r93", "r94", "r98", "r101", "r108", "r109", "r110", "r114", "r115", "r334", "r335", "r430", "r444" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share attributable to common stockholders-basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r56", "r90", "r91", "r92", "r93", "r94", "r101", "r108", "r109", "r110", "r114", "r115", "r334", "r335", "r430", "r444" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share attributable to common stockholders-diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r111", "r112", "r113", "r116" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-Based Compensation", "terseLabel": "Incremental stock based compensation expense" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted Average Remaining Recognition Period (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unamortized stock-based compensation costs for unvested awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized stock-based compensation balance for unvested options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Options", "terseLabel": "Options to purchase common stock" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r49", "r50", "r51", "r85", "r86", "r87", "r89", "r95", "r97", "r117", "r155", "r220", "r227", "r299", "r300", "r301", "r310", "r311", "r333", "r350", "r351", "r352", "r353", "r354", "r356", "r372", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r71", "r200" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial assets or liabilities measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r336", "r337", "r345" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair value" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "verboseLabel": "Schedule of fair value of warrants using the Black Scholes option pricing model" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r336", "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r196", "r198", "r199", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r246", "r337", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r336", "r337", "r339", "r340", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r196", "r231", "r233", "r238", "r246", "r337", "r390" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r196", "r198", "r199", "r231", "r233", "r238", "r246", "r337", "r391" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r196", "r198", "r199", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r246", "r337", "r392" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails", "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r341", "r345" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r341", "r345" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of aggregate fair values of the Company's warrant liability" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "verboseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Initial fair value of Warrant Liability - Common Warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Warrants exercised" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFairValuesOfCompanySWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r196", "r198", "r199", "r231", "r233", "r234", "r235", "r236", "r237", "r238", "r246", "r390", "r391", "r392" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r144", "r145", "r151", "r152", "r153", "r156", "r157", "r158", "r159", "r160", "r164", "r166", "r167", "r168", "r197", "r218", "r331", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total financial liabilities measured at fair value on a recurring basis" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r59" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Operations" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r172", "r174" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r79", "r307", "r308", "r309", "r312", "r313", "r314", "r315", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r70" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r70", "r365" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Change in operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r70" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "verboseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 7.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest Receivable, Current", "terseLabel": "Interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Schedule of contractual maturities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENTS" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r336" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Marketable securities" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r150", "r420", "r433", "r453", "r469" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of lease related costs" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LEASES" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Summary of maturities of lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r369" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r369" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r369" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r369" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r369" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r29", "r78", "r132", "r154", "r179", "r180", "r181", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r321", "r326", "r327", "r348", "r381", "r382" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r78", "r154", "r348", "r383", "r422", "r439" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r8", "r31", "r78", "r154", "r179", "r180", "r181", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r321", "r326", "r327", "r348", "r381", "r382", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r9", "r10", "r11", "r14", "r15", "r78", "r154", "r179", "r180", "r181", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r321", "r326", "r327", "r348", "r381", "r382" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total noncurrent liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NONCURRENT LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Dividend yield", "terseLabel": "Dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Contractual term (in years)", "terseLabel": "Expected term (in years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Risk-free interest rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r68" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r68", "r69", "r72" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r43", "r46", "r51", "r53", "r72", "r78", "r88", "r90", "r91", "r92", "r93", "r96", "r97", "r106", "r129", "r130", "r133", "r134", "r136", "r154", "r179", "r180", "r181", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r335", "r348", "r427", "r441" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net Loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r90", "r91", "r92", "r93", "r98", "r99", "r107", "r110", "r129", "r130", "r133", "r134", "r136" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders-basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r100", "r102", "r103", "r104", "r105", "r107", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders-diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncollaborativeArrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangement Other than Collaborative [Member]" } } }, "localname": "NoncollaborativeArrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSE), NET:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses", "verboseLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r129", "r130", "r133", "r134", "r136" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r364", "r370" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseCostDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "LEASES" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r361" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r361" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r361" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes operating lease liability.", "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Statement of Financial Position" } } }, "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r360" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r71" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r367", "r370" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r366", "r370" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term - operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLeasesLeaseTermsAndDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r3", "r84", "r128", "r330" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r26", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 8.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other prepaid expenses and current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": { "auth_ref": [ "r37", "r38", "r40" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and after adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax", "verboseLabel": "Unrealized gain (loss) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r44", "r47", "r49", "r50", "r52", "r54", "r220", "r350", "r355", "r356", "r428", "r442" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r44", "r47", "r318", "r319", "r324" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive gain (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r30", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r61" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r62", "r64", "r139" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchase of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r230", "r232", "r238", "r239", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r252" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r283", "r284", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r283", "r284", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r17", "r204" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityAuthorizedStockDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityAuthorizedStockDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r17", "r204" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, par value $0.0001; 10,000,000 shares authorized as of September 30, 2022 and December 31, 2021; 0 shares issued and outstanding as of September 30, 2022 and December 31, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses & other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r5", "r169", "r171" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance expenses" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidRent": { "auth_ref": [ "r6", "r170", "r171" ], "calculation": { "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Rent", "terseLabel": "Prepaid rent expenses" } } }, "localname": "PrepaidRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "auth_ref": [ "r62", "r63", "r139" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from maturities of available-for-sale securities" } } }, "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r62", "r63", "r139" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from sale of available-for-sale securities" } } }, "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r65", "r298" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Exercise of stock options for common stock under Equity Incentive Plan" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r65" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from Warrant Exercises", "terseLabel": "Exercise of Warrants", "verboseLabel": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r43", "r46", "r51", "r67", "r78", "r88", "r96", "r97", "r129", "r130", "r133", "r134", "r136", "r154", "r179", "r180", "r181", "r184", "r185", "r186", "r187", "r188", "r190", "r191", "r318", "r322", "r323", "r328", "r329", "r335", "r348", "r431" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesLiquidityAndGoingConcernDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r240", "r375", "r376", "r378" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r375" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Payments to related party" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r373", "r374", "r376", "r379", "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTIES" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedParties" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r66" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedLabel": "Repayments of short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r306", "r418", "r456" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs)", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r227", "r383", "r438", "r450", "r452" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesLiquidityAndGoingConcernDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r85", "r86", "r87", "r89", "r95", "r97", "r155", "r299", "r300", "r301", "r310", "r311", "r333", "r447", "r449" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potential dilutive securities excluded from the computation of diluted net loss per share attributable to common stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Marketable securities by type", "verboseLabel": "Marketable securities by maturity" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of marketable securities by security type" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "verboseLabel": "Schedule of computation of basic and diluted net loss per common share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r291", "r302" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expenses" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r336", "r337" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets or liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r377", "r378" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r253", "r255", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r283", "r284", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock units outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r261", "r279", "r282" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of options outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r16", "r17", "r18", "r76", "r118", "r119", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r209", "r213", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r228", "r256" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrants outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r70" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Awarded (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "verboseLabel": "Nonvested at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Valuation Assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Volatility (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Released (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Awarded (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Outstanding at end of period ( in shares)", "periodStartLabel": "Outstanding at beginning of period ( in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "terseLabel": "Summary of restricted stock units outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized (in shares)", "verboseLabel": "Maximum number of shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for future issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercisable at end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Options exercised (in dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r280" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value of options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding (in dollars)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period (in shares)", "periodStartLabel": "Outstanding at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r262", "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period (in dollars per share)", "periodStartLabel": "Outstanding at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r273", "r274", "r275", "r276", "r277", "r278", "r280", "r281", "r283", "r284", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationTables", "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r268" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "terseLabel": "Nonvested at end of period (in dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Outstanding at end of period (in dollars)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationRsusDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationPlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationValuationAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares", "terseLabel": "Nonvested at end of period (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "periodEndLabel": "Nonvested at end of period (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "verboseLabel": "Issue price (in dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r26", "r423", "r424", "r435" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r75", "r84" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r33", "r49", "r50", "r51", "r85", "r86", "r87", "r89", "r95", "r97", "r117", "r155", "r220", "r227", "r299", "r300", "r301", "r310", "r311", "r333", "r350", "r351", "r352", "r353", "r354", "r356", "r372", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Cash Flows" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Comprehensive Income (Loss)" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Statements of Stockholders' Equity" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r85", "r86", "r87", "r117", "r419" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquityParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r17", "r18", "r220", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued under ESPP" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensation2019EmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r17", "r18", "r220", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r220", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Restricted Stock Units released for common stock issued under Equity Incentive Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r220", "r227", "r267" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "terseLabel": "Exercise of options for common stock issued under Equity Incentive Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockBasedCompensationOptionsActivityDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r17", "r18", "r220", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r33", "r220", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options for common stock issued under Equity Incentive Plan" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r23", "r24", "r78", "r137", "r154", "r348", "r383" ], "calculation": { "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r77", "r205", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r219", "r227", "r229", "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r357", "r385" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event." } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r357", "r385" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r357", "r385" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r357", "r385" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r384", "r386" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsDetails", "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityCommonStockAndEquityDistributionAgreementDetails", "http://www.appliedtherapeutics.com/role/DisclosureStockholdersEquityJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Sale of stock" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesStockIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernWithinOneYear": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether there was substantial doubt about ability to continue as going concern within one year after date financial statements are issued.", "label": "Substantial Doubt about Going Concern, within One Year [true false]", "terseLabel": "Substantial Doubt about Going Concern, within One Year" } } }, "localname": "SubstantialDoubtAboutGoingConcernWithinOneYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesLiquidityAndGoingConcernDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r144", "r145", "r151", "r152", "r153", "r197", "r218", "r331", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r462", "r463", "r464", "r465", "r466", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsTables" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementColumbiaDetails", "http://www.appliedtherapeutics.com/role/DisclosureLicenseAgreementMiamiUniversityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r81", "r231", "r432" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "U.S. government agency debt securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsFvHierarchyDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsByTypeDetails", "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsUnrealizedLossesAndFairValuesOfAvailableForSaleSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of unrealized gains and losses on investments.", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "terseLabel": "Unrealized Gain (Loss) on Investments" } } }, "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r120", "r121", "r123", "r124", "r125", "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrants Liability", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareAntiDilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS" } } }, "localname": "WarrantsAndRightsNoteDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureFairValueMeasurementsWarrantsValuationDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithJune2022OfferingDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails", "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesPreferredStockDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Expiration term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureWarrantsIssuedWithSeriesBPreferredStockDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r100", "r110" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common stock outstanding-diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r98", "r110" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common stock outstanding-basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.appliedtherapeutics.com/role/DisclosureNetLossPerCommonShareEpsDetails", "http://www.appliedtherapeutics.com/role/StatementCondensedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=116846462&loc=SL51888449-203568" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r229": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r252": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r316": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r347": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "https://asc.fasb.org/topic&trid=2155941" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r371": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r380": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r433": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r457": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r458": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r459": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r460": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r461": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r462": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r463": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r464": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r465": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r466": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r467": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r468": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r469": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r470": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r471": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(3)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" } }, "version": "2.1" } ZIP 91 0001558370-22-017009-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-22-017009-xbrl.zip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�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�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end